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Abbreviations 
AI Adequate intake, the average observed daily level of intake by a population 
group of apparently healthy people, used when a population reference intake 
cannot be determined 
Acute RfD Acute reference dose, an estimate of a daily oral exposure for an acute 
duration (24 hours or less) to the human population (including susceptible 
subgroups) that is likely to be without an appreciable risk of adverse health effects 
over a lifetime 
As(III) Arsenite (arsenous acid) 
As(V) Arsenate(arsenic acid) 
ATSDR Agency for Toxic Substances and Disease Registry (USA) 
BMD Benchmark dose, the dose of a substance that is expected to result in a 
predetermined level of an adverse effect (called the benchmark response, BMR) 
BMDL Lower confidence limit of the benchmark dose 
BW Body Weight 
CONTAM Panel EFSA´s Panel on Contaminants in the Food Chain 
DMA Dimethylarsinic acid  
EC European Commission 
EFSA European Food Safety Authority  
ESPGHAN The European Society of Paediatric Gastroenterology, Hepatology 
and Nutrition 
EPA Environmental Protection Agency (USA) 
EU European Union 
FAO Food and Agriculture Organization of the United Nations 
FSA Food Standards Agency (United Kingdom) 
FSMP Foods for Special Medical Purposes 
IARC International Agency for Research on Cancer (France) 
IC-PMS Inductively Coupled Mass Spectrometry 
ICT Idiopathic Copper Toxicosis 
IMM Institute of Environmental Medicine; Karolinska Institutet (Sweden) 
IOM Institute of Medicine (USA) 
IQ Intelligence Quotient 
JECFA Joint FAO/WHO Expert Committee on Food Additives 
LBW Low Birth Weight, defined as <2.5 kg 
LOAEL Lowest observed adverse effect level, the lowest dose associated with 
negative health effects/toxic effects 
LOQ Limit of Quantification 
MMA Methylarsonic acid 
MRL Maximum Residue Limit 
MOE Margin of exposure, the ratio between a defined point on the dose-response 
curve for the adverse effect and the human intake 
NAG N-acetyl glucosaminidase 
NFA National Food Agency (Sweden) 
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NOAEL No observed adverse effect level - the highest dose not associated with 
negative health effects/toxic effects 
NRC The National Research Council (USA) 
NNR Nordic Nutrition Recommendations 
PCBF Processed Cereal-based Foods 
PTWI Provisional tolerable weekly intake 
PKU Phenylketonuria 
RI Recommended Intake, expressed as average daily intake over time 
RP Reference Point, The NOAEL and/or the LOAEL for the critical effect of a 
substance, forms the reference point for a risk assessment of a chemical in food. when 
animal data have to be used. 
RR Relative Risk, the ratio of the risk of disease in exposed individuals to the risk of 
disease in non-exposed individuals 
SCF Scientific Committee on Food (EU) 
SMR Standardized Mortality Ratio, a ratio between the observed number of 
deaths in an study population and the number of deaths that would be expected.  
SNR Swedish Nutrition Recommendations 
TDI Tolerable Daily Intake, an estimate of the amount of a substance in food or 
drinking water, expressed on a body mass basis (usually mg/kg body weight), 
which can be ingested daily over a lifetime by humans without appreciable health 
risk 
TWI Tolerable Weekly Intake, an estimate of the amount of a substance in food 
or drinking water, expressed on a body mass basis (usually mg/kg body weight), 
which can be ingested weekly over a lifetime by humans without appreciable 
health risk 
WHO World Health Organization 
UL Upper Level, according to EFSA (2006) the maximum chronic daily intake of 
a nutrient (from all sources) judged to be unlikely to pose a risk of adverse health 
effects to humans  
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Summary and conclusions 
Infants and young children are often regarded as two particularly vulnerable 
groups in terms of food safety. They may be at risk of high exposures to conta-
minants and minerals at sensitive developmental stages. Also, the requirements 
for essential nutrients due to their rapid growth and development make them 
vulnerable to deficiencies of essential minerals.  
 
In the present survey the National Food Agency (NFA) analysed and assessed 
contaminants and minerals in infant formulae and certain foods for children.  
The analysed items cover the relevant products from all producers present in the 
Swedish market in spring 2011. In total 92 different products were analysed for 
arsenic, cadmium and lead unintentionally present in foods, so-called contami-
nants, as well as the essential minerals manganese, iron and copper. The result  
of the project is presented in one report with three parts: 
 
• Contaminants and minerals in foods for infants and young children –
analytical results, Rapport 1/2013, Part 1 (1) 
• Contaminants and minerals in foods for infants and young children – risk and 
benefit assessment, Rapport 1/2013, Part 2  
• Contaminants and minerals in foods for infants and young children – risk and 
benefit management, Rapport 1/2013, Part 3 (2) 
 
In the present report, Part 2, intakes of the selected contaminants and minerals 
from the analysed products were assessed following the principles of risk analysis. 
Intakes of the contaminants arsenic, cadmium and  lead were compared with the 
available tolerable intakes or reference points. For the essential minerals manga-
nese, iron and copper, intakes were discussed in relation to recommended daily 
intakes and tolerable upper levels or tolerable daily intakes, when these values 
were available. The chemical analyses are presented in report Part 1 (1). Risk 
management and assessment of compliance with legislation were carried out by 
the NFA in processes parallel to this project and is presented in a separate report, 
Part 3 (2). 
 
The results from the risk assessment show that rice-based infant food purchased  
in Sweden could be a significant exposure source of inorganic arsenic. Arsenic 
levels in rice drinks exceed the EU standard value of 10 μg/L in drinking water. 
The estimated intakes per portion (1 dl) from rice-based infant food are close to 
the lower confidence limit on the benchmark dose (BMDL01) value identified by 
European Food Safety Authority (EFSA).  
 
The estimated cadmium intakes were below the tolerable daily intake (TDI) for all 
products. However, a number of uncertainties exist regarding the level of protect-
tion provided to infants and children from the TDI established by EFSA. The rea-
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sons are that cadmium uptake is probably higher in children compared to adults, 
and it may be discussed if the TDI covers all potential health effects associated 
with cadmium exposure restricted to early-life. Based on this, consideration of an 
extra margin to the established cadmium TDI in the case of children may be 
needed.  
 
For lead, EFSA regards that a margin to the reference point (RP) of a factor of 10 
or more would ensure that there is no appreciable risk for a clinically significant 
effect on intelligence quotient (IQ) in children. For foods for special medical 
purposes (FSMP) used as the sole source of nutrition, the margin to the RP was 
generally lower than a factor of 10. It should be noted that there is already a 
potential concern for effects on neurodevelopment at current levels of exposure to 
lead for infants and children. This suggests that the exposure to lead should be 
reduced as much as possible.  
 
From a nutritional point of view, the intakes of manganese, iron and copper from 
the analysed products were found to be adequate. However, some uncertainties 
exist about the dietary manganese requirements of infants and young children.  
The exposure assessment also identified potential problems with high manganese 
intakes from some gruels and porridge products and FSMP products when com-
paring with the TDI established by the World Health Organization (WHO). 
However, this TDI for manganese was based on weak scientific evidence and 
should not be considered as a definite level under which there is no reason for 
concern. Copper intakes from some FSMP products were high compared to upper 
level (UL) for children from 1 year of age. Intakes of manganese and copper from 
infant and follow-on formulae were not of concern compared to the currently 
available reference values.  
 
During the assessment of intakes of the minerals some shortcomings of existing 
data were revealed. In order to evaluate if the concentration of a mineral in parti-
cular food products is within the acceptable or optimal range, upper and lower 
levels of intakes must be established. We conclude that a revision of the AI and an 
establishment of an UL or corresponding values for manganese are urgently need-
ed in order to define an optimal range of manganese concentrations in products 
intended for infants and young children. Also, an UL for iron for infants and 
young children and an UL for copper for infants below the age of 1 year must be 
established. Risk-benefit assessments are needed for manganese, iron and copper 
in relation to estimated intakes by infants and young children and should be 
undertaken by researchers or international expert groups. Such assessments are 
essential for updated legislation and control in order to ensure adequate and safe 
foods for infants and young children. 
 
It is alarming that products intended for use by infants and young children contain 
such amounts of contaminants that they potentially could result in adverse health 
effects. These age groups are particularly vulnerable to exposures of certain conta-
minants and minerals and effects on development may be irreversible. We call for 
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action to use presently available methods to reduce concentrations of contami-
nants such as arsenic and lead  in foods intended for infants and young children. 
Furthermore, we urge that health-based guidance values for children’s cadmium 
exposure and for low and high intakes of essential minerals be updated in order to 
ensure adequacy and safety of foods for infants and young children.  
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Sammanfattning och slutsatser  
Barn under tre år, i synnerhet spädbarn, kan löpa hög risk att drabbas av negativa 
hälsoeffekter om de utsätts för kontaminanter och höga halter av mineraler vid 
vissa viktiga stadier i utvecklingen. I den åldern kan barn också lättare få brist på 
essentiella mineraler på grund av hög tillväxttakt och stort näringsbehov under 
utvecklingen.  
 
I den här studien har Livsmedelsverket analyserat kontaminanter och mineraler  
i modersmjölksersättningar, grötar, vällingar och andra produkter som kan konsu-
meras av spädbarn och småbarn. De analyserade produkterna kommer från alla 
producenter som fanns representerade på den svenska marknaden våren 2011. 
Halterna av kontaminanterna arsenik, kadmium och bly samt de essentiella mine-
ralerna mangan, järn och koppar analyserades i 92 produkter.  
 
Resultatet från Livsmedelsverkets studie presenteras i tre delrapporter: 
  
• Contaminants and minerals in foods for infants and young children –
Analytical results, Rapport 1/2013, Part 1(1) 
• Contaminants and minerals in foods for infants and young children – risk and 
benefit assessment, Rapport 1/2013, Part 2 
• Contaminants and minerals in foods for infants and young children – risk and 
benefit management, Rapport 1/2013, Part 3(2). Finns även på svenska – 
Kontaminater och mineraler i livsmedel för spädbarn och småbarn. Del 3 
Hanteringsrapport, Rapport 1/2013. 
 
I denna rapport, dvs delrapport 2, presenteras Livsmedelsverkets värdering av 
riskerna och nyttan med de funna nivåerna av kontaminanter och mineraler i 
produkterna enligt riskanalysens principer. I värderingen har det uppskattade 
intaget från produkterna och risken för hälsoeffekter bedömts när det gäller höga 
intag av kontaminanter och mineraler samt låga intag av mineraler. I delrapport 1 
(1) redovisas halterna från de kemiska analyserna och i delrapport 3 (2) presen-
teras riskhanteringen, det vill säga vilka åtgärder Livsmedelsverket avser att vidta 
och de överväganden som ligger till grund för dessa. 
 
Resultaten från riskvärderingen visar att risbaserade produkter köpta i Sverige kan 
vara en betydande källa till oorganisk arsenik. Denna studie visar att koncentra-
tionen av arsenik i risdrycker kan vara högre än EU:s gränsvärde för dricksvatten, 
som är 10 mikrogram/liter. Det uppskattade intaget av arsenik från en deciliter av 
risbaserad dryck ligger nära det referensvärde för negativa hälsoeffekter som 
identifierats av den europeiska myndigheten för livsmedelssäkerhet, Efsa.  
 
Det uppskattade intaget av kadmium underskred det så kallade tolerabla dagliga 
intaget (TDI) för alla analyserade produkter. Det är dock oklart om kadmiumni-
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våer under det TDI som fastställts av Efsa innebär att spädbarn och små barn 
skyddas mot negativa hälsoeffekter av kadmium. Orsakerna till att detta är tvek-
samt är att kadmiumupptaget sannolikt är högre hos barn än hos vuxna, och att 
TDI kanske inte inbegriper alla de hälsoeffekter som är associerade med intag av 
kadmium tidigt i livet. Man bör därför överväga en extra marginal för barns intag 
av kadmium till det TDI som gäller för vuxna. 
 
Efsa anser att ett intag av bly som ligger tio gånger under ett visst uppskattat häl-
somässigt referensvärde innebär att det inte finns någon risk för klinisk relevanta 
effekter på intelligenskvoten (IQ) hos barn. För vissa livsmedel som kan användas 
som enda näringskälla och är avsedda för barn med speciella medicinska behov 
(FSMP), var marginalen till det uppskattade hälsomässiga referensvärdet mindre 
än en faktor tio. Den blyexponering vi har idag anses bekymmersam när det gäller 
att risken för effekter på den neurologiska utvecklingen. Exponeringen för bly bör 
därför minska så mycket som möjligt. 
 
Från nutritionell synpunkt var intagen av mangan, järn och koppar från de analy-
serade produkterna tillräckliga. Viss osäkerhet finns dock beträffande spädbarns 
och småbarns behov av mangan. Utvärderingen visade också att det finns poten-
tiella problem med höga manganintag från vissa välling- och grötprodukter samt 
vissa FSMP-produkter, om man jämför med det TDI som fastställts av WHO. Det 
vetenskapliga underlaget för detta TDI-värde är dock tveksamt, varför även intag 
under TDI kan ge anledning till oro. Intaget av koppar från några FSMP-produkter 
var högt i jämförelse med tolerabelt övre intag (UL) för barn under ett år. Intagen 
av mangan och koppar från modersmjölksersättningar och tillskottsnäringar gav 
däremot ingen anledning till oro om man jämför med nu tillgängliga hälsobase-
rade referensvärden. 
 
I samband med utvärderingen av intaget av de analyserade mineralerna har kun-
skapsluckor identifierats. För att kunna bedöma om koncentrationen av ett mineral 
i en speciell livsmedelsprodukt är inom ett acceptabelt eller optimalt intervall, 
måste det finnas fastställda maximi- och miniminivåer för intaget. Vår uppfattning 
är att det är nödvändigt att fastställa hur stort manganbehov små barn har och att 
fastställa ett UL-värde eller motsvarande värde för mangan för att kunna definiera 
ett optimalt intervall för koncentrationerna av mangan i produkter avsedda för 
spädbarn och småbarn. Även UL för järn för spädbarn och småbarn samt UL för 
koppar för barn under ett år måste fastställas. Det behövs risk- och nyttovärde-
ringar av mangan, järn och koppar i relation till uppskattade intag hos spädbarn 
och småbarn, och dessa utvärderingar bör utföras av forskare eller internationella 
expertgrupper. Sådana värderingar är viktiga för att uppdatera lagstiftningen och 
kontrollen för att säkerställa att mat avsedd för spädbarn och småbarn är närings-
mässigt lämplig och säker. 
 
Det är alarmerande att produkter avsedda för spädbarn och småbarn innehåller 
sådana halter av kontaminanter att de potentiellt kan leda till negativa hälso-
effekter. Dessa åldersgrupper är speciellt känsliga för exponering för vissa konta-
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minanter och mineraler och effekterna på barns utveckling kan vara irreversibla. 
Vi vill uppmana berörda aktörer att använda tillgängliga metoder för att reducera 
koncentrationerna av kontaminanter som arsenik och bly i livsmedel avsedda för 
spädbarn och småbarn. Det är även angeläget att hälsobaserade riktvärden för 
kadmiumexponeringen hos barn samt referensvärden för låga och höga intag av 
essentiella mineraler uppdateras för att säkerställa att livsmedel för spädbarn och 
småbarn är näringsmässigt lämpliga och säkra.  
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Introduction 
Infants and young children are often regarded as two particularly vulnerable 
groups in terms of food safety. These groups may be especially vulnerable to high 
exposures from contaminants and minerals at important stages of development. 
Furthermore, the requirements for essential nutrients due to rapid growth and 
development put these groups at risk of deficiencies of essential minerals. It is 
therefore essential that products intended for use by infants and young children 
contain minerals in amounts that satisfy their nutritional requirements without 
leading to adverse effects. In addition, products must not contain contaminants in 
amounts that could lead to negative health effects.  
 
Concerns about adverse health effects of high concentrations of manganese and 
possibly also iron in infant formulae were raised in a study by Ljung et al, who 
also found arsenic, cadmium and lead in foods for infants (3). This report as well 
as other data encouraged the NFA to initate a project to analyse and assess conta-
minants and minerals in infant formulae and certain foods for children. Because 
the addition of copper to foods for infants and children has been questioned (4), 
copper was also included in the project. 
 
Products to be included in the present survey were chosen on the basis of producer 
and type of products, aiming to cover products from all producers present in the 
Swedish market in spring 2011. The analysed elements were arsenic, cadmium 
and lead unintentionally present in foods, so called contaminants, as well as the 
essential minerals manganese, iron and copper. Ninety two products intended for 
infants (0-12 months) and young children (1-3 years), including a limited number 
of products not explicitly intended for consumption by children, were analysed in 
this survey. 
 
In the present part of the report, the intakes of arsenic, cadmium and lead, were 
evaluated in relation to guideline values for upper intake levels and risk for 
development of adverse health effects in infants and young children. The potential 
adverse effects of low and high intakes of manganese, iron and copper were 
identified and discussed. Furthermore, the potential benefits (here defined as the 
absence of risk) and risks considering the requirements and vulnerability of 
infants and young children to these minerals were evaluated. A possible need for 
revised risk assessments of the essential minerals manganese, iron and copper was 
evaluated.  
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Materials and Methods 
This section includes a description of the selection and sampling of products, 
analyses of contaminants and minerals in the product and the intake assessment  
of selected products. For further details of product identification, selection, samp-
ling and analyses, the reader is referred to the National Food Agency’s report 
“Concentrations of contaminants and minerals in foods for infants and young 
children –analytical results”(1). 
 
Food categories included in the project: 
 
• Foods for Special Medical Purposes (FSMP) for infants (0-12 months) 
and young children (1-3 years). In order to facilitate the intake assessment 
for this product cartegory, FSMP was further divided into FSMP that can 
be used as the sole source of nutrition and FSMP used as partial nutrition 
in this report. 
 
• Infant formulae and follow-on formulae  
 
• Processed cereal-based foods for infants and young children (PCBF) 
This category includes porridge and gruel products. 
 
• Breast milk and foodstuffs for normal consumption include breast milk 
from a sample of Swedish women and foods that young children might 
consume which are not explicitly intended for children according to the 
label.  
 
The project did not include “baby foods” (main dishes and desserts) and so called 
“growing up milks” (milks intended for young children aged 12 months to 3 
years). The reason for this was that products where concentrations of contami-
nants and manganese were expected to be of concern, such as cereals (including 
rice) and soy, were prioritised.  
Selection and sampling 
Products to be included in analysis were chosen on the basis of producer and type 
of product. A list of analysed food products and labelling information can be 
found in Appendix I. 
 
Samples were purchased in supermarkets and pharmacies in the counties of Upp-
sala, Stockholm and Gävleborg, Sweden, as well from web pages marketing the 
products. In total 253 samples of 92 different products were collected. Sampling 
was carried out between 4 May 2011 and 13 October 2011. For each product 
samples from three different batches were included, unless only two batches 
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(n=21) or one batch (n=5) were available during the period of sampling. Samples 
were all given a unique number. 
 
In addition, a composite sample of human milk collected week 3 post-partum 
from 30 volunteers during 2008, 2009 and 2010 (n=90) was analysed. A more 
detailed description of the selection and sampling of products can be found 
elsewhere (1). 
 
Determination of concentrations of contaminants and minerals 
The samples were analysed by ICP-MS (inductively coupled plasma mass spec-
trometry) using two different methods. Concentrations of manganese, iron and 
copper were determined during October and November 2011 at NFA by an 
accredited method (ISO/IEC 17025 by SWEDAC - Swedish Board for Accredi-
tation and Conformity Assessment). Concentrations of arsenic, cadmium and lead 
were determined both at the National Food Agency using the above-mentioned 
accredited method and at ALS Scandinavia AB, Luleå, Sweden, using a method 
with a higher sensitivity. The method at ALS was the same as the accredited 
method for routine analysis of these types of samples, with the exception of a 
lower dilution (5). The results from ALS with the lower reporting limits were used 
for the risk assessment in this report. 
 
A composite sample from the 3 batches of each product was transferred into 2 
tubes, of which one was used for the analysis at the NFA, and the other was sent 
to be analysed at ALS. All samples were stored either at room temperature or in  
a refrigerator (‘ready for use’ samples) until the day of analysis. Products were 
analysed on an “as purchased” basis, i.e. either as dry powders or in liquid form. 
In the determination analysis, powders were converted into ready-to-eat products 
by using dilution factors calculated on a weight to weight basis according to 
instructions on the package. Only contribution by the specific product is included 
in the results, which means that the contribution of contaminants in water or milk 
during dilution was not accounted for. For further details about the method of 
analysis and the result of the chemical analyses see part 1 of the report. 
Intake assessment 
In this report, exposure refers to the dietary exposure of contaminants and 
minerals from the analysed products only, unless otherwise stated. 
 
The results are presented as concentrations of the contaminant or mineral in the 
ready-to eat-product, in mg or µg per kg product in Appendices II-VII. The 
product categories (FSMP, infant formulae and follow-on formulae, PCBF and 
other foods) were further divided in order to make relevant intake estimations. In 
order to assess whether products fell within established acceptable ranges of 
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intakes, we calculated intakes per day or per portion of each contaminant or 
mineral. The assumptions made for estimations of intakes in each category are 
presented below. For some contaminants and minerals, the contribution (to the 
total intake) from water to be mixed with the product was also assessed. Details 
regarding assumed concentrations in water and calculations can be found in each 
chapter. 
Infant formulae 
Products in this category are recommended from 0 and 4 months of age, according 
to the labelling on the packages. For all products, intakes per day or per kg body 
weight per day were estimated. For infant formula intended from  birth, intakes 
were calculated using a weight of 4.2 kg for a girl at 3 weeks of age (6) and an 
estimated consumption of 700 ml per day (7, 8). For products recommended from 
4 months, a weight of 6.6 kg for a girl (6) and an estimated consumption of 800 
ml were used (7). 
Follow-on formulae 
These products are recommended for infants from 6 months and 8 months respect-
tively and should be consumed as part of an increasingly varied diet. However, 
because the size of one portion is difficult to estimate, intakes per day or per kg 
body weight per day were estimated. For products recommended from 6 months 
of age (7.7 kg), an estimated daily consumption of 900 ml per day was used, 
assuming energy requirements according to FAO (9) and little intake of comple-
mentary foods or breast milk. For the one product recommended from 8 months, a 
weight of 8.5 kg and consumption of 500 ml per day were assumed based on 
formula intake in the Euro-growth study (7).  
FSMP used as sole source of nutrition 
Foods recommended to children of 0-12 months are included in this product 
category. These foods are intended for a wide range of conditions, for example 
prematurity, allergy, malnutrition and phenylketonuria (PKU). Where package 
information indicated that the product could be used as the sole source of 
nutrition, the products were put in this category. However, most products in this 
category may also be used together with other foods. For all products in this 
category, intakes per day or per kg body weight per day were estimated. For 
FSMP that could be used as the only source of nutrition from birth, intakes were 
calculated using a weight of 4.2 kg for a girl at 3 weeks of age (6) and an estima-
ted consumption of 700 ml per day (7, 8). For products intended for use by prema-
ture or low birth weight infants, we used the weight 2.5 kg and an estimated daily 
intake of 400 ml. For FSMP recommended as the sole source of nutrition from 12 
months (9.8 kg), a consumption of 900 ml per day based on energy requirements 
was assumed (9) where no information on recommended intake was found on the 
package. The energy content of products in the FSMP category was higher than in 
infant formulae and follow-on formulae.  
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FSMP as partial nutrition, daily intakes 
The package information on some FSMP products indicated that the product 
should be used together with other foods. For the products Nutramigen 2 lipil, 
PKU anamix infant lcp+ and XP Maxamaid an intake per day or per kg body 
weight per day was estimated because the portion sizes were difficult to establish. 
For Nutramigen 2 lipil, recommended from 6 months of age, an estimated daily 
consumption of 900 ml per day was used, assuming little complementary food 
intake and food and energy requirements according to FAO (9). PKU anamix 
infant lcp+ and XP Maxamaid are intended for children with PKU and daily 
consumption should be based on protein requirements. For PKU anamix infant 
lcp+ the FAO protein requirements were used to estimate the daily protein 
requirement (for an infant weighing 4.2 kg) to 5.5 g protein per day (10). The 
protein concentration of the product is 2 g/100 ml and daily consumption of PKU 
anamix infant lcp+ was set at 300 ml/day. A daily protein requirement of 11 g was 
estimated for a child aged 12 months consuming XP Maxamaid (10). Product 
protein concentration was 4 g/100 ml and hence a daily consumption of 300 
ml/day was used. 
FSMP as partial nutrition, intakes per portion 
For some FSMP products, package information indicated that the product should 
be used together with other foods. Intakes of metals were calculated per portion 
for the following products: Fresubin energy fibre (200 ml), Frebini energy fibre 
drink (200 ml) and PKU gel (50 g), all recommended for use from 12 months. 
Gruel 
Cereal-based gruels are common complementary foods in Sweden and belong to 
the category PCBF. Where recipes were given in number of spoons, the density of 
the products was calculated to assign portion sizes in grams. Several recipes were 
often given. Since a child can easily consume a larger amount of gruel than of 
porridge at one meal, the portion size was set to the recipes on the package that 
gave a final amount of 200-237 g gruel. The weight of a girl (6) at the lowest age 
for which the product was recommended (7.7-9.8 kg) was used to calculate the 
intake per portion. For the contaminants the values in tables are conservative and 
do not include the potential contributrion from a milk product. However, products 
to be mixed with a milkproduct were not included in summary tables for iron and 
copper in order not to present misleadingly low values of these minerals in parti-
cular gruels.  
Porridge 
Porridges belongs to the category PCBF. For all products, an intake per portion 
was calculated using the same principles as for gruels. We used the weight of a 
girl (6) at the lowest age for which the product was recommended (6.6-9.8 kg) to 
calculate the intake per portion. Calculated intakes are based on product mixed 
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with water, if not stated otherwise. Portion sizes of 50-225 g were used according 
to instructions for appropriate preparation on the labels. 
Foodstuffs for normal consumption 
For drinks based on soy or oats, one portion was set at 100 ml. This was assumed 
to be a reasonable portion size for a 1-year-old child. For Pama ‘minute rice’, 
Rolled oats and Oat toasted and milled, a portion size of 130 g was used.  
Breast milk  
In order to compare breast milk with infant formula, intakes of contaminants and 
metals were calculated based on a body weight of 4.2 kg for a girl at 3 weeks of 
age (6) and an estimated consumption of 700 ml per day (7, 8). 
Assessment of risks and benefits 
This evaluation followed the principles of risk analysis and included hazard iden-
tification, hazard characterisation, exposure assessment and risk characterisation 
(11). Intakes of the contaminants arsenic, cadmium and lead were compared with 
the available tolerable intakes or reference points. Since contaminants are not 
essential nutrients, there are no insufficient intakes.  
 
For the essential minerals manganese, iron and copper, intakes were discussed in 
relation to recommended daily intakes and tolerable upper levels or tolerable daily 
intakes, when these values were available. While risk refers to health considera-
tions at upper levels of intakes, the benefit of these minerals was described in 
terms of a reduced risk of adverse health effects such as a state of deficiency. For 
example, both adverse health effects of insufficient intakes and adverse health 
effects of excessive intakes of each mineral were discussed under the heading 
“hazard identification”.  
 
The process of comparing risks and benefits of the minerals was based on an 
EFSA Scientific Opinion (12) However, literature reviews for identification and 
characterisation of hazard and reduced adverse effects were not as systematic and 
extensive as may be expected of a full risk benefit assessment.  
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Arsenic (As)  
Hazard identification  
Arsenic (As) is ubiquitous in the environment and is usually present in small 
amounts (1.5-2 mg/kg) in the bedrock. However, concentrations vary consider-
ably, and leakage from naturally occurring arsenic-rich minerals and sediments 
into groundwater is a growing worldwide public-health problem. In addition, there 
is increasing concern about elevated concentrations in locally grown food of plant 
origin, e.g., rice, maize and beans, as well as in root and leafy vegetables (13, 14). 
Arsenic occurs in the environment in both inorganic and organic forms. People are 
exposed to arsenic mainly through drinking water and food. In water, arsenic is 
present mainly in two inorganic forms, as arsenate (AsV) and arsenite (AsIII), 
which are the most toxic forms to humans. Within the EU there is a limit of 10 
μg/L of total arsenic in drinking water (15). Seafood may contain high concentra-
tions of arsenic, in the mg/kg range, but the forms present are mainly organic 
arsenicals, e.g. arsenobetaine and arsenosugars with low toxicity. In many count-
ries, arsenic-contaminated groundwater is used for irrigation of cereals and root 
and leafy vegetables. Rice seems to accumulate arsenic more efficiently compared 
to other commodities (16, 17). Levels up to 160 μg/kg of inorganic arsenic have 
also been detected in rice even from areas with groundwater not contaminated by 
arsenic (18). In root and leafy vegetables growing in an arsenic-contaminated 
area, inorganic arsenic represented 30-100 % and 70-100 % of the total arsenic, 
respectively (13). Several studies have revealed that inorganic arsenic is the pre-
dominant form of arsenic species in raw rice, ranging from 40 to 100 %, irrespec-
tive of rice varieties, types of rice, growing seasons or geographical variations 
(19).  
 
In 2009, EFSA concluded that inorganic arsenic exposures from food and water 
across 19 European countries have been estimated to range from 0.13 to 0.56 
μg/kg bw per day for average consumers, and from 0.37 to 1.22 μg/kg bw per day 
for 95th percentile consumers. The food categories “fish and seafood” and “cereal 
and cereal products” were the predominant contributors to overall total arsenic 
and rice, due to its high content of total arsenic, was the main contributor to the 
inorganic arsenic forms. High consumers of rice in Europe, such as certain ethnic 
groups, were estimated to have a daily dietary exposure of inorganic arsenic of 
about 1 μg/kg bw per day. EFSA also concluded that children under three years of 
age are the most exposed to inorganic arsenic, with exposure estimates in two 
different studies showing an inorganic arsenic intake ranging from 0.50 to 2.66 
μg/kg bw per day and that the dietary exposure to inorganic arsenic, including 
from rice-based foods, is in general estimated to be about 2 to 3 times that of 
adults. Milk intolerant children substituting rice-drink formulae were not included 
in these estimations (20). 
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Recently, four studies (3, 21-23) have been published where arsenic has been 
detected in rice-based infant food. The infant foods were obtained from national 
supermarket chains and from national pharmacies in Sweden, the United Kingdom 
and Spain. The Institute of Environmental Medicine (IMM), Karolinska Institutet, 
Stockholm, Sweden has analysed the levels of essential (iron, manganese, copper) 
and potentially toxic elements (arsenic, cadmium, lead) in infant formulae, gruels 
and porridges (3). Total arsenic concentrations of 30 μg/kg were found in the 
ready-to-eat rice-based gruels and porridges intended for infants from 4 months. 
Such an amount of arsenic will contribute to an exposure of as much as 1 μg/kg 
body weight per portion. In a study by Carbonell-Barrachina et al, concentrations 
of inorganic arsenic between 29 and 121 μg/kg product (mean 69 μg/kg), repre-
senting 64 % (range 36-89 %) of the total amount of arsenic, were found in thir-
teen samples of gluten-free infant rice intended for consumption from 4 months of 
age (21). In 17 different “baby rice” products studied by Meharg et al, the concen-
trations of inorganic arsenic ranged from 60 to 160 μg/kg product (mean 117 
μg/kg) (22) and in 15 different rice drinks the concentrations of inorganic arsenic 
ranged from 7.1 to 21 μg/L (mean concentration 13 μg/L) (23). In these studies 
the concentration of inorganic arsenic was on average 53 % (range 33-69 %) and 
67 % (range 55-86 %) of the total amount of arsenic, respectively. 
 
Rice-based gruels, porridges and drinks are often recommended for children who 
are lactose intolerant or have a diagnosis of cow’s milk protein allergy. A survey 
of total and inorganic arsenic in rice drinks was carried out by the Food Standards 
Agency (FSA) in the UK in 2008. The results of the FSA survey were in accord-
ance with the results obtained by Meharg et al (23). The concentrations of inorga-
nic arsenic ranged from 5 to 20 μg/L (mean concentration 13 μg/kg) and repre-
sented 56 % of the total arsenic concentration. Twelve of the 17 analysed rice 
drinks exceeded the EU total arsenic limit of 10 μg/L in drinking water. Because 
of a concern for high exposure to arsenic, the FSA advises parents not to give rice 
drinks to children younger than 4.5 years (24) and in Denmark the advice is not to 
give rice drinks to children younger than 3 years of age, especially to children 
below 10 kg in weight (25). 
 
Arsenic is not included in the Swedish National Monitoring Programme, but in 
2001 the NFA conducted a survey of arsenic, cadmium and lead in different types 
of rice available on the Swedish retail market. An average of 64 % (range 17-100 
%) of the total arsenic in rice in this survey consisted of inorganic arsenic. The 
concentrations of inorganic arsenic ranged from 40 to 190 μg/kg product “as sold” 
(mean concentration 111 μg/kg) (26).  
Hazard characterisation  
Inorganic arsenic is highly toxic and is classified as a human carcinogen (Group 
1) on the basis of sufficient epidemiological evidence for carcinogenicity in 
humans. Inorganic arsenic causes cancer in the urinary bladder, lung, skin and 
possibly also in the kidney and liver (27). Chronic exposure to inorganic arsenic is 
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also associated with a variety of non-cancerous effects in humans, such as 
peripheral vascular insufficiency, liver- and neurotoxicity, diabetes mellitus and 
hypertension (28, 29). However, all these effects have been studied in adults only.  
 
Arsenic readily passes through the placenta in humans (30) and recent studies 
indicate adverse effects on pregnancy outcomes, reduced birth weights and 
increased morbidity in infectious diseases during infancy (31-33).  
 
Very little arsenic is excreted in breast milk. Fängström et al (34) reported low 
concentrations of arsenic, at about 1 µg/L, in breast milk, despite high arsenic 
exposures via drinking water (up to 1,000 μg/L). Most of the arsenic in breast 
milk was in the inorganic arsenite form (AsIII). Low concentrations of arsenic 
have also been reported in Swedish breast milk (median 0.55 µg/L) (35).  
 
Recently published epidemiological studies show that children may be susceptible 
to inorganic arsenic. Early-life exposure to low levels of inorganic arsenic in 
drinking water (<50 µg/L) has been associated with increased infant mortality and 
morbidity, mainly due to impaired immune function (31-33).  
 
During foetal development and early childhood, the brain is particularly vulner-
able to arsenic. Experimental and epidemiological studies have shown associa-
tions between foetal exposure to arsenic and neurotoxicity and behavioural 
changes. Prenatal exposure of mice to lower doses of arsenic (50 µg/L) has been 
shown to result in learning deficits (36).  
 
Exposure to arsenic through drinking water has been associated with impaired 
cognitive function in school-aged children in a few cross-sectional studies (37, 
38). In those studies children’s intellectual function was reduced in relation to 
exposure to arsenic in drinking water, after adjustment for socio-demographic 
covariates and water manganese. Children with water arsenic levels above 50 
μg/L achieved significantly lower performance and full-scale scores than children 
with water arsenic levels below 5 μg/L. Adverse effects of arsenic exposure on the 
IQ in pre-school girls have also been found in a longitudinal study (39).  
 
Data suggests that exposure to arsenic during early life or in utero may result in an 
increase in liver and lung cancer mortality as well as an increase in respiratory 
disease in later life (40, 41). The long-term mortality impact of early-life exposure 
has been investigated in the city of Antofagasta in Northern Chile. This city has 
had a distinct period of very high arsenic exposure that began in 1958 and lasted 
until 1971, when an arsenic removal plant was installed. The investigators com-
pared cancer mortality rates under the age of 20 years with those of an unexposed 
region, focusing on children that were born during (1958-1970; ~ 870 µg/L), 
shortly before (1950-1957; ~ 90 µg/L) or after (1971-1981; < 100 µg/L) the high 
exposure period. The investigators found that those exposed to high arsenic con-
centrations, such as young children, had an increased liver cancer mortality with a 
relative risk (RR) of 10.6 (95 % CI, RR=2.9–39.2) while mortality from the most 
common childhood cancers, leukemia and brain cancer, was not increased in the 
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exposed population (40). Mortality from lung cancer and bronchiectasis diseases 
among adults 30-49 years old in Antofagasta in relation to early-life exposure has 
also been investigated. The results showed a significantly increased standardised 
mortality ratio (SMR) for lung cancer (SMR = 7.0, 95 % CI, 5.4-8.9) and bronch-
iectasis (SMR = 12.4, 95 % CI, 3.3-31.7) for those born just before the high-
exposure period (1950-1957) and exposed in early childhood. For those born 
during the high-exposure period (1958-1970) with probable exposure in utero and 
early childhood, the SMR for lung cancer was 6.1 (95 % CI, 3.5-9.9) and the SMR 
for bronchiectasis was 46.2 (95 % CI, 21.1-87.7) (41).  
 
Humans metabolise inorganic arsenic via methylation to methylarsonic acid 
(MMA) and dimethylarsinic (DMA), which are both excreted in the urine. The 
formation of DMA metabolite can be considered a detoxification mechanism, 
whereas the MMA fraction is associated with an increased risk of adverse health 
effects (42-44).  
 
Exposure assessment 
Estimated intakes for all individual products are detailed in Appendix II. Median 
arsenic concentrations in the different ready-to-eat products are summarised in 
Table 1. Product categories have been divided into two main groups depending on 
whether the consumption scenario used for the products in a given category 
covers a whole day (Table 2) or a single portion (Table 3).  
 
In the exposure assessment, it is assumed that all arsenic in the different products 
is in the inorganic form. As shown in Table 1, the highest arsenic concentrations 
in the investigated ready-to-eat products were found in the rice-based gruels and 
in the rice-based porridges, and ranged from 8.4 to 19 µg/kg (median 17 µg/kg) 
and from 4 to 41 µg/kg (median 23 µg/kg), respectively. The arsenic concentra-
tions were much lower in the gruels and porridges based on oat, wheat, rye, spelt 
or corn and ranged from 0.65 to 6.5 µg/kg. 
 
The arsenic concentrations in the ready-to-eat infant formulae and follow-on 
formulae ranged from 0.54 to 4.6 µg/kg (Table 1). Arsenic concentrations in rice 
drinks were 18 and 30 µg/kg while in oat and soya drinks, arsenic concentrations 
were ≤ 2 µg/kg. 
 
The estimated daily median intakes ranged between 0.05 and 0.12 µg/kg bw while 
the estimated daily intakes for individual products ranged between 0.02 and 0.86 
µg/kg bw (Table 2). The highest estimated daily intake of 0.86 µg/kg bw was 
from the FSMP product Minimax enteral formula for children, which contained 
11 µg/kg arsenic (see Appendix II). According to the labeling,  this product con-
tains 11.8 g carbohydrate per 100 mL, including rice flour, maltodextrin and lac-
tose. The estimated intake, as a reference, from breast milk was 0.09 µg/kg bw 
(Table 2). For the product categories in Table 3, the estimated intakes per portion 
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range between 0.01 and 0.49 µg/kg bw, and the estimated intakes per portion  
for individual products range between 0.007 and 0.89 µg/kg bw. The estimated 
intakes per portion for FSMP products when used as partial feeding (range bet-
ween 0.02 and 0.05 µg/kg bw) were lower compared to the other product catego-
ries. The estimated intake from rice drinks, assuming a consumption of 100 ml, 
was 0.19 and 0.31 µg/kg bw (Table 3) while the estimated intake of arsenic from 
the soya and oat drinks was ≤ 0.02 µg/kg bw. 
 
Table 1. Summary of median concentrations and (range) of total arsenic in ready-
to-eat* baby food. 
Product category No. of  
products 
Arsenic 
concentration  
µg/kg 
Infant formula  9 0.77 (0.54-0.90) 
Follow-on formula  4 0.88 (0.71-4.6) 
FSMP as sole source of nutrition 21 0.90 (0.49-11) 
FSMP as partial feeding 6 1.7 (0.68-3.7) 
Gruel oat-, wheat-, rye- or corn-based 10 0.67 (0.54-1.5) 
rice-based 4 17 (8.4-19) 
Porridge oat-, wheat- or spelt-based 16 1.7 (0.86-6.5) 
rice-based 10 23 (4.0-41) 
 
Foodstuffs for normal consumption 
Soya drink 4 0.96 (0.81-1.7) 
Oat drink 3 0.88, 1.0, 2.0 
Rice drink 2 18, 30 
Porridge/gruel oat-based 2 0.53, 0.61 
rice-based 1 32 
*Products were analysed on an “as sold basis” and the results for powders are converted into ready-to-eat 
products by using dilution factors.  
 
 
Table 2. Summary of estimated daily intakes of arsenic expressed as µg/day and 
µg/kg bw/day from infant formula, follow-on formula, FSMP as sole source of 
nutrition and FSMP as partial nutrition. 
Product category Age 
(months) 
No. of  
products 
Median intake and (range) 
µg/day µg/kg bw/day 
Infant formula  0-4 9 0.55 (0.38-0.63) 0.12 (0.08-0.15) 
Follow-on formula  6-8 4 0.80 (0.64-2.3) 0.10 (0.08-0.27) 
FSMP as sole source of 
nutrition 
0-12 21 0.57 (0.23-6.7) 0.12 (0.06-0.86) 
FSMP as partial feedinga 0-12 3 0.20, 0.21, 1.3 0.02, 0.05, 0.17 
Breast milkb 3 weeks - 0.38 0.09 
aThe intake of these products was calculated as daily intakes in accordance with calculations for intakes of 
follow-on formulae. bArsenic concentration (median=0.55 µg/L (SD=0.15)) in 64 samples of human milk 
collected in Sweden (35). An infant 3 weeks old, weighing 4.2 kg and consuming of 700 ml breast milk per 
day was assumed.
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Table 3. Summary of estimated median intakes of arsenic expressed as µg/portion 
and as µg/kg bw per consumed portion from gruel, porridge, FSMP as partial 
feeding (51 - 237g) and from soya, oat and rice drinks (100 ml) 
Product category Age 
(months) 
No. of  
produ
cts 
Median intake and (range) 
µg/portion µg/kg 
bw/portion 
Gruel  oat-, wheat-
, rye- or 
corn-based 
6 – 12 10 0.16 (0.12-0.35) 0.02 (0.02-0.05) 
rice-based 4 4.0 (2.0-4.5) 0.49 (0.26-0.58) 
Porridge oat-, wheat- 
or spelt-
based 
4 – 12 16 0.28 (0.12-0.77) 0.04 (0.02-0.09) 
rice-based 10 2.6 (0.66-5.9)  0.37 (0.10-0.89) 
FSMP as partial feeding 12 3 0.18, 0.40, 0.47 0.02, 0.04, 0.05 
 
Foodstuffs for normal consumption 
Soya drink 12 4 0.10 (0.08-0.17) 0.01 (0.01-0.02) 
Oat drink 12 3 0.09, 0.10, 0.20 0.01, 0.01, 0.02 
Rice drink 12 2 1.8, 3.0 0.19, 0.31 
Porridge/ 
gruel  
oat-based  12 2 0.07, 0.08 0.007, 0.008 
rice-based 12 1 4.2 0.43 
 
Risk characterisation 
The World Health Organization (WHO) has classified arsenic as a human car-
cinogen (27, 45). The US National Research Council (NRC) has performed a risk 
assessment of arsenic in drinking water and estimated that the lifetime cancer 
risks for lung and bladder cancer is 3 to 4 cases per 1,000 individuals at a drinking 
water concentration of 10 µg/L (1L/day), which is the permissible level in drink-
ing water within the EU. This estimation greatly exceeds the tolerable limit of one 
extra case of cancer per 100,000 individuals (29).  
 
The EFSA Panel on Contaminants in the Food Chain (CONTAM Panel) model- 
led the dose-response data from key epidemiological studies and estimated bench-
mark doses (BMDs) corresponding to a benchmark response of 1 % extra risk 
(BMD01). Resulting BMDL01 (the lower 95
th confidence limit of the BMDL01) 
values varied between 0.3 and 8 µg/kg body weight per day for cancers of the 
lung, skin and bladder, as well as skin lesions (20). 
 
In the seventy-second meeting of the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA) in 2010, a BMDL of 3.0 μg/kg body weight per day (range: 2-
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7 μg/kg body weight per day) was proposed for inorganic arsenic. This BMDL 
corresponded to a 0.5 % increased incidence of lung cancer determined from 
epidemiological studies (46). The JECFA: s provisional tolerable weekly intake 
(PTWI) for inorganic arsenic of 15 μg/kg body weight/week (equivalent to 2.1 
μg/kg body weight/day) from 1988 is in a region comparable to the BMDL values 
identified by EFSA and JECFA, respectively. Thus, EFSA and JECFA considered 
that a PTWI of 15 μg/kg body weight was no longer appropriate as protection 
against adverse health effects. Consequently, JECFA withdrew its previous PTWI 
(46). It should be noted, however, that all risk assessments mentioned above are 
based on chronic effects, especially cancer, in adults with long-term exposure to 
arsenic. 
 
In the present investigation, arsenic concentrations in the ready-to-eat baby food 
ranged from 0.5 to 41 µg/kg. The highest arsenic concentrations were found in the 
porridge products based on wholegrain rice (100 %), (31 and 41 µg/kg) and in 
porridge products based on rice flour (28 and 29 µg/kg). However, in the porrid-
ges based on rice or oats/wheat flour with added fruits or vegetables the arsenic 
concentrations ranged from 4.6 to 23 µg/kg (Appendix II). In two gruel products 
based on 89 % and 84 % rice flour, the arsenic concentrations were 17.6 and 16.5 
µg/kg, respectively. The lowest arsenic concentrations were found in corn-based 
gruels (range 0.5-1.5 µg/kg).  
 
The estimated intake of arsenic per portion from the investigated rice-based 
gruels, which are intended for infants from 6 months of age, was 0.49 µg/kg body 
weight, while for rice-based porridges intended for infants from 4 months of age 
was 0.37 g/kg body weight per portion. This estimated intake is higher than the 
intake by adults consuming 1 L drinking water containing arsenic at the EU 
standard value of 10 μg/L (0.17 µg/kg body weight per day). It should be emphas-
ised that even this relatively low level of exposure is associated with an increased 
risk of cancer. The lifetime cancer risks of lung and bladder cancer were estimated 
to be 3 to 4 cases per 1000 individuals at a drinking water concentration of 10 
µg/L (29).  
 
Among the FSMP used as a sole source of nutrition, an enteral formula (Minimax 
enteral formula for children) for infants from 6 months of age for dietary manage-
ment of disease-related malnutrition contained the highest concentration of arsenic 
(11 µg/kg). The estimated daily intake of arsenic for infants consuming this for-
mula is 0.86 µg/kg body weight.  
 
The concentrations of arsenic in the two investigated rice drinks were 18 and 30 
μg/L. Both values exceeded the EU standard value of 10 μg/L in drinking water. 
The estimated intake of arsenic from the rice-based drinks, assuming a consump-
tion of 100 ml, was 0.19 and 0.31 µg/kg body weight (Table 3). If, however, the 
intake is based on the NFA recommendation for children of 500 ml milk/day, the 
intake of arsenic would amount to 1.6 µg/kg body weight.  
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Discussion 
Several studies have shown that rice contains elevated concentrations of arsenic. 
This is due to its efficiency in accumulating arsenic into the grains compared to 
other cereal crops. Inorganic arsenic is the predominant form of arsenic in rice. 
(19). In the present investigation the highest arsenic concentrations in the ready-
to-eat products were found in the porridges based on wholegrain rice (up to 41 
µg/kg) and on rice flour (up to 29 µg/kg) as well as in rice drinks (up to 30 µg/ 
kg). Similar results have previously been reported for infant foods purchased in 
Sweden, the United Kingdom and Spain. 
 
The estimated intake of arsenic from a single portion of 51 g of rice-based 
porridge intended for infants from 4 months of age is 2.1 μg arsenic, i.e. 0.32 
μg/kg body weight. The estimated intake of arsenic from 100 ml of the rice-based 
drinks is 3.0 μg arsenic, i.e. 0.31 µg/kg body weight. These estimated intakes, 
assumed from a single portion of 51 g or 100 ml consumption per day, are higher 
than the intake by adults consuming 1 L drinking water containing inorganic 
arsenic at the EU  parametric value (limit value)  of 10 μg/L (0.17 µg/kg body 
weight per day). Even this relatively low level of exposure via drinking water is 
associated with an increased risk of lung and bladder cancer (29). 
 
Rice drinks are an alternative for children who are lactose intolerant or who have 
a diagnosis of cow´s milk protein allergy. Formulas based on rice protein have 
also become available for infants with cow´s milk protein allergy  (47). In the 
present investigation, however, no rice-based formulae or follow-on formulae 
were analysed, but in a recent study inorganic arsenic levels of 12 µg/kg were 
found in rice-based formula (48).  
 
Levels of arsenic were much lower in the gruels and porridges based on oat, 
wheat, rye, spelt or corn. It should be noted, however, that the contribution from 
water to the total daily dietary intake of arsenic could be even higher. In Sweden, 
arsenic concentrations up to 260 μg/L have been detected in private drinking wells 
with a 95th percentile of 10.14 μg/L (49).  
 
The estimated dietary exposures to arsenic of infants from single portions of rice-
based food were within the range of BMDL01 values (0.3 to 8 μg/kg bw per day). 
Cancerous and non-cancerous effects in adults have been identified in this range 
due to long-term exposures (20), but in infants there are no reference points at 
present. Children, however, seem to be very susceptible to toxic effects of inorga-
nic arsenic. Early-life exposure to low levels of inorganic arsenic in drinking 
water has been associated with increased infant morbidity and mortality, as well 
as impaired child development (31, 37-39, 50). Moreover, data suggests that 
exposure to arsenic during early-life or in utero may produce an increase in liver 
and lung cancer mortality as well as an increase in respiratory disease in later life 
(40, 41). More research on the association between arsenic exposure during early 
childhood and subsequent adverse health effects later in life, including develop-
ment of cancer, is needed.   
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Conclusion 
The present investigation shows that rice-based infant food purchased in Sweden 
could be a significant exposure source of inorganic arsenic. The estimated intakes 
per portion from those products are close to the BMDL01 value identified by 
EFSA.The arsenic intake can be even higher if rice-based infant food is prepared 
with water containing arsenic. The investigation also shows that arsenic levels 
exceeding the EU standard value of 10 μg/L in drinking water can be found in 
rice-based drinks. The low content of arsenic in breast milk is an important argu-
ment for recommending breast-feeding.   
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Cadmium (Cd) 
Hazard identification 
Cadmium (Cd) is a heavy metal that occurs naturally and as an environmental 
contaminant. Non-ferrous metal mining and refining, manufacture and application 
of phosphate fertilizers, fossil fuel combustion, and waste incineration (e.g. 
sewage sludge) and disposal are the main anthropogenic sources of cadmium in 
the environment (51).  
 
For non-smokers, food is the major source of cadmium exposure (52). The highest 
cadmium concentrations can  be found in offal products, such as liver and kidney, 
certain wild mushrooms, and shellfish (53, 54). Foods from plants generally con-
tain higher concentrations of cadmium than meat, egg, milk and dairy products, 
and fish muscle (55). He and Singh (56) reported that, for plants grown in the 
same soil, accumulation of cadmium decreased in the order: leafy vegetables > 
root vegetables > grain crops. Cereal products and potatoes contribute most to the 
dietary cadmium exposure of the general Swedish population (57).  
Kinetics 
Generally speaking, the absorption of cadmium following oral exposure depends 
on physiologic status (age; body stores of iron, calcium, and zinc; pregnancy 
history etc) and on the presence and levels of ions and other dietary components 
ingested together with cadmium. Individuals with low body stores of iron may 
have a higher absorption than those with adequate iron stores (51). This is 
probably due to up-regulation of divalent metal transporter 1, which has a high 
affinity for cadmium (58). The absorption of cadmium from the diet is about  
1-10 % for adults (men and individuals with adequate iron status are probably in 
the lower range of this interval while individuals with low iron stores and iron 
deficencies are in the higer range) (51, 59). Absorption appears to be higher in 
newborns and infants, and in contrast to adults, independent of iron status (59, 
60). The type of diet may also influence cadmium uptake: for example it has been 
observed that the bioavailability of cadmium is lower for a diet that includes 
shellfish once a week or more, compared to a diet low in shellfish (61).  
 
The highest concentrations of cadmium can be found in the liver and kidney. For 
chronic dietary exposure, the kidney constitutes the target organ where cadmium 
accumulates, with a biological half-life of around 10-30 years (55). The cadmium 
concentration in the kidney is proportional to the concentration in urine. Because 
of this, the urinary cadmium concentration can be used as a marker of long-term 
exposure (62). Cadmium is also excreted in the faeces (51). 
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Health effects 
The sensitive target organs of chronic cadmium toxicity are the kidneys and bones 
following oral exposure, and the kidneys and lungs following inhalation exposure. 
Other effects that have been observed in humans and/or animals include reprodu-
cetive toxicity, hepatic effects, haematological effects, and immunological effects 
(51). There are also studies that suggest a role for dietary cadmium in cancer 
development, and an association between cadmium and increased mortality (55, 
63-65). The International Agency for Research on Cancer (IARC) has classified 
cadmium as a human carcinogen (group I) on the basis of sufficient evidence for 
carcinogenicity in both humans and experimental animals (66). According to the 
IARC: “Cadmium and cadmium compounds cause cancer of the lung. Also, 
positive associations have been observed between exposure to cadmium and 
cadmium compounds and cancer of the kidney and of the prostate” (67). 
 
In humans, the effects of cadmium have mostly been studied in adults. Cadmium-
induced renal damage is characterised by proximal tubular reabsorptive dysfunc-
tion. The earliest signs of tubular toxicity are increased excretion of low-molecul-
ar weight proteins, such as β2-microglobulin (β2-M) and α1-microglobulin (α1-
M), also called protein HC, and retinol-binding protein (RBP). The increased 
excretion of such low-molecular weight proteins is an accepted indicator of kid-
ney damage and regarded as an adverse effect in adults (55). After prolonged 
and/or high exposure the tubular injury may progress to glomerular damage with 
decreased glomerular filtration rate, and eventually to renal failure.  
 
Cadmium can also cause bone damage, either via a direct effect on bone tissue or 
indirectly as a result of renal dysfunction. While it is well known that high cad-
mium exposure can cause bone damage, the relationship between low cadmium 
exposure and increased risk of osteoporosis and fractures in adults is now more 
frequently discussed (68-70).  
 
Information regarding potential effects of cadmium exposure that are relevant in 
an early human life context are quite limited. Environmental exposure to cadmium 
is known to induce oxidative stress in adults, and recent studies suggest that early-
life exposure to cadmium via breast milk may also induce oxidative stress (71).  
A few small cross-sectional epidemiological studies indicate an adverse effect of 
cadmium exposure on child development, supported by experimental studies 
showing cadmium-induced neurotoxicity (59). A number of quite small cross-
sectional studies have also indicated that cadmium exposure may have a negative 
effect on foetal growth (59). Recently, in a large, population-based, longitudinal 
mother-child cohort in Bangladesh (n = 1,616) an association between maternal 
cadmium exposure and and birth size in girls (but not in boys) was observed (72). 
Even more recently, based on data from the same cohort (n = 1,305), an associa-
tion between early-life cadmium exposure and lower child intelligence scores is 
argued (73). 
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Hazard characterisation 
As discussed above, some data exists regarding the potential effects of cadmium 
exposure in an early-life context, for example observed effects on foetal growth, 
which may be considered as critical effects in assessments that focus on infants 
and children. However, reliable dose-response relationships needed for a quanti-
tative health risk assessment are not available. Early markers of kidney damage 
are instead used as the critical endpoint in the present assessment, which is in line 
with traditional cadmium risk assessments. It should be noted, however, that the 
use of such critical endpoints implies a long-term exposure context, and does not 
account for the potential health effects that might be relevant for early-life expo-
sure.  
 
Dose-response assessment using a variety of early markers of kidney damage has 
identified urinary cadmium reference points for early kidney effects in adults, as a 
result of long-term exposure, between 0.5 and 3 μg Cd/g creatinine (55).  
 
In 2009, EFSA performed a risk assessment of cadmium (58) and established a 
tolerable weekly intake (TWI) of 2.5 micrograms cadmium per kilo body weight. 
Increased excretion of the kidney marker β2-M was used as the critical endpoint 
in this assessment. A meta-analysis of epidemiological data was performed using 
the benchmark dose (BMD) method. Lower confidence bounds on the BMD 
(BMDLs) in the range of 4-6 μg Cd/g creatinine were obtained, depending on 
choices made in dose-response modelling. The lowest BMDL value of 4 μg Cd/g 
creatinine was selected as the reference point (RP): it is the dose resulting in a 5 % 
increased risk of adverse levels of β2-M, where “adverse levels” are defined as 
β2-M values above the 95th percentile. To account for the fact that data on group 
means were used instead of individual observations an uncertainty factor of 4 was 
applied to the RP (4 μg Cd/g creatinine), which resulted in a critical concentration 
in urine of 1 μg Cd/g creatinine. 
 
The TWI is developed by toxicokinetic modelling using data on 680 Swedish 
never-smoking women (56-70 years of age) living in the town of Uppsala and part 
of the Swedish Mammography Cohort (74). The urinary cadmium concentration 
resulting from a long-term dietary cadmium intake of 2.5 μg/kg bw per week (the 
TWI) was estimated to be lower than the critical concentration of 1 μg Cd/g crea-
tinine for 95 % of the studied population. EFSA considered the risk of adverse 
effects on the kidney function at an individual level, associated with the dietary 
exposures across Europe, to be very low, but concluded that the current exposure 
to cadmium at the population level should be reduced (58). 
 
Using the same epidemiological dataset, the JECFA established a provisional 
tolerable monthly intake of 25 μg Cd/kg bw (75). If expressed on a weekly basis, 
this value is about twice as high as the EFSA TWI. As a consequence, EFSA was 
asked by the European Commission to confirm their TWI. A number of method-
logical differences in the derivation of the respective guidance values were identi-
fied. Following this evaluation, EFSA concluded that the approach they had 
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adopted was appropriate, and their TWI (2.5 μg/kg bw/week) was maintained in 
order to ensure a high level of consumer protection (76).  
 
Investigations indicate that a critical cadmium concentration in urine in the same 
range as that established by EFSA (1 μg Cd/g creatinine)  also appears to be rele-
vant with respect to an increased risk of osteoporosis and fractures (0.5-1 μg Cd/g 
creatinine) (59, 77). The TWI of 2.5 μg Cd/kg bw/week (corresponding to 1 μg 
Cd/g creatinine) expressed on daily basis, i.e. 0.36 μg Cd/kg bw/day (TDI equi-
vialent), was used as a reference in this assessment, and as pointed out before, this 
accounts for the long-term exposure, but it does not account for potential effects 
relevant in a early-life context. This introduces an uncertainty that needs to be 
considered. 
Exposure assessment 
Estimated intakes for all individual products are presented in Appendix III. 
Summary results for different product categories are presented in Tables 4 and 5. 
Product categories have been divided into two main groups depending on whether 
the consumption scenario used for the products in a given category covers a whole 
day (Table 4) or a single portion (Table 5). 
 
For product categories in Table 4, estimated cadmium intakes for individual 
products range between 0.01 and 0.20 µg/kg bw/day. One FSMP product used as 
the sole source of nutrition is associated with a cadmium intake higher than 0.1 
µg/kg bw/day (see Appendix III). An estimate of the intake from breast milk is 
given as a reference in Table 4.  
 
In Table 5, estimated cadmium intakes for individual products range between 
0.001 and 0.19 µg/kg bw/day. Two gruel products, three porridge products, and 
one product in the category foodstuffs for normal consumption are associated with 
intakes higher than 0.1 µg/kg bw/day (see Appendix II). 
 
Table 4. Summary of estimated intakes of cadmium (µg/kg bw/day). 
Product category Age 
(months) 
N Intakea 
 
Infant formula 0-4 9 0.04 (0.01-0.08) 
Follow-on formula 6-8 4 0.03 (0.01-0.04) 
FSMP as sole source of 
nutrition 
0-12 21 0.03 (0.01-0.2) 
FSMP as partial feeding 0-12 3 0.01, 0.02, 0.04 
Breast milk 3 weeks 90 0.02b 
aMedian (range).  
bA cadmium concentration in breast milk of 0.1µg/kg was used (a composite sample of human 
milk collected w 3 post-partum from 30 volunteers during 2008, 2009 and 2010; n = 90 samples 
were pooled in the analysis). An infant weighing 4.2 kg (weight used for infants 0-4 months) and 
consuming 700 ml breast milk per day was assumed. 
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Table 5. Summary of estimated intakes of cadmium (µg/kg bw/portion). 
Product category Age 
(months) 
N Intakea 
 
Gruel 6-12 14 0.03 (0.003-0.19) 
Porridge 4-12 26 0.05 (0.002-0.16) 
FSMP as partial feeding 12 3 0.01, 0.02, 0.04 
Foodstuffs for normal 
consumption 
12 12 0.03 (0.001-0.14) 
aMedian (range). 
 
Contribution from drinking water 
The median cadmium concentration in municipal drinking water in Sweden is 
below 0.01 µg/l based on analyses from approximately 1,500 water purification 
plants between 2008 and 2011 (4,002 analyses in total). Combining a value of 
0.01 µg/l with a consumption of 630 ml water (used for preparing 700 ml infant 
formula) by a child with a body weight of 4.2 kg (about 3 weeks old) results in a 
cadmium intake of 0.0015 µg /kg bw/day. 
Risk characterisation 
Summary results of estimated cadmium intakes expressed in terms of a percentage 
of the TDI (2.5 µg/kg bw/week/7 ≈ 0.36 µg/kg bw/day) are given Table 6, and 
summary results of estimated intakes expressed in terms of the number of portions 
required to reach the TDI are given in Table 7. Product-specific information is 
given in Appendix II.  
 
For product categories in Table 6, the estimated median exposure to cadmium is 
about 10 % of the TDI. Exposures higher than 20 % of TDI are observed for one 
infant formula and three FSMP products used as the sole source of nutrition. The 
highest estimated cadmium exposure was around 50 % of the TDI (FSMP product 
used as the sole source of nutrition).  
 
For product categories in Table 7, the estimated median number of portions to 
reach the TDI for cadmium is around 10. The number of portions to reach the TDI 
is less than 6 for three gruel products, seven porridge products, and three food-
stuffs for normal consumption. 
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Table 6. Summary of estimated intakes of cadmium expressed in terms of a 
percentage of the TDI of 0.36 μg/kg bw/day. 
Product category Age 
(months) 
N % of TDIa More than 20 
% of TDIb 
Infant formula 0-4 9 11 (3-21) 1 
Follow-on formula 6-8 4 8 (3-11) 0 
FSMP as sole source 
of nutrition 
0-12 21 9 (4-55) 3 
FSMP as partial 
feeding 
0-12 3 4, 7, 12 0 
aMedian (range).  
bThe number of products associated with exposure that are higher than 20 % of the TDI. 
 
 
 
Table 7. Summary of estimated intakes of cadmium expressed in terms of the 
number of portions required to reach the TDI of 0.36 μg/kg bw/day. 
Product category Age 
(months) 
N No. of portions 
to reach TDIa 
Less than 6 
portions to 
reach TDIb 
Gruel products 6-12 14 12 (2-105) 3 
Porridge 4-12 26 7 (2-175) 7 
FSMP as partial 
feeding 
12 3 9, 16,  67 0 
 Foodstuffs for normal 
consumption 
12 12 12 (3-442) 3 
aMedian (range). 
bThe number of products for which the no. of portions to reach the TDI is less than 6. 
Discussion 
For cadmium, there is a margin to the TDI for all products. For most products the 
estimated exposure is a factor 5 below the TDI, or 6 portions or more are required 
to reach the TDI. For a few gruel products, porridge products and other products, 
however, the number of portions needed to reach the TDI can be regarded to be 
too low if consumed on a long-term basis (i.e. 2-3).  
 
Cadmium uptake may be higher in infants and children than in adults, and the TDI 
only considers the life-long exposure context. It may be debated if and how such 
uncertainties should be accounted for, i.e. the relevance of considering an extra 
uncertainty factor and in that case its size, when using the present TDI. The identi-
fication of products (Tables 6 and 7) that contribute with more than 20 % of the 
TDI, or products for which the number of portions to reach the TDI is less than 6, 
is not used to indicate a health concern. However, it highlights that for some 
investigated products, the estimated exposure may potentially be higher than 
Livsmedelsverkets rapportserie nr 1/2013                                                                             33 
desired if account is taken of possible limitations in the TDI with respect to the 
early-life context that this assessment concerns. 
Conclusion 
In general, estimated intakes of cadmium appear not to be of high concern with 
respect to long-term exposure and the health context the TDI is based on. How-
ever, a number of uncertainties exist regarding the level of protection when using 
the EFSA-derived TDI for infants and children, which may require the considera-
tion of an extra margin to the TDI. 
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Lead (Pb) 
Hazard identification 
Lead (Pb) is a heavy metal that occurs naturally and, to a greater extent, as an 
environmental contaminant. Anthropogenic sources of lead include the mining 
and smelting of ore, manufacture of products containing lead, combustion of coal 
and oil, and waste incineration. Many anthropogenic sources of lead, most notably 
leaded gasoline, lead-based paint, lead solder in food cans, lead-arsenate pesti-
cides, and shot and sinkers, have been eliminated or strictly regulated due to 
lead’s persistence and toxicity (78). 
 
Human exposure to lead can occur via food, water, air, soil and dust or dirt. Food 
is the major source of exposure to lead (79). The highest lead concentrations can 
be found in liver, kidney and meat from game, certain wild mushrooms, and 
shellfish (53, 54, 79). Basic food products such as fish, meat, cereals, vegetables 
and dairy products  generally have low levels. EFSA concluded that cereal pro-
ducts contributed most to the dietary lead exposure of the general European 
population (79). Non-dietary exposure to lead is likely to be of minor importance 
for the general adult population in the EU, while for children, house dust and soil 
can be an important source of exposure to lead. 
Kinetics 
The extent and rate of absorption of lead through the gastrointestinal tract depend 
on characteristics of the individual (e.g. age, fasting state, nutritional calcium and 
iron status and pregnancy etc.), the amount of lead ingested  and on physicoche-
mical characteristics of the ingested lead (e.g. particle size, mineralogy, solubility, 
and lead species) (78). The toxicokinetics of lead in children appear to be similar 
to those in adults, with the exception of a higher absorption of ingested lead in 
children. Children can absorb 40-50 % of an oral dose of water-soluble lead com-
pared to 3-10 % for adults. Children who are iron or calcium deficient have higher 
blood lead concentrations than children who are iron or calcium replete. Absorp-
tion of lead may increase during pregnancy (78). 
 
The distribution of lead in the body is route independent (78). The principal 
vehicle for the transport of lead from the intestine to the various body tissues is 
the red blood cells, in which lead is bound primarily to haemoglobin (80). Lead in 
blood is considered to be the best indicator of the concentration of lead in soft 
tissues, reflecting recent and, to some extent, past exposure. The half-life of lead 
in blood and soft tissues is about 20-40 days, whereas in the skeletal pool the half-
life of lead is approximately 10-30 years (78-80). In adults, about 80-95 % of the 
total body burden of lead is found in the bones, compared with about 73 % in 
children (78, 80). Lead is excreted primarily in urine and faeces regardless of the 
route of exposure (78). 
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Lead can be transferred from the mother to the foetus. The maternal/foetal blood 
lead concentration ratio, indicated from cord blood lead measurements, is approxi-
mately 0.9. Maternal lead can also be transferred to infants during breastfeeding. 
Studies have reported lead concentrations in maternal blood and breast milk. In 
general, these studies indicate that breast milk/maternal blood concentration ratios 
are < 0.1, although values of 0.9 have been reported (78). 
Health effects 
The most sensitive targets for lead toxicity are the developing nervous system, the 
haematological and cardiovascular systems, and the kidneys. However, due to the 
multi-modes of action of lead in biological systems, lead could potentially affect 
any system or organs in the body (78). IARC classified inorganic lead as probably 
carcinogenic to humans (Group 2A, evidence inadequate in humans, sufficient in 
animals) (81). According to EFSA: “Overall, extensive experimental evidence 
shows that various water-soluble and water-insoluble lead compounds can induce 
kidney tumours in rodents. In addition, one study showed that renal tumours can 
occur in the absence of lead-induced nephropathy. It is also noteworthy that the 
induction of brain gliomas, which are rarely spontaneous, occurred after oral 
exposure to lead in rats. Lead proved to be an effective renal tumour carcinogen/ 
promoter in rats and mice exposed to various organic renal carcinogens.” (78). 
 
Signs of acute lead intoxication include dullness, restlessness, irritability, poor 
attention span, headaches, muscle tremor, abdominal cramps, kidney damage, 
hallucinations, loss of memory, encephalopathy. Signs of chronic lead toxicity 
include tiredness, sleeplessness, irritability, headaches, joint pain, and gastro-
intestinal symptoms (80).  
 
Lead interferes with the activity of several of the enzymes involved in the bio-
synthesis of haem. The anaemia induced by lead is primarily the result of both 
inhibition of haem synthesis and shortening of erythrocyte lifespan (78). 
According to WHO (80) anaemia occurs at blood lead levels in excess of 40 
μg/100 ml in children and 50 μg/100 ml in adults. 
 
In humans, the central nervous system is the main target organ for lead toxicity. 
One of the major concerns regarding lead toxicity is the cognitive and neurobe-
havioural deficits that are observed in children exposed to lead. There is consider-
able evidence demonstrating that the developing brain is more vulnerable to the 
neurotoxicity of lead than the mature brain. In children, elevated blood lead levels 
are associated with a reduced IQ score and reduced cognitive functions up to at 
least seven years of age. There is some evidence that this subsequently in adults 
leads to a reduced grey matter volume in the brain, especially in the prefrontal 
cortex. In a number of studies in adults an association between blood lead concen-
tration, elevated systolic blood pressure and chronic kidney disease has been 
identified at relatively low blood lead levels (79). 
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Hazard characterisation 
In 2010, EFSA performed a risk assessment of lead (79). Neurotoxicity, cardio-
vascular effects and renal toxicity were identified as the critical effects. The 
developing brain was identified as the most vulnerable organ for lead exposure. 
Epidemiological data on the three endpoints was analysed using the benchmark 
dose (BMD) method.  
 
EFSA (79) did not regard it to be appropriate to derive health-based guidance 
values for lead (e.g. tolerable weekly intake), since the epidemiological data pro-
vided little or no evidence for the existence of thresholds for the critical endpoints. 
Because of this EFSA derived reference points and calculated approximate 
margins of exposure. The arguments behind the statements of EFSA (79) and 
FAO/WHO (75) regarding the non-existence of thresholds for lead toxicity are not 
fully clear. However, EFSA recommendations include that further efforts should 
be made to increase the understanding of the lead dose-response relationship. 
Developmental neurotoxicity  
Lanphear et al (82) conducted a detailed analysis of pooled data from seven 
international cohort studies and reported an inverse relationship between the blood 
lead concentration and the concomitant IQ score after adjustment for confounders. 
This was based on data on children of ages between 4 years and 10 months, and 7 
years, in six cohorts, and at ages between 5 years and 10 years in one cohort. 
EFSA used the same data on 1,333 children in their analysis (79). EFSA per-
formed the BMD calculations based on standard multiple regression models (83). 
As the dependent variable the full IQ score was used. Covariates included study 
site, birth weight, HOME score, maternal education and maternal IQ, as these 
variables were found to be statistically significant in the original analysis (82). 
The BMD analysis was done using each of the four blood lead exposure variables 
available: concurrent lead, peak lead, life time average lead and early childhood 
lead.The BMDL (the lower 95th confidence limit on the BMD) corresponding to a 
1% change in full scale IQ score (i.e. a decrease in IQ by 1 point on the full scale 
IQ score) was estimated from the data. The benchmark response of 1 % was 
selected because such a change was within the range of observable values and 
could have significant consequences for human health on a population basis (79, 
84). Besides the consideration of different dose measures, different dose-response 
models (a linear, logarithmic, and piecewise linear model) were also considered in 
the BMD analysis, resulting in a range of BMDL values. EFSA concluded that 
concurrent blood lead was the most reliable dose measure for assessing effects on 
developmental neurotoxicity: this measure is suggested to best reflect steady state 
concentrations of lead in the body of children (79, 82). Based on concurrent blood 
lead levels, the BMDL resulting from the piecewise linear model was selected. 
EFSA regarded that uncertainties when using this model, relative to the others, 
were of least importance. The reference point (BMDL) for developmental neuro-
toxicity was determined to 12 μg/l (blood lead). Using the Integrated Exposure 
Uptake Biokinetic Model for Lead in children, this corresponds to a dietary lead 
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exposure in infants and children of 0.5 μg lead/kg bw per day. This assumes 
negligible exposure from air, and from soil and dust (79). EFSA concluded that  
a margin of exposure of 10 or greater (an exposure of 10% of the RP or lower) 
should be sufficient to ensure that there was no appreciable risk of a clinically 
significant effect on IQ. At lower margins of exposure, but greater than 1 (expo-
sures between 10 % and 100 % of the RP), the risk is likely to be low, but not 
such that it could be dismissed as of no potential concern (79). 
Other effects  
EFSA (79) also established reference points for renal and cardiovascular effects 
for adults. The reference point (BMDL) for kidney effects in adults was deter-
mined to 15 μg/l (blood lead). Using the equation of Carlisle and Wade (85), this 
corresponds to a dietary lead exposure of 0.63 μg/kg bw per day when assuming 
negligible exposure from air and soil. The reference point (BMDL) for effects on 
systolic blood pressure in adults was determined to 36 μg/l (blood lead) and 8.1 
μg/g (tibia bone mineral lead). Using the equation of Carlisle and Wade (85), the 
BMDL of 36 μg/L, based on blood lead, corresponds to a dietary lead exposure of 
1.50 μg/kg bw per day. This assumes negligible exposure from air and soil. 
Exposure assessment 
Estimated intakes for all individual food products are presented in Appendix IV. 
Summary results for different product categories are presented in Tables 8 and 9. 
Product categories have been divided into two main groups depending on whether 
the consumption scenario used for the products in a given category covers a whole 
day (Table 8) or a single portion (Table 9). 
 
For product categories in Table 8, estimated intakes for individual products range 
between 0.02 and 0.14 µg/kg bw/day. One follow-on formula, and five FSMP 
products used as the sole source of nutrition are associated with intakes higher 
than 0.1 µg/kg bw/day (see Appendix IV). An estimate of the intake from breast 
milk is given as a reference in Table 8; this intake (0.35 µg/kg bw/day) is at the 
upper end of the intake interval estimated for the analysed products, but below the 
RP of 0.5 µg/kg bw/day.  
 
In Table 9, estimated intakes for individual food products range between 0.001 
and 0.26 µg/kg bw/portion. One gruel product, one porridge product, and one 
FSMP product used as partial feeding are associated with intakes higher than 0.1 
µg/kg bw/day (see Appendix IV). 
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Table 8. Summary of estimated intakes of lead (µg/kg bw/day). 
Product category Age 
(months) 
N Intakea 
 
Infant formula 0-4 9 0.04 (0.04-0.08) 
Follow-on formula 6-8 4 0.05 (0.03-0.14) 
FSMP as sole source 
of nutrition 
0-12 21 0.07 (0.03-0.14) 
 
FSMP as partial 
feeding 
0-12 3 0.02 (0.04-0.10) 
Breast milk 3 weeks 90 0.35b 
aMedian (range). 
bA lead concentration in breast milk of 2.1 µg/kg was used (a composite sample  
of human milk collected w 3 post-partum from 30 volunteers during 2008, 2009  
and 2010; n = 90 samples were pooled in the analysis). An infant weighing 4.2 kg  
(weight used for infants 0-4 months) and consuming 700 ml breast milk per day  
was assumed. 
 
 
Table 9. Summary of estimated intakes of lead (µg/kg bw/portion). 
Product category Age 
(months) 
N Intakea 
 
Gruel 6-12 14 0.01 (0.01-0.21) 
Porridge 4-12 26 0.01 (0.004-0.26) 
FSMP as partial 
feeding 
12 3 0.04, 0.04, 0.12 
 
Foodstuffs for normal 
consumption 
12 12 0.003 (0.001-0.01) 
aMedian (range).  
Contribution from drinking water 
The median lead concentration in municipal drinking water in Sweden is 0.11 µg/l 
based on analyses from approximately 1,500 water purification plants between 
2008 and 2011 (4,518 analyses in total). Combining this median value with a con-
sumption of 630 ml water (used for preparing 700 ml infant formula) by a child 
with a body weight of 4.2 kg (about 3 weeks old) results in a lead intake of 0.017 
µg/kg bw/day. 
 
Risk characterisation 
For developmental neurotoxicity, the reference point (RP) for lead is 0.5 µg/kg 
bw/day. Summary results of estimated intakes expressed in terms of a percentage 
of the RP are given in Table 10, and summary results of estimated intakes expres-
sed in terms of the number of portions required to reach the RP are given in Table 
11. Product-specific information is given in Appendix IV.  
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For product categories in Table 10, the estimated median exposure is in the range 
of 8-14 % of the RP. Exposures higher than 10% of the RP are observed for three 
infant formulae, two follow-on formulae, 16 FSMP products used as the sole 
source of nutrition, and one FSMP product used as partial feeding. 
 
In Table 11, the number of portions to reach the RP varies between and within the 
different product categories, but is generally larger than 10. The number of port-
ions to reach the TDI is less than 10 for two gruel products, two porridge pro-
ducts, and one FSMP product used as partial feeding. 
 
 
Table 10. Summary of estimated intakes of lead expressed in terms of a 
percentage of the RP of 0.5 μg/kg bw/day. 
Product category Age 
(months) 
N % of RPa More than 10 
% of RPb 
Infant formula 0-4 9 8 (7-16) 3 
Follow-on formula 6-8 4 10 (6-27) 2 
FSMP as sole source 
of nutrition 
0-12 21 14 (6-27) 16 
FSMP as partial 
feeding 
0-12 3 5, 8, 20 1 
aMedian (range).  
bThe number of products associated with exposure that are higher than 10 % of the RP. 
 
 
Table 11. Summary of estimated intakes of lead expressed in terms of the number 
of portions required to reach the RP of 0.5 μg/kg bw/day. 
Product category Age 
(months) 
N No. of portions 
to reach RPa 
Less than 10 
portions to 
reach RPb 
Gruel products 6-12 14 50 (2-86) 2 
Porridge 4-12 26 49 (2-119) 2 
FSMP as partial 
feeding  
12 3 4, 11, 13 1 
Other 12 12 162 (36 - 454) 0 
aMedian (range).  
bThe number of products for which the no. of portions to reach the RP is less than 10. 
Discussion 
For several products the margin to the RP is greater than a factor of 10 (an esti-
mated daily intake less than 10 % of the RP, or more than 10 portions required to 
reach the RP). EFSA regards that a margin to the RP equal to a factor of 10 would 
ensure that there is no appreciable risk of clinically significant effects on IQ. For 
exposures higher than this (10-100 % of the RP) EFSA states that the risk is likely 
to be low, but not such that it could be dismissed as of no potential concern. In 
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this context, some concerns can be identified with individual products in this 
assessment, in particular for the FSMP products used as the sole source of nutria-
tion, for which 16 out of 21 individual products are associated with exposures 
higher than 10 % of the RP.  
 
Conclusion 
The present assessment supports the conclusions made by EFSA in its risk assess-
ment that there is a potential concern for effects on neurodevelopment at current 
levels of exposure to lead for infants and children. Also, other studies indicate that 
the current blood lead levels in Swedish children are in the range of the RP of 12 
μg/l (86). This suggests that exposure to lead should be reduced as much as 
possible.  
  
Livsmedelsverkets rapportserie nr 1/2013                                                                             41 
Manganese (Mn) 
Nutritional background 
Physiological function of manganese 
Manganese is an essential nutrient, necessary as a cofactor for several enzymes 
and important for the normal development of the foetus. Manganese is utilised by 
superoxide dismutase − an antioxidant enzyme − and plays a role in the activation 
of glycosyltransferase, which is necessary for mucopolysaccharides found in 
cartilage, bone and other connective tissues (87). 
Dietary sources of manganese  
Manganese is found in a variety of foods and concentrations vary considerably. 
The highest concentrations (exceeding 10 mg per kg) have been detected in 
grains, nuts and rice (88). Other sources of manganese in foods are, for example, 
vegetables, legumes, fruits and tea (89). In a Swedish study of market baskets (90) 
the highest average percentage contribution to the total daily supply of manganese 
came from cereal products (61 %), followed by fruit (18 %), sugar and sweets  
(8 %), vegetables (6 %) and potatoes (4 %) (91). Moreover, manganese may be 
found in drinking water. Currently there is, to our knowledge, no nation-wide 
compilation of detected concentrations of manganese in drinking water from 
Swedish municipalities, but according to unpublished data the average concen-
tration in groundwater used as drinking water in Sweden is 150 ± 510 μg/L, 
median 60 μg/L (92).  
Recommendations and intakes   
When data is judged to be insufficient to set a population reference intake such as 
a RI, an adequate intake (AI) may be used to estimate adequacy of intakes. 
According to the American Institute of Medicine (IOM) (93) the AI)  for children 
0-6 months of age is set at 3 μg/ day based on the intake from breast milk. For 
children 7-12 months of age AI was set at 600 μg/day based on an estimated 
intake from food. For children 1-3 years old and 4-8 years old, AI was set at 1.2 
mg/day and 1.5 mg/day respectively. Breast milk may contain concentrations of 
manganese in a range of 3.1-7.5 μg/L, although maternal intake via drinking water 
and foods varies considerably. According to Ljung & Vahter (3) infant formulae 
have been found to contain manganese in a concentration range of 25-499 μg/L - 
not including additional manganese from drinking water. Many infant formulae 
contain about hundred times higher concentrations than those found in breast 
milk. Concentrations of manganese in the product ready for consumption could be 
even higher, as the water used for preparation may also contain manganese. 
Analysis of market baskets representing a typical Swedish diet (exluding drinking 
water) showed an average daily exposure of 4.0 mg in adults (91), indicating that 
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intakes in the adult population are well above the AI set by IOM (currently 1.8 
mg/day for women and 2.3 mg/day for men). According to the Swedish market 
basket study, cereal-based products contributed to more than 60 % of manganese 
intake in adults. Because cereal is a part of the diet for most infants and young 
children, a substantial contribution of natural manganese from complementary 
foods can be assumed. 
 
Hazard identification  
Adverse effects of insufficient manganese intake 
Manganese deficiency in humans can result in impaired growth, poor bone forma-
tion and skeletal defects, reduced fertility and birth defects, abnormal glucose 
tolerance, and altered lipid and carbohydrate metabolism (88). The development 
of an erythaematous rash on the torsos of young men placed on a manganese-
depleted diet has been observed (94). In experimental animals a variety of adverse 
effects has been described, for example impaired growth, skeletal abnormalities, 
reproductive deficits, ataxia of the newborn, and defects in lipid and carbohydrate 
metabolism (88). Consequently, deficiency seems to cause comparable effects in 
experimental animals and humans. 
 
Some data suggest that a suboptimal manganese status may occur in humans with 
epilepsy, osteoporosis, or exocrine pancreatic insufficiency, in individuals under-
going chronic haemodialysis, and in children with Perthes’ disease or phenylke-
tonuria (88). It is, however, not clear whether manganese deficiency has a role in 
the development of these diseases (89). 
Adverse effects of excessive manganese exposure 
Subtle neurobehavioural effects have been identified as the most critical endpoint 
in studies of manganese in experimental animals and manganese in high doses is 
regarded as a neurotoxic substance. The mechanisms by which manganese exerts 
neurotoxicity have not been clearly explained, though it is known that manganese 
is a cellular toxicant that can impair transport systems, enzyme activities, and 
receptor functions (95, 96). Neurotoxic effects in humans have mainly been 
shown in occupational studies of inhalation of high doses of manganese by work-
ers (97). Furthermore, neurobehavioural and neurotoxic effects in several species 
of experimental animals (mice, rats, guinea pigs and monkeys) have been demon-
strated following both inhalation and oral intake of manganese.  
The studies in rats are probably of limited value as absorption is not regulated in  
a similar way in humans. Moreover, it has been demonstrated that distribution of 
manganese in the brain in rats compared to nonhuman primates (in this case the 
marmoset) is different (98). Studies in monkey may be more relevant since the 
Livsmedelsverkets rapportserie nr 1/2013                                                                             43 
postnatal development of the brain in primates is likely to be more similar to that 
of humans.  
Many epidemiologic studies including children have been carried out in order  
to investigate potential associations between intake of manganese from drinking 
water and/or levels of manganese in blood/hair on the one hand and results of a 
variety of tests regarding behaviour, hyperactivity, learning ability and intelli-
gence on the other (99-101). In conclusion, these studies indicate that  relatively 
low intakes of manganese by children may affect the nervous system in a negative 
way, which has been demonstrated predominantly in disturbances of the behave-
our (92) and/or in intellectual impairments (100). In addition, an association bet-
ween manganese exposure from water and neurological effects in elderly indivi-
duals has been indicated in an epidemiological study (102).  
 
Hazard characterisation  
Adverse effects of insufficient manganese intake 
Manganese deficiency seems to be extremely rare in humans. This is probably due 
to the ubiquitous presence of manganese in foods. At present no published data 
regarding the prevalence of manganese deficiency have been found. According to 
Aschner & Aschner (103) naturally occurring deficiency states of manganese have 
not been recognised and Hardy et al (104) states that there is very little evidence 
of manganese deficiency being clinically relevant in humans.  
Adverse effects of excessive manganese exposure 
It has been estimated that approximately 1-5 % of ingested manganese is absorbed 
from the gastrointestinal tract. The absorption of manganese is regulated in adults, 
as it is subject to homeostatic control, which means that the absorption is reduced 
when intake of manganese is high. However, in infants this regulation is not yet 
fully developed, which may result in considerably higher exposure in infants in 
comparison with adults (103). In addition, infants have a low bile flow, which 
may result in lower excretion of manganese via bile. The retention of manganese 
in infants is thus higher than in adults (103).  
 
Manganese in human milk appears in the trivalent oxidation state bound to lacto-
ferrin. Lactoferrin is the major iron-binding protein in milk. In infant formula, 
manganese is in the divalent oxidation state and different mechanisms from those 
operating in the absorption of manganese from human breast milk are likely to be 
involved (87). Since individuals with low iron stores have been found to absorb 
more manganese than individuals with normal iron stores, interaction between the 
absorption of manganese and iron clearly exists, i.e. iron status affects the uptake 
of manganese (105). 
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Experimental animals 
Studies on experimental animals like the mouse, rat, guinea pig, and monkey have 
demonstrated that oral intake of manganese may be associated with neurotoxic 
effects. However, neither an no observed adverse effect level (NOAEL) nor a 
dose-response regarding neurotoxicity could be demonstrated in the studies in 
experimental animals assessed by the Scientific Committee on Food (SCF) 
according to the latest opinion expressed in 2000 (88). In young growing rats the 
lowest dose level associated with neurotoxic effects (neuronal degeneration in 
cortical and cerebellar sections of the brain) has been found at an oral dosage of 
0.28 mg/kg body weight (106), which may be suggested as an lowest observed 
adverse effect level (LOAEL) for this kind of effect. Effects of this kind at this 
dose level have, however, not consistently been observed in growing rats. Some 
investigators report effects at considerably higher dose levels. For example 
Dorman et al (107) did not observe any adverse histological changes in the brain 
region of growing rats exposed to 11 or 22 mg of manganese per kg body weight. 
Generally, the sensitivity seems to decrease with age as several studies on rats 
indicate that higher doses are generally needed to induce neurotoxic effects in 
adult rats, but also in this case results are not entirely consistent. The lowest dose 
associated with neurobehavioural effects (in this case learning ability) in adult rats 
(females) has been reported to be 0.36 mg/ kg body weight (108). In infant rhesus 
monkeys the lowest found dose levels associated with neurotoxic effects have 
been found at 300 μg/kg body weight (109). In this study neurobehavioural effects 
of manganese in daily dosages of 100 and 300 μg/kg body weight, administered in 
soy-based infant formula, were investigated. The results of this study indicate that 
components (including manganese) in soy formula may influence brain 
development as reflected in behavioural measures. In this context, it should be 
noted that soy-based infant formulae also contain other substances, for example 
phytoestrogens, phytates and aluminium, which potentially can result in negative 
health effects. In adult monkeys the lowest dose levels associated with neurotoxic 
effects are 6.9 mg/kg body weight during 18 months for monkeys  (110). Data 
regarding the bioavailability of manganese after oral administration of infant 
formula to monkeys are currently lacking. As non-human primates are more 
physiologically similar to humans than rodents in this respect, studies in monkeys 
provide information that to a higher extent applies to humans. 
Humans 
A number of epidemiological studies focusing on manganese neurotoxicity in 
children have been published. A review of those published 1977-2007 has been 
provided by Menez-Filho et al 2009 (99). Moreover, some additional studies have 
been published during the last five years (see below). Some examples and results 
from the epidemiological studies will be briefly mentioned in the following. It 
should be noted that most of these studies have been performed with a cross- 
sectional design and the quality of several of the studies may be questionable. 
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Children who drank water with an average concentration of manganese of at least 
0.241 mg/L during 3 years performed more poorly in school and in the WHO 
neurobehavioural core test battery compared to children who drank water with 
manganese ≤ 0.04 mg/L (111, 112).  
In some other studies it was observed that manganese levels in hair are higher in 
learning disabled children than in reference children, see Collipp et al (113), Pihl 
and Parkes  (114). These authors concluded that it is possible that excess manga-
nese ingestion could lead to learning or behavioural impairment in children. As a 
number of other agents, including lead, also might have affected the results, the 
observed association is not sufficient to establish a cause-effect relationship (114).  
Takser et al (115) conducted a prospective epidemiological study to determine 
the long-term effect of manganese exposure in utero on children’s psychomotor 
development. This French cohort consisted of 247 healthy pregnant Parisian 
women and their babies and the children were examined at 9 months, 3 years and 
6 years. At 3 years of age negative relationships were found between blood levels 
of manganese and psychomotor sub-scales of attention, non-verbal memory and 
hand skills. However, no significant associations were observed between cord 
blood manganese concentration and general psychomotor indices at this age, or 
for the other studied age groups. These results suggest that early psychomotor 
development could be affected by environmental manganese exposure in utero. 
 
Higher prenatal manganese exposure at gestational week 20
 
 was found to be 
significantly correlated with distinct behavioural outcomes in a pilot study of 11-
13 year old children by Ericson et al (116). These individuals were more impul-
sive, inattentive, aggressive, defiant, disobedient, destructive and hyperactive. A 
standardised test of cognitive ability and achievement performed by the children 
did not, however, show lower scores in comparison with reference children.  
 
In a cross-sectional epidemiological study of 142 children (10-year-olds) in Bangla-
desh, a statistically significant relationship between decreasing intelligence scores and 
increasing manganese levels (800 µg manganese/L) in drinking water was found (11).  
Khan et al (117) found dose–response associations between concentrations of man-
ganese in drinking water and classroom behaviour, which suggests that those in the 
first quartile of exposure (< 265 μg/L) differed significantly from those consuming 
drinking water with higher levels of manganese. The study included 201 children 
(8-11 years) and was performed with a cross-sectional design in Bangladesh. 
In Quebec, Canada, Bouchard et al (118) were able in an epidemiological study of 
46 children (ages 6-15 years) to demonstrate a statistically significant relationship 
between increased levels of oppositional behaviours and hyperactivity and increa-
sed levels of manganese in drinking water. This study was followed up by another 
cross-sectional study of 362 children (ages 6-13 years), published in 2011 (100). 
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The main results of this study suggest that exposure to manganese at levels com-
mon in groundwater is associated with intellectual impairment (lower IQ scores) 
in children. A strong association between manganese concentrations and IQ scores 
was detected, with a difference of 6.2 full scale IQ points between the children 
exposed to water containing 1 and 216 µg manganese/L (median of lowest and 
highest quintiles). There was a significant association between manganese intake 
from drinking water, but interestingly not manganese from the diet, and elevated 
manganese concentration in children’s hair. 
Henn et al 2010 (119) studied 448 Mexican children born 1997-2000 with a 
longitudinal design in order to investigate associations between manganese 
exposure during early life and neurotoxic effects. Blood samples collected from 
children at 12 and 24 months of age were analysed for manganese levels. Bayley 
Scales of Mental and Psychomotor Development were used at 6-month intervals 
between 12 and 36 months of age to assess mental and psychomotor development. 
An inverted U-shaped association between 12-month blood manganese and 
concurrent mental development scores (compared with the middle 3 manganese 
quintiles) was found for the lowest manganese quintile. This 12-month manganese 
effect was apparent but diminished in mental development scores at later ages. At 
24 months the levels of manganese were not associated with neurodevelopment. 
The authors´ interpretation is that these results indicate a biphasic dose-response 
relationship between manganese exposure at lower exposure levels and infant 
neurodevelopment.  
The cohort mentioned above was also studied by Henn et al (101), in order to 
investigate possible interactions between manganese and lead in early childhood. 
In addition, possible interactions between manganese and potentially toxic metals 
such as lead have also been shown to occur. It was clearly shown that co-exposure 
of manganese and lead was associated with more severe neurodevelopmental 
effects than those expected from exposure to each metal alone. 
According to Takser et al (115) and Henn et al (101), it is possible that there is a 
window of susceptibility to manganese exposure. They suggest that the strongest 
neurotoxic effects may occur during foetal life and early infancy  possibly before 
12 months of age.  
 
When interpreting the results of the epidemiological studies it should be emphasi-
sed that most of them are performed with a cross-sectional design with a rather 
limited number of participants, with the exception of two prospective investiga-
tions of infants (101, 115). Moreover, in many of the studies it is not known 
whether the observed effects can be solely attributable to excess manganese or if 
other components of drinking water or diet could have influenced the result, as 
they were not monitored or accounted for in the analyses. Furthermore, control for 
potential confounders often seems to be insufficient. In most studies the partici-
pating children were 10 years old or older and it is not clear whether the observed 
associations may be the result of exposure in early infancy or later in childhood. 
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Another problem in these studies is that a validated biomarker for manganese 
exposure is lacking (99). When interpreting possible associations between manga-
nese intake and studied outcomes in the mentioned studies these limitations 
should be considered. Even though there are many limitations, the results of these 
studies taken together indicate that neurotoxic effects after oral exposure to 
manganese can develop in children and that these effects are similar to those 
observed in adults environmentally or occupationally exposed to manganese.  
NOAEL based on manganese intake 
An NOAEL has been estimated to 11 mg manganese per day by WHO, 2004 
(120). This NOAEL emanates from a Canadian study of 100 young women about 
30 years old (121) and is based on calculated daily intakes of manganese and not 
on actual measurements of manganese intakes. Furthermore, the health status of 
the subjects in this study was not commented on. In the assessment by WHO 
(120) there were no comments regarding possible adverse/toxic effects in the 
study or why this value was chosen as NOAEL.  
UL, TDI and RfD 
No UL for infants could be established by EFSA, 2006 (88) or the British Expert 
Group on Vitamins and Minerals (EVM), 2003 (122) as relevant toxicological 
data were lacking. In a risk assessment performed by WHO (120) a TDI of 
manganese was established. This TDI was based on the estimated NOAEL of 11 
mg/day (mentioned above) which was divided by an uncertainty factor of three. 
Using an adult body weight of 60 kg, a TDI of 60 μg Mn/kg body weight was 
derived. In addition, the American Environmental Protection Agency (EPA) 
established in 1996 an acute oral reference dose (RfD) at 0.14 mg/kg, i.e. 140 
μg/kg body weight/day in an assessment based on oral intake studies (123). This 
RfD was based on an occasional intake of 10 mg manganese per day, which was 
considered safe by EPA, and an assumed body weight of 70 kg (124). Confidence 
in the oral RfD is regarded as medium by EPA and it should be observed that 
“quantitative information to indicate toxic levels of manganese in the diet of 
human is not available”.  
Biomarkers of manganese status 
Several potential indicators of manganese exposure are available, for example 
manganese concentrations in blood, urine, hair and saliva. Manganese concentra-
tions in blood could be used as a biomarker of exposure on a group basis and to 
measure recent exposure. Overall, however, none of the mentioned biomarkers is 
at present regarded as a sufficiently sensitive and valid indicator of exposure for 
individual biomonitoring. Moreover, the mechanisms of manganese toxicity are 
not yet clarified and hence no reliable biomarkers have been established to eva-
luate adverse effects of manganese exposure. As it is beyond the scope of this 
assessment to discuss these issues in detail, the reader is referred to Zheng et al 
(125) for a comprehensive review and discussion. 
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Maximum limits and guideline values for manganese in foodstuffs 
Drinking water 
WHO states in a background document (120) to the third edition of the drinking 
water guideline, 2004, that “A health-based value of 0.4 mg/l can be derived for 
manganese based on the upper range value of manganese intake of 11 mg/day, 
identified using dietary surveys, at which there are no observed adverse effects, 
using an uncertainty factor of 3 to take into consideration the possible increased 
bioavailability of manganese from water, allocating 20 % of the TDI to drinking-
water and assuming the consumption of 2 litres of water per day by a 60 kg adult“. 
However, in 2011 this guideline value was withdrawn; as it “is well above con-
centrations of manganese normally found in drinking-water, it is not considered 
necessary to derive a formal guideline value”, according to WHO (126). Although 
the scientific background (including the derivation of the TDI) to the previously 
established WHO guideline value may be questionable, the decision by WHO not 
to apply any maximum limits in drinking water, has been criticised by Frisbie et 
al (127) who emphasise that: “drinking water or potential drinking water supplies 
with manganese concentrations above 400 μg manganese/L are found in a sub-
stantial number of countries worldwide”.  
Infant formula 
For infant formula there is, according to the Commission Directive 2006/141/EC 
(128), a maximum limit of 100 μg manganese/100 kcal, which corresponds to 
about 650 μg/L (92). The maximum level of 100 μg manganese/100 kcal is the 
maximum limit in infant formula recommended by the SCF in its report 2003 
(129), which was the basis for the Commission Directive (129). However, how 
this maximum limit in formula has been derived by the SCF is not clear. The SCF 
states that this value is: “below the estimated LOAEL in adults for manganese 
contents in water (4.2 mg/L).” This LOAEL is based on results from a study 
performed in Greece (102) from which an LOAEL of 4.2 mg per day – not per 
litre was derived. The consequence of this misinterpretation is that the calcula-
tions are based on an LOAEL which is twice that of the actual level in the men-
tioned study. In addition, this LOAEL is based on effects observed in persons of a 
different age category (older than 50 years), as neurological symptoms, indicating 
chronic poisoning by manganese, which clinically resembles symptoms of 
Parkinson’s disease, were studied. Furthermore, the intake estimates in this study 
were based on calculations from the manganese contents in drinking water and not 
on actual intakes. These shortcomings in the process of establishing a maximum 
limit in infant formula described above, were initially discussed by Ljung et al 
(130). According to the European Society of Paediatric Gastroenterology, Hepa-
tology and Nutrition (ESPGHAN) a maximum level of 50 μg/100 kcal is recom-
mended based on the concentration in unfortified soy-based formula (131). 
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Exposure assessment  
Estimated intakes for all individual products are presented in Appendix V. 
Summary results for different product categories are presented in Tables 12 and 
13 below. Product categories have been divided into two main groups depending 
on whether the consumption scenario used for the products in a given category 
covers a whole day (Table 12) or a single portion (Table 13). The intake from 
breast milk is given as a reference in Table 12. The concentration of manganese 
was 4 µg per kg breast milk (See Appendix V, Table 7). This value is within the 
range for average manganese concentrations in breast milk reported in the 
literature (92). 
 
 
Table 12. Summary of estimated daily intakes of manganese - expressed as 
µg/day and as µg/kg body weight/day from infant formula, follow-on formula, 
FSMP as the sole source of nutrition, FSMP as partial nutrition and from breast 
milk. 
Product category No. of 
products 
Age 
(months) 
Intakea  
(µg/day) 
Intake  
(µg/kg bw/day) 
Infant formula  9 0-4 66 (15-110) 10 (4-26) 
Follow-on formula  4 6-8 136 (39-180) 21 (5-21) 
FSMP as sole source 
of nutrition 
21 0-12 316 (34-2256) 69 (8-230) 
FSMP as partial 
feedingb 
 
3 0-12 580 (200-780) 75 (48-80) 
Breast milk - 3 weeks 2.8 (-) 0.7 (-) 
 aValues are median (range) 
bNutramigen 2 lipil, XP Maxamaid and PKU anamix infant lcp+ (recommended daily intake) 
 
 
 
Table 13. Summary of estimated intakes expressed as µg manganese per kg body 
weight per consumed portion from gruel, porridge, FSMP as partial feeding and 
other products a 
Product category No. of 
products 
Age 
(months) 
Intakea 
(µg/portion) 
Intake  
(µg/kg 
bw/portion) 
Gruel  14 6-12 257 (9-350) 33 (1-46) 
Porridge  26 4-12 376 (114-989) 43 (16-128) 
FSMP as partial 
feedingb 
3 12 415 (351-764) 42 (36-78) 
Foodstuffs for 
normal consumption 
12 12 147 (16-1154) 15 (2-118) 
 aValues are median (range)  
b Fresubin energy fibre drink, PKU gel and Frebini energy fibre drink 
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As is evident from Tables 12 and 13, the highest exposure is to be expected from 
intake of products categorised as FSMP as the sole source of infant nutrition and 
as partial infant nutrition and porridge.  
 
The product category “Foodstuffs for normal consumption” contains a wide range 
of products and even within the same product category, for example oat drinks, 
manganese concentrations vary from 157 to 800 µg /kg due to variations in 
natural content. The analysed soy drinks generally had high concentrations of 
manganese (1,567-1,983 µg /kg) due to naturally high levels of manganese. 
Intakes of manganese from foodstuffs for normal consumption thus vary consider-
ably and some products such as rolled oats, oat toasted and milled and some soy 
products may contribute to high exposure.  
Estimation of the contribution of manganese from drinking water 
As mentioned previously the concentrations of manganese in the water used for 
preparation and hence the potential contribution from water should also be con-
sidered. As manganese in a concentration of 300 μg/L is considered acceptable in 
private wells in Sweden, the total exposure could be considerably higher after 
consumption of products ready to eat with a low concentration of manganese. This 
could result in daily exposures with narrow margins to the TDI for formula pro-
ducts as well. The maximum level for manganese in drinking water supplied by 
the municipalities is, according to current Swedish legislation, 50 μg/L. Some 
examples of contributions of manganese from drinking water are presented in the 
risk characterisation below. 
 
Risk characterisation  
Daily intakes from the analysed products in relation to AI 
According to the present intake assessment, the AI of 3 µg per day for 0-6 months 
will be reached after consumption of all analysed infant formulae as they contri-
bute with 5-30 times the AI. A daily intake of 3 µg per day will also be reached 
with follow-on formulae from 6 months. One product recommended from 8 
months contributes with 30 % of the AI and additional sources of manganese for 
the infant to reach an AI of 600 µg for the age 7-12 months are needed. Daily 
intakes from most FSMP products that may be used as the sole source of nutrition 
are well above the AI for the different age groups. However, the contribution of 
manganese from three FSMP products will not reach the AI level according to our 
calculations: Neocate Advance (42 % of AI at 12 months), Resource Minimax  
(47 % of AI at 12 months) and NutriniKid Multi Fibre (90 % of AI at 12 months). 
However, the products may be consumed together with other foods, adding to 
total manganese intake. 
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Table 14. Summary of estimated intakes expressed in terms of the number of 
portions required to reach the AI of 3 µg /day for 0-6 months, 600 µg/day for 7-12 
months and 1,200 µg/day for products recommended from 12 months. 
Product category No. of 
products 
Age  
(months) 
Number of portions 
required to reach the AI 
a 
Gruel 14 6-12 0 (0-4) 
Porridge 26 4-12 0 (0-4) 
 Foodstuffs for normal 
consumption 
12 12 1 (0-15) 
FSMP as partial feeding b 3 12 3 (2-3) 
aValues are median (range) 
bFresubin energy fibre drink, PKU gel and Frebini energy fibre drink 
 
Daily intakes from the analysed products in relation to TDI 
In the tables below, median and range for daily intakes and number of portions 
needed in order to reach TDI are displayed. The TDI applied in these calculations 
is 60 ug/kg body weight/day established by WHO (120).  
 
 
 
Table 15. Summary of estimated intakes – as a percentage of the TDI.  
Product category No. of 
products 
Age 
(months) 
Intake as percent of 
TDIab 
Infant formula  9 0-4 17 (6-44) 
Follow-on formula  4 6-8 30 (8-35) 
FSMP as sole source of 
nutrition 
21 0-12 115 (14-384) 
FSMP as partial feeding 3 0-12 125 (79-133) 
aValues are median (range) 
bThe tolerable daily intake (TDI) : 60 µg/kg bw/day (WHO, 2004) (120) 
 
 
Table 16. Number of portions needed in order to reach TDI. 
Product category No. of 
products 
Age 
(months) 
Number of portions to 
reach TDIab 
Gruel  14 6-12 2 (1-53) 
Porridge  26 4-12 1 (0-4) 
FSMP as partial feeding 3 12 1 (1-2) 
Foodstuffs for normal 
consumption 
12 12 4 (1-37) 
aValues are median (range) 
bThe  tolerable daily intake (TDI) : 60 µg/kg bw/day (WHO, 2004) (120) 
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The exposure from infant formula and follow-on formula does not exceed the  
TDI and the margins seem to be sufficient in the products analysed. Some FSMP 
used as the sole source of infant nutrition and FSMP as partial feeding clearly 
exceed the TDI.  
 
The exposure from porridge can in a number of cases be fairly high and the 
number of portions in order to reach the TDI may be rather small. This is also the 
case for a couple of gruel products. When the TDI is reached by consuming even 
less than one or two portion(s) daily, the concentration of manganese shuoldt not 
be regarded as acceptable. In this context it is, however, also important to be 
aware of the uncertainties in the establishment of the used TDI. (For more details 
see the “Drinking water” section below). Not all products have, however, been 
fortified. Some products contain manganese naturally in high concentrations. The 
products included in “Foodstuffs for normal consumption” create a heterogeneous 
category including a variety of foods. In some specific products concentrations are 
high and consumption of these products could thus be problematic.  
Contribution from drinking water 
A reasonable estimation of the contribution from drinking water, assuming a con-
centration of 50 µg/L and an intake of 630 mL water by a child with a body 
weight of 4.2 kg (about 3 weeks old) would be 32 μg, i.e. 8 μg/kg body weight. A 
consumption of 630 mL is assumed as it would correspond to the amount of water 
needed to prepare 700 mL of formula, which is our estimated consumption by 
infants of this age. The intake of manganese from formula would then increase 
almost twofold, but still below the TDI. If we assume a type of worst case scen-
ario with a water concentration of 300 µg/L, the contribution of manganese from 
drinking water would amount to 189 μg, i.e. 45 μg/kg body weight under the same 
assumptions as above. Clearly, for formula this exposure would result in an intake 
below but close to the TDI. 
Discussion 
Manganese deficiency seems to be extremely rare in humans, because manganese 
is commonly present in foods and drinking water. Currently, the prevalence of 
manganese deficiency is not known. The risk of development of neurotoxicity is 
considered to be higher in infants than in adults as infants have not developed the 
ability either to regulate the absorption of manganese or to eliminate manganese 
effectively. These circumstances may result in an excessive body exposure of in-
fants to manganese (92). In addition, children are more vulenerable, as the deve-
lopment of the neuronal system − including the brain −  is intense during child-
hood. According to a recent literature search performed at the NFA, there is 
currently limited information about manganese homeostasis in infants. Further-
more, it is likely that different mechanisms may operate in the gastrointestinal 
absorption of manganese from human milk and infant formula (87). 
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Mild neurotoxic effects have been observed in monkeys at a dose level of 300 
μg/kg body weight (109). When considering this study and the fact that the 
nervous system of younger animals in general seems to be more sensitive than 
that of adults (92), it may be argued that the TDI of 60 μg/kg body weight is too 
high as there should be safety factors for interspecies extrapolation and inter-
individual variations and an extra safety factor as LOAEL has been used instead 
of NOAEL (which was not available). As relevant data are lacking it is not 
possible to propose a TDI. However, it seems reasonable to suggest a “provisio-
nal TDI for infants”  in the range of 5-15 μg/kg body weight based on the the 
lowest found dose level associated with neurotoxic effects  at 300 μg/kg body 
weight in the study by Golub (109) and a safety factor of at least 20-30 to allow 
for interspecies differences and the use of LOAEL.  
 
Associations between intake of manganese and neurotoxicity have been demon-
strated for different biomarkers (concentrations of manganese in blood and hair), 
different cognitive tests and sources of exposure. None of these studies is entire-
ly convincing regarding toxic effects of manganese in children. In most epide-
micological studies exposure data are commonly reported as blood levels of 
manganese, while some studies report concentrations in drinking water as the 
exposure parameter. In addition, kinetic studies dealing with associations bet-
ween actual oral intake and blood levels are currently lacking. In consequence,  
it is not possible to relate blood levels to oral exposure. Moreover, many of the 
epidemiological studies have been performed in countries where malnutrition 
and concurrent infections in children may be common (for example Bangladesh 
and Mexico), which may result in a change in sensitivity towards manganese 
toxicity. These circumstances, as well as the fact that most studies have been 
performed with a cross-sectional design, make it difficult to use these studies in 
order to estimate a safe intake level. Nevertheless, these studies could support 
the findings in experimental studies.  
 
Epidemiological studies that have detected some kind of association between 
manganese exposure and adverse effects indicate that children are more sensitive 
to negative health effects of manganese in comparison with adults. More, well 
designed epidemiological studies are, however, warranted in order to confirm 
these associations. In addition, further studies are required in order to develop 
appropriate animal models reflecting susceptible human subpopulations like 
infants and children.  
 
In “Guidelines for Drinking-water Quality”, 2004(126), WHO established  
a health-based guideline value for manganese of 400 μg/L, but the scientific 
background to this value has been questioned and it has been argued that the 
application of this guideline value probably does not protect against negative 
health effects in young children (younger than 1 year old) (92). Moreover, this 
guideline value was withdrawn in 2011, based on an opinion of WHO that it was 
not considered necessary to derive a formal guideline value because 0.4 mg/L 
would be well above concentrations of manganese normally found in drinking-
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water. The highest concentration of manganese recommended by the SCF  (90) in 
infant formula is 100 μg/100 kcal (corresponding to about 650 μg/L), but also in 
this case the scientific background has been questioned (130). Consequently, 
children receiving formula prepared from water containing manganese may be at 
risk of over-exposure to manganese.  
 
According to ESPGHAN a maximum level of 50 μg/100 kcal is recommended 
based on the concentration in unfortified soy-based formula. It is possible that a 
higher concentration of manganese in formula in comparison with breast milk is 
justifiable, since manganese is an essential element, which is less bioavailable in 
formula than in breast milk. It is, however, questionable whether a 100-fold higher 
manganese concentration in formula is justifiable (92). This is also the conclusion 
drawn by the National Board of Health and Welfare in a report on environmental 
health (132). The maximum limit of manganese in formula has to be set at a level 
where additional input from the mixing water does not affect the safety of the 
final product ready for consumption. 
 
In the present study of foods for infants and young children high concentrations  
of manganese have been detected mainly in FSMP as the sole source of nutrition, 
although in line with the current permitted range, and in porridge products inten-
ded for infants and young children as well as in some other products intended for 
consumption by this group of consumers. Similar analytical results have been 
found in an investigation performed by the IMM (3).  
The use of AI and TDI for evaluating risk benefit of manganese  
in foods for infants and young children 
In order to evaluate whether the content of a micronutrient in a particular food 
product is within the acceptable or optimal range, upper and lower levels of 
intakes must be established. However, when AI for manganese and this TDI are 
used for different age groups, the shortcomings of these values become apparent. 
 
In Table 17 it is shown that the daily intake of manganese required to reach the  
AI varies according to age. These values are based on manganese intakes from 
human milk (< 6 months) and other foods (≥ 7 months). The daily intake of 
manganese that corresponds to the TDI (60 µg/kg bw/day according to WHO 
(120) at different ages and body weights is also displayed in this table.  
 
It is not biologically plausible that manganese requirements would change to this 
extent between 6 months (3 µg/day) and 7 months (600 µg/day) and between 11 
months (600 µg/day) and 12 months (1,200 µg/day). In addition, the scientific 
basis for the TDI is also weak. The calculation of the number of portions to reach 
the AI and TDI is misleading as this TDI at ages above 8 months (510 µg/day) is 
lower than the AI (600 µg/day). In this case, an optimal range of the manganese 
content in infant foods cannot be established and evaluation of the manganese 
concentration of the studied products is not possible. Hence, revision of the AI 
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and establishment of an UL for manganese are urgently needed in order to be able 
to define an optimal range of manganese in products intended for infants and 
young children. 
 
 
Table 17. Examples of how the AI and the daily intake of manganese that 
correspond to the TDI vary with age and body weight. 
Age  
(months) 
Body weight 
(kg) 
AI a of manganese 
(µg/day) 
Daily intake of 
manganese that 
corresponds to TDIb 
(µg/day) 
0 (3 weeks) 4.2 3 252 
4 6.6 3 396 
6 7.7 3 462 
8 8.5 600 510 
12 9.8 1,200 588 
aThe adequate intake (AI ) 0-6 mo 3µg, 7-12 mo 600 µg, 1-3 years 1200 µg (IoM, 2001) (93) 
bThe  tolerable daily intake (TDI) : 60 µg/kg bw/day (WHO, 2004) (120) 
 
Conclusion  
This overview of risks and benefits associated with the intake of manganese 
shows that more data are needed before a conclusive risk and benefit assessment 
can be performed. Manganese is an essential nutrient needed as a cofactor for 
many enzymes. Deficiency of manganese has, however, not been recognised as  
a nutritional problem in humans, probably due to the ubiquity of manganese in 
foods.  
 
Neurotoxic effects associated with oral exposure to manganese have been reported 
from studies in experimental animals. In addition, data from several epidemiologi-
cal studies in different countries such as Canada, Bangladesh and Mexico indicate 
associations between manganese exposure in children and impairments in behave-
our and intelligence. Currently, relevant data on certain aspects of manganese 
toxicity and epidemiology are lacking. The adequacy and safety of manganese via 
foods intended for infants and young children should therefore be carefully con-
sidered in relation to potential benefits and risks. 
 
In the present survey of food products intended for infants and young children, 
high concentrations of manganese have been detected mainly in FSMP used as 
sole sources of nutrition, porridge products and in some other products intended 
for consumption by this group of consumers. The detected concentrations of 
manganese are, however, in line with the current permitted range for FSMP 
products.  
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When considering recommended consumptions of these food products from the 
manufacturers or when estimating intakes per portion, the intake of manganese for 
some products is close to or even exceeds the TDI applied (60 µg/kg body weight/ 
day established by WHO in 2004). This does not seem to be scientifically justi-
fied, especially since this TDI for several reasons must be regarded as very uncer-
tain. Consequently, more data regarding the daily requirements of manganese 
during infancy and childhood are urgently required in order to be able to define 
the optimal range of intake more accurately.  
 
What is especially important is that the homeostatic regulation of manganese in 
infants may not yet have been developed at the time when the infants are consum-
ing the products containing high concentrations of manganese. This is likely to 
result in considerably higher manganese exposure in infants in comparison with 
adults (103). According to Swedish paediatric expertise there are no advantages of 
such high manganese intakes during infancy −  not even when considering pro-
ducts categorised as FSMP (133). Thus, manganese fortification of products 
intended for infants and possibly also young children could be questioned and 
even considered potentially harmful.  
 
In conclusion, the current maximum limits for manganese in drinking water, 
infant formulae and FMSP seem to be based on unconvincing scientific data and  
a new risk benefit assessment is required  as soon as sufficient scientific data are 
available.  
  
Livsmedelsverkets rapportserie nr 1/2013                                                                             57 
Iron (Fe) 
Nutritional background 
Physiological function of iron 
Iron is essential in oxygen supply as a component of haemoglobin and for oxygen 
storage as a component of myoglobin. Iron is also a component of enzymes with 
functions in the metabolism of energy and proteins and in the synthesis of pro-
teins, tissues, hormones and neurotransmitters. Because iron easily reacts with 
oxygen, mechanisms have evolved that tightly limit the uptake of iron and control 
the reactivity of iron in the body (134). 
Iron requirements in infancy 
Full term, normal birth weight infants below 6 months do not generally need any 
iron in addition to the amounts provided by human milk. The newborn infant has 
a high blood concentration of haemoglobin, which declines during the first few 
weeks of life (135). The iron that was bound in Hb is then transferred to iron 
storage. Up to around 6 months of age the iron need of the infant is covered by the 
release of endogenous iron. Iron concentrations in the blood of infants, but not in 
human milk, depend on maternal iron status. At around 6 months, additional 
intake beyond what is available in breast milk becomes necessary. Estimated daily 
iron requirements in 6-12 month old children are 0.9-1.3 mg/kg body weight 
(135).  
Iron absorption 
Iron absorption depends on total iron intake, dietary factors and the iron status of 
the individual. Bioavailability of iron differs between different types of foods, and 
is assumed to be about 10 % from a mixed diet. Bioavailability of iron is lower in 
cereal-based foods (non-haem iron) than iron in meat products (haem iron). Phyta-
tes inhibit uptake of iron from many vegetable sources of iron, including iron in 
soy-based formulas. Humans do not actively excrete iron and protection from iron 
overload occurs through down-regulation of absorption (135). However, research 
indicates that down-regulation of iron absorption may be less effective up to 9 
months of age (136). When iron stores are sufficient, the peptide hormone hepci-
din blocks iron uptake by inhibiting ferroportin-mediated transport. On the con-
trary, in iron deficiency, hepcidin levels are low. Up-regulation of iron absorption 
does occur in infants with low iron status.  
Recommendations for iron intake in infants and young children  
A RI has not been set for infants below the age of 6 months because of the 
assumption that breast milk provides the iron to fulfil the iron requirements at this 
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age. From 6 months to 5 years of age, Swedish nutrition recommendations (SNR) 
state 8 mg/day as the RI (137). The RI is based on calculations of iron require-
ments in infancy and childhood in the Nordic nutrition recommendations (NNR) 
(138). The up-regulation of iron absorption when iron stores are low has not been 
accounted for in the factorial model from which the iron requirements of infants 
are obtained (135). This could lead to an overestimation of requirements. Conse-
quently, the scientific background to determine iron requirements of infants would 
be strengthened by information from intervention studies.  
Iron intake by infants and young children 
The concentration of iron in human milk is approximately 0.3 mg/L and the 
literature show gastrointestinal absorption to be about 50 %. In infants who are 
exclusively breastfed, the iron intake is approximately 0.2 mg/day if they consume 
700 ml milk per day. Infants  consuming infant formula as the sole source of 
nutrition may reach an intake of 6 mg/day iron from formulas complying with 
iron content regulations (131). The higher concentrations of iron in infant formula 
than in breast milk could, at least partly, be explained by previous assumptions of 
much lower bioavailability of iron from infant formula than from breast milk. 
However, lower iron levels in infant formula have been recommended in recent 
years (139). 
 
Important iron sources in older children and adults are meat and meat products, 
pulses, cereals and green vegetables. Breast milk provides sufficient iron for most 
infants below 6 months. In the second half of infancy and in young children, iron- 
fortified products are important iron sources. In a study of one-year-old Swedish 
children, iron-fortified gruel, follow-on formula and porridge contributed with  
64 % of the total iron intake while meat contributed with 17 % of the total iron 
intake in this age group (140). Studies from the 1980s indicate that diets of the 
majority of infants at 6 and 12 months meet iron requirements (141, 142). A study 
of 90 one-year-old children in Sweden indicates a mean iron intake of 9 mg/day 
(140). 
 
Hazard identification 
Adverse effects of insufficient iron intake 
A summary of the negative effects of iron deficiency can be found in the British 
Scientific Advisory Committee of Nutrition´s report Iron and Health (134). Iron 
deficiency anaemia is associated with impaired neurodevelopment, and the conse-
quences seem to be irreversible. Iron deficiency anaemia has also been associated 
with impairment of several arms of the immune system. 
 
Randomised controlled trials provide evidence that iron deficiency anaemia is 
associated with impaired development of motor function in children less than 
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three years of age (134). It is, however, not possible to identify cut-off levels of 
iron status indicators at which child development may be impaired. One potential 
mechanism could be impaired brain development as suggested by evidence both 
from animal and human studies. Iron is needed in the production of myelin, which 
builds up a lipid cover around nerve cells to facilitate/speed up neurotransmission. 
Iron is also a catalytic element involved in the synthesis of neurotransmitters. 
Definitions of anaemia and of iron deficiency vary between studies, making com-
parisons difficult. A number of factors that often coincide both with iron defi-
ciency anaemia and with child development could act as confounders. Environ-
mental factors such as psychosocial, economic and biomedical factors found to be 
associated with iron deficiency anaemia may explain some of the association bet-
ween iron deficiency anaemia and impaired child development. 
Adverse effects of excessive iron exposure 
Acute iron toxicity in children is often due to accidental ingestion of iron supple-
ments. The symptoms after ingestion of large amounts of iron are nausea, vomi-
ting, loose stools, haemorrhagic necrosis of the gastrointestinal mucosa that, at 
very high doses, may result in hypovoalemic shock, multi-organ failure and death 
(134). High intakes of iron may lead to impaired liver function. Chronic iron 
toxicity may occur in primary haemochromatosis, when high iron uptake leads to 
high incorporation of iron in tissues and organs.  
 
High iron intakes may lead to adverse effects through the capacity of facilitating 
oxidative reactions or by interactions with other transitional metals. Interactions 
have been found among iron, copper, manganese, cobalt, cadmium, lead, and zinc. 
One example is that iron in infant formula may reduce copper absorption and 
status (143, 144). To describe these interactions in detail is, however, beyond the 
scope of this report. 
 
It has been hypothesised that high iron concentrations in tissues are associated 
with an increased risk of cancer, cardiovascular disease, infection and inflame-
mation and several other conditions (134). The data to support that these condi-
tions are related to high intakes of iron are almost exclusively derived from 
investigations in adults. The exceptions are growth and infection, as evidence 
from randomised controlled trials suggests that iron supplementation of iron- 
replete infants and children may impair physical growth and increase the risk of 
certain infections (145). A recent study indicates that iron-replete infants may be 
at risk of adverse effects on development by consuming an infant formula with a 
high iron concentration (146).  
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Hazard characterisation  
Adverse effects of insufficient iron intake  
Iron deficiency anaemia is a worldwide problem, particularly prevalent in low 
income countries. Infants, young children and women of childbearing age are risk 
groups for developing iron deficiency anaemia. Low iron status of women, high 
prevalence of low birth weight and infections make infants and children in low 
income populations at high risk. Because iron is accumulated in the foetus in the 
last trimester of pregnancy, infants who are born premature or with a low birth 
weight have lower iron stores at birth and are at risk of iron deficiency (147, 148). 
There are reports of lower iron stores in children fully breastfed for 6 months 
compared to children who received complementary foods before 6 months (149, 
150). Non-dietary factors associated with lower serum ferritin are male sex (148) 
and rapid weight gain (151). The prevalence of iron deficiency anaemia is very 
low during the first 6 months of life in European infants, and increases from 2- 
3 % at 12 months to 3-7 % at 1 to 3 years of age (135). In a study of 90 randomly 
selected Swedish one-year-old healthy children, about 10% were iron-depleted,  
as defined by having a serum ferritin ≤ 12 µg/L (140).  
 
Adverse effects of excessive iron exposure 
Intakes of 40-60 mg/kg body weight cause adverse health effects and intakes 
around 100 mg/kg body weight may lead to death (134). For individuals with 
primary haemochromatosis (0.5 % of the population), safety margins between 
normal iron intakes and risk of adverse effects are not evident  and these indivi-
duals are at risk of developing negative health effects following iron supple-
mentation (88). 
 
Doses of 1 mg/body weight/day supplemental iron may cause impaired length 
gain in iron-replete infants aged between 4 and 9 months (152). Adverse effects of 
iron supplementation in low-income countries on morbidity caused by infections 
has been observed at doses of 12-200 mg ferrous sulphate/day (145). Some inter-
actions between iron and other minerals may have implications for growth and 
development in infancy. The potential functional implications of lower copper 
status associated with the consumption of iron at high concentrations are not 
known.  
 
A UL of 10 mg non-haeme iron per day in addition to habitual dietary iron was set 
by NNR to protect against biochemical iron overload (serum ferritin 300 µg/L) 
(138). EFSA has not established a UL for iron because of a lack of scientific data 
(153). The IOM in the USA set a UL of 45 mg/day from all sources for adults and 
children from 14 years of age (93). For children younger than 14 years, the UL 
was set at 40 mg/day by the IOM. The UL for adults was based on gastrointestinal 
side effects of supplementation. It is not clear how the extrapolation from the UL 
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value for adults to the value for infants and children was made. In the United 
Kingdom, a guidance level of 17 mg/day of supplemental iron was set, based on 
gastrointestinal side effects of supplementation, while data was considered too 
limited in order to propose an UL for iron intake. A provisional maximum 
tolerable daily intake of 0.8 mg/kg bw/day was established by JECFA in 1983 
(154). This figure was used by Rasmussen et al (2006) to suggest a temporary 
guidance level of 10 mg/day for infants and children 1-3 years old (155). Because 
of the lack of scientific data for establishing UL values, we do not find it justified 
to use any value for the quantification of a possible risk of high iron exposures 
from infant foods. This should, however, not be interpreted as a lack of concern 
for adverse health consequences as a result of high iron intakes in infancy.  
 
Biomarkers of iron status 
The level of too low iron intake at which risks of development of adverse effects 
occur has been difficult to quantify. Studies often use biomarkers in blood or 
plasma to measure the risk of iron deficiency and iron deficiency anaemia. 
Anaemia is often used as an indicator of iron status of infants because testing 
haemoglobin concentrations in the blood is cheap and easy to perform. Haemo-
globin levels may be low for a number of reasons other than iron deficiency, for 
example due to infections. A widely used indicator of iron status is serum ferritin, 
which is proportional to ferritin storage. One disadvantage of serum ferritin is that 
it is also an acute phase reactant that may be elevated in infection and inflamma-
tion. The cut-off values to identify infant anaemia (blood haemoglobin < 110 g/L) 
and iron deficiency (serum ferritin < 12 µg/L) used by WHO (156) have been 
criticised for overestimating anaemia and iron deficiency, and therefore lower 
levels have been suggested (157). Other indicators of iron status are, for example, 
concentrations of serum transferrin and zinc protoporphyrine. Optimally, several 
indicators should be used to identify iron deficiency. Studies where a distinction 
between anaemia and iron deficiency anaemia has not been made are difficult to 
evaluate because of the various potential causes of anaemia besides iron 
deficiency. 
 
Exposure assessment  
Estimated intakes for all individual products are presented in Appendix VI. 
Summary results for different product categories are presented in Tables 18 and 
19. Product categories have been divided into two main groups depending on 
whether the consumption scenario used for the products in a given category 
covers a whole day (Table 18) or a single portion (Table 19).  
 
On average, the daily iron intake from infant formulae was 2.4-5.1 mg (Table 18). 
The iron concentrations in the studied infant formulae were 3.5-6.9 mg/kg. The 
levels stated in LIVSFS 2008:2 (which is the implementation of directive 2006/ 
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141/EG): 0.3-1.3 mg/100 kcal corresponds to 2.0-9.1 mg/L when assuming 70 
kcal/100 ml in infant formula. In breast milk, the concentration was 0.28 mg/L, 
which is in line with previously published breast milk concentrations (135). An 
infant consuming 700 ml breast milk per day would hence have an iron intake of 
0.2 mg iron/day. The iron concentrations in the four studied follow-on formulae 
were 7.8-9.4 mg/kg. The products in the category of FSMP are used for treatment 
of malnutrition, allergy or PKU. The range of iron concentrations in this category 
was wide. Iron-fortified gruel or porridge is recommended during the second half 
of infancy because of the high iron requirements at this age. There is a large 
variation in the iron concentrations of gruel and porridge products. Most products 
in the category “foodstuffs for normal consumption” have low iron concentra-
tions.  
 
Table 18. Summary of estimated iron intakes from infant formula, follow-on 
formula, FSMP as the sole source of nutrition, FSMP as partial nutrition and  
from breast milka 
Product category Age 
(months) 
No. of 
products 
Intake  
(mg /day) 
Infant formula  0-4 9 4.0 (2.4-5.1) 
Follow-on formula  6-8 4 7.0 (4.7-7.9) 
FSMP as sole source  
of nutrition 
0-12 21 5.3 (2.7-10.0) 
FSMP as partial feedingb 0-12 3 4.8 (2.2-10.9) 
Breast milkc 3 weeks  0.2 
 aValues are median (range) 
bNutramigen 2 lipil, XP Maxamaid and PKU anamix infant lcp+ 
cA composite sample of human milk collected week 3 post-partum, n=90  
 
 
 
Table 19. Summary of estimated intakes of iron per consumed portion from gruel, 
porridge, FSMP as partial feeding and  foodstuffs for normal consumptiona 
Product category Age 
(months) 
No. of 
products 
Intake  
(mg/portion) 
Gruelb  6-12 12 2.6 (1.2-3.8) 
Porridge b 4-12 21 2.1 (0.3-3.14) 
FSMP as partial feedingc 12 3 3.0 (2.8-3.9) 
Foodstuffs for normal 
consumption 
12 12 0.21 (0.01-1.2) 
 aValues are median (range) 
bProducts to be mixed with any kind of milk are not included in this table  
cFresubin energy fibre drink, PKU gel and Frebini energy fibre drink 
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Risk characterisation 
 
Intakes in relation to RI 
We did not compare iron intakes from infant formulae below 6 months with any 
reference intake, as there is no RI for infants less than 6 months of age. The average 
iron intake from follow-on formulae (Table 18) is slightly below the RI. The 
estimated daily intake of BabySemp 3 follow-on formulae, recommended from 8 
months of age, results in an intake of less than the RI. According to our calcula-
tions, additional sources of iron are needed in addition to this product in order to 
reach the RI. All products in the FSMP category recommended for infants 6 months 
or older (n = 8) contain iron sufficient to cover the RI, except for Neocate advance, 
recommended from 12 months (5.4 mg/day) and Minimax enteral formula for 
children, recommended from 6 months (5.4 mg/day). It is, however, possible that 
these products are prescribed for use in combination with other foods.  
 
The number of portions required to reach the RI by consumption of gruel or 
porridge only varies from 3 to 10 for products recommended from 6 months. These 
products should be mixed with water (Table 20). Products that are recommended 
for infants from 4 months have not been compared with an RI since no RI is 
available below 6 months. However, those products have lower iron concentrations 
than products intended for infants from 6 months. For products recommendded 
from 6 months that should not be mixed with water, the iron concentration of added 
breast milk or follow-on formula will determine the iron concentration of the final 
product. First Flavour and Céréales Cacao should be mixed with the baby’s usual 
milk according to the package information. One of the porridge products (Organic 
seven grain cereal) with a relatively low iron concentration should be mixed with a 
milk product. If mixed with Follow-on formula 2 from Holle the final concentration 
will be 0.9 mg/kg and 9 portions are needed to reach RI with this product. Some 
products that should be mixed with water contain iron concentrations in the lower 
range: Wholegrain porridge multigrain and Mild wholegrain porridge from HIPP 
and Oat porridge from Holle. These are non-fortified organically grown products. 
Rice, soy and oat drinks are not important sources of iron. 
 
Table 20. Summary of estimated iron intakes expressed in terms of number  
of portions required to reach the RI of 8 mg/daya 
Product category Age 
(months) 
No. of 
products 
Number of 
portions to reach 
RI 8 mg/day 
Gruel b 6-12 12 3 (2-7) 
Porridge b 6-12 13 4 (3-10) 
FSMP as partial feeding 12 3 3 (2-3) 
Foodstuffs for normal 
consumption 
12 12 55 (6-700) 
aValues are median (range) 
bProducts recommended to infants less than 6 months and products to be mixed with any kind of 
milk are not included in this table  
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Contribution from water 
Iron in groundwater may contribute to iron status (158). The general contribution 
of water to iron nutrition is probably small in Sweden, although high iron con-
centrations may occur in private wells. Public water may contain 0.2 µg/L when 
reaching the consumer (SLVFS 2001:30). For a 3-month-old infant, this corre-
sponds to an additional intake of 126 µg per day from the 630 ml water needed to 
prepare 700 ml infant formula.  
Discussion  
Iron is an essential and particularly important nutrient for development of infants. 
There are still a number of questions concerning the risks and benefits of iron 
intake during this vulnerable period. Iron requirements increase rapidly in the 
second half of infancy and infants in risk groups may have difficulties in reaching 
sufficient intakes, although most infants meet dietary iron requirements according 
to older studies (141, 142). It is, however, possible that the feeding pattern of 
infants has changed in terms of product choices since these studies were perform-
ed. Data on 12-month-old children indicate that porridge and gruel are outstanding 
as sources of dietary iron (140). Our study shows that the choice of gruel or 
porridge could make a large difference to the iron intake of an infant. Swedish 
population based data on infant feeding practices are needed to increase our 
understanding of important determinants of iron nutrition in infancy.  
 
The risk of possible adverse effects in relation to high iron intakes could not be 
evaluated based on established tolerable upper intake levels and hence no safe 
daily intake could be determined. Some products in the FSMP category contain 
concentrations of iron which lead to intakes of about 10 mg/day compared to daily 
intakes of up to 5 mg/ day from infant formula. We are not able to quantify a risk 
of development of adverse health effects at this or other levels of intake. Further-
more, we are not aware of the scientific justification for the higher iron concentra-
tions in the FSMP category than in infant formulae.  
 
A discussion about the risks following low and high iron intakes should take into 
account the physiological changes in iron metabolism during the first year of life. 
At an age of below 6 months, most infants need little iron. Breast milk or formula 
with intakes that correspond to the amounts absorbed from breast milk would be 
sufficient to cover iron needs for most infants at this age because endogenous iron 
compensates for low intakes. Around 6 months, most infants do need additional 
iron sources beside breast milk. Current RI does not take into account the increas-
ed efficiency of iron uptake when iron stores in the body are insufficient, which 
means that there may be an in-built overestimation of iron requirements. On the 
other hand, research indicates that iron absorption cannot be down-regulated 
efficiently by infants before 9 months of age and too high intakes could thus infer 
a health risk. Infants and children who are iron-replete are at risk of adverse 
consequences of excessive iron intake. It is, however, uncertain if the adverse 
effects on growth and infections noted in iron supplementation trials occur to the 
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same extent when food is fortified with iron. After 9 months of age, the benefits of 
iron for some individuals in a population could perhaps outweigh the potential 
risks of excess intakes as absorption is then under physiological regulation. The 
potential risks of high iron intakes from fortified products are poorly investigated 
in infants and young children. In particular, long term studies are few. 
Considering the seriousness of the potential adverse health effects, such as 
impaired growth and development, caution should be taken in assuring that infants 
and young children are not consuming excess iron. An important step would be to 
establish ULs for iron in infants and young children. A complete risk-benefit 
assessment of the iron intake from infant formula and other iron fortified products 
is yet to be done. 
Conclusion 
The iron intake from most of the studied follow-on formulae and FSMP for use as 
the sole source of nutrition meets the RI of iron from 6 months. There is no RI of 
iron before 6 months. There is a large variation in the iron concentrations of 
porridge and gruel and some products are important iron sources while others 
contribute less to iron nutrition in infancy. Infants and young children are at risk 
of iron deficiency because of high requirements due to growth and development. 
Infants with inadequate iron nutrition are at risk of irreversible negative effects on 
development. On the other hand, infants below 9 months may be particularly 
sensitive to high iron intakes because of immature regulation of iron. Excess iron 
intake in infants and young children may have serious implications such as 
impaired development and growth. It is a matter of concern that the level of iron 
intakes at which negative health effects may occur is not quantified for infants. 
Iron requirements for infants and the tolerable upper level of intake should be 
defined and established before an optimal level of iron fortification of food 
products for infants and young children can be determined. In particular, it is 
urgent that an UL of iron for infants and young children is established. 
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Copper (Cu) 
Nutritional background 
Physiological function of copper 
Copper is an essential trace element, as it is a component of many enzymes and 
proteins in living organisms. As a cofactor in enzymes involved in the defence 
against oxidative stress, copper seems to play an important role (159). Copper is 
required for normal growth of infants, host defence mechanisms, bone strength, 
maturation of erythrocytes and leukocytes, iron transport, and brain development 
(160). Both deficiency and excess of copper can result in varied symptoms in, for 
example, the haematopoietic system, the skeleton, the liver, and the brain (160).  
Dietary sources of copper 
There is high variability in the copper content of different foods, depending on the 
type of food but also on the place of cultivation, season, processing and cooking 
methods. Copper is found in all kinds of food and the highest concentrations are 
found in nuts and seeds and cocoa (about 10 mg/kg). Meat, fish, vegetables and 
cereals generally contain lower concentrations of copper (0.5-2 mg/kg). Public 
drinking water pipes from municipal waterworks leading to private properties are 
not made of copper and the public drinking water contains no copper. In contrast, 
about 80% of the drinking water pipes inside private households are made of 
copper. Depending on the chemical composition of the water, temperature, pipe 
length and contact time copper can be dissolved in the water that has been 
stagnant in the private property pipes. The intake of copper from drinking water is 
estimated to a couple of milligrams daily, but variation in intake may be 
considerable (161).  
Copper absorption 
Normal adults  regulate the amounts of copper absorbed and excreted. This 
regulation takes place in the liver. Whether an effective regulation of copper also 
operates in infants is at present not clarified. Copper accumulates in the foetus 
mainly during the third trimester of pregnancy. Premature and low birth weight 
infants are therefore at higher risk of copper deficiency than full term infants 
(160). Copper accumulates in the liver to a higher level than is tolerated in adults. 
For the neonate, this acts as a reserve to avoid copper deficiency in the first 
months of life. At about 6 months of age, liver reserves are found to contain the 
same concentrations as those of adults (160). Copper absorption depends on the 
copper nutrition of the individual and the type of animal or plant source of copper. 
Zinc, iron, certain amino acids, ascorbic acid, and fructose also affect copper 
uptake. Of special importance in infant nutrition is zinc. However, reduced Cu 
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absorption seems to be present only at high zinc intakes. Copper absorption from 
from breast milk is estimated to 80 % (160).  
Recommendations and intakes of copper  
The requirements of copper in infancy are high, due to rapid growth and brain 
development. The recommended intake for infants 0-23 months is 0.3 mg/day and 
for children 2-5 years old 0.4 mg/day (137). Daily intake of copper from foods has 
been found to be in the range of 1-2 mg/day in adults and 0.6-0.8 mg/day in young 
children (162). Analysis of market baskets representing a typical Swedish diet 
(exluding drinking water) showed intakes of 1.3 mg/day for adults. 
 
Hazard identification  
Adverse effects of insufficient copper intake 
Severe deficiency of copper may be associated with a variety of symptoms related 
to reduced activity of enzymes containing copper, for example neutropaenia and 
anaemia and in addition impaired development in children (88). The symptoms of 
copper deficiency are well characterised due to the presence of conditions that 
lead to abnormal copper metabolism such as in Menke´s disease. Patients with 
Menke´s disease develop a severe copper deficiency with, for example, severe 
mental impairment, growth failure, hypothermia, loss of skin and hair pigmen-
tation, bone fractures, retinal dystrophy and premature death (160). 
Adverse effects of excessive copper exposure  
An excessive intake of copper has an irritating effect on the gastrointestinal tract 
and has previously been used to induce vomiting in the event of poisoning. High 
intakes of copper may in the long run lead to liver damage. Certain heritable 
diseases are known to result in impairment of the normal metabolism of copper in 
the body. Wilson’s disease, which is an autosomic recessive disorder, will lead to 
an accumulation of copper mainly in the liver and the brain. In Idiopathic Copper 
Toxicosis (ICT) abnormally high levels of copper in the liver have been found in 
infants and young children. 
 
Hazard characterisation  
Adverse effects of insufficient copper intake 
Copper deficiency is not common in humans, but may occur, for example in 
patients receiving total parenteral nutrition for a long time (88). Of importance, 
mainly in low-income countries, is that infants recovering from malnutrition may 
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develop copper deficiency (160). In particular infants fed mainly cow´s milk and  
a high intake of refined carbohydrates such as polished rice are at high risk of de-
veloping symptoms of copper deficiency. Premature infants are at higher risk of 
developing copper deficiency in the neonatal period than infants born at term.  
Adverse effects of excessive copper exposure 
Acute effects (abdominal pain and vomiting) after ingestion of copper compounds 
may occur after doses in the range of 10-15 mg (163). In general chronic effects 
due to copper ingestion are rare as the mechanisms of homeostasis are effective, 
but certain subpopulations may be more vulnerable (88). There is probably a 
genetic susceptibility that explains that some individuals cannot tolerate moderate 
to high intakes of copper, but the extent and mechanism of this are not fully 
understood. There are some data suggesting an association between a high intake 
of copper from drinking water and diarrhoea in children and gastrointestinal 
disturbances and acute liver failure (88).  
 
In a Swedish study from 2003, including 430 children, a total of 4,703 samples  
of drinking water from the homes of the children were analysed (161). A median 
concentration of 0.61 mg copper/L was found in the study, and the 10th and 90th 
percentiles were found to be 0.04 mg/L and 1.57 mg/L respectively. The occur-
rence of vomiting and diarrhoeas experienced by the children during 12 weeks 
were studied, but no associations between these outcomes and concentration of 
copper in the drinking water were found. In adults, studies from Chile have de-
monstrated symptoms of vomiting starting at concentrations of 4 mg/L in women 
and of 6 mg/L in men. No symptoms were observed at a concentration of 2 mg/L 
(164). 
 
Wilson’s disease is an uncommon disease and the incidence is estimated to 1 
person in 30,000 (88). If untreated, Wilson´s disease will result in accumulation of 
copper in the liver and the brain. The consequences may be hepatitis, haemolysis 
and liver failure (88). A high liver copper concentration does not by itself 
necessarily lead to tissue damage. In healthy full term neonates hepatic copper 
concentrations may at birth be similar to those observed in individuals with 
Wilson´s disease. It is, however, not known why these large amounts of copper in 
the liver do not induce adverse effects (165).  
 
The disease ICT, which is very rare (165), is probably caused by a combination of 
heredity and high intake of copper early in life (88). Studies from, for example, 
Germany on children up to 12 months old have not shown any effects on the liver 
after exposure to concentrations up to 2 mg/L (166).  
Upper level of tolerable intake of copper 
When establishing an upper level of tolerable intake of copper, the potential 
development of liver damage was considered, since this was regarded a better 
indicator of chronic exposure than the gastrointestinal effect which is the result of 
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acute exposure. In the United States, the IOM has set an UL of copper at 10 mg 
daily for adults on the basis of effects on the liver (93). EFSA has established an 
UL of copper at 5 mg per day based on the same study used by the IOM (88). The 
difference between these values is explained by the fact that EFSA has applied a 
safety factor of 2 in order to consider the potential variation in the population. In 
addition, EFSA (88) has set ULs of copper for children on the basis of relative 
body weights (standard body weights were used): 1-3 years old: 1 mg/day, 4-6 
years old: 2 mg/day, 7-10 years old: 3 mg/day and 11-17 years old: 4 mg/day. 
Currently there is no UL established by EFSA or the IOM for infants 0-12 months 
old. According to a recently published paper (165), current copper ULs should be 
reevaluated as there are new experimental data (data from clinical trials and 
experimental studies in primates) as well as new biomarkers of copper status 
(such as some copper-dependent enzymes and chaperones. 
Biomarkers of copper status 
Sensitive and specific Cu status biomarkers have not yet been identified. The 
currently used biomarkers, cuproenzymes such as the acute phase protein cerulo-
plasmin and Cu-Zn-superoxide dismutase, are influenced by dietary and environ-
mental factors (167). These biomarkers may also increase during inflammation, 
pregnancy, ageing and a number of diseases, and copper deficiency could be 
masked as a consequence of these conditions (165). Superoxide dismutase 3, the 
predominant form of SOD in serum, has also received attention as a potential 
index of copper status (165). Cu chaperones are considered potential promising 
biomarkers that responds to both Cu deficiency and excess, but their reliability  
has yet to be established (167).  
Exposure assessment  
Estimated intakes for all individual products are presented in Appendix VII. 
Summary results for different product categories are presented in Tables 21 and 
22. Product categories have been divided into two main groups depending on 
whether the consumption scenario used for the products in a given category 
covers a whole day (Table 21) or a single portion (Table 22). As is evident from 
Tables 21 and 22, the highest exposure is to be expected from intake FSMP as 
sole source of infant nutrition and FSMP as partial infant nutrition (168). The 
intake from breast milk is given as a reference in Table 21. The concentration of 
copper was 1,120 µg per kg breast milk (1). However, this value does not seem to 
be within the range for most average copper concentrations (200-600/L) in breast 
milk reported in the literature (160, 168).  
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Table 21. Summary of estimated intake (µg/day) of copper  from infant formula, 
follow-on formula, FSMP as sole source and partial source of nutrition and breast 
milk. 
Product group Age 
(Months) 
Number of 
products 
Intake  
(µg/day)a 
Infant formula 0-4 9 252 (232-370) 
Follow-on formula 6-8 4 340 (166-353) 
FSMP as sole source of nutrition 0-12 24 340 (140-1233) 
FSMP as partial feedingb 0-12 3 484 (170-786) 
Breast milkc 3 weeks  787 
aValues are median and (range) 
bNutramigen 2 lipil, XP Maxamaid and PKU anamix infant lcp+ (recommended daily intake) 
cA composite sample of human milk collected week 3 post-partum, n=90  
 
 
Table 22. Summary of estimated intakes of copper - as µg per consumed portion 
from gruel, porridge, FSMP as partial feeding and foodstuffs for normal 
consumption 
Product group Age 
(Months) 
Number of 
products 
Intake (µg per 
consumed 
portion)a 
Gruel products 6-12 14 39 (5-94) 
Porridge products 4-12 26 55 (17-161) 
FSMP as partial feedingb 0-12 3 308 (160-580) 
Foodstuffs for normal 
consumption 
12 12 51 (5-143) 
aValues are median and (range) 
bFresubin energy fibre drink, PKU gel and Frebini energy fibre drink 
 
Risk characterisation 
Daily intakes from the analysed products in relation to RI 
There is at present no recommended intake established for infants 0-6 months of 
age. For infants and children 6-23 months the RI is set at 0.3 mg/day. Intake of 
copper from products intended for infants > 6 months were compared to RI. All 
follow-on formula recommended from 6 months of age had concentrations which 
lead to intakes higher than the RI. According to our calculations, BabySemp 3 
follow-on formula, from 8 months of age had a concentration (0.33 mg/kg), 
corresponding to 55 % of the RI, and additional sources of copper are needed to 
fulfil the RI. Products in the categories of FSMP, as sole and partial feeding, 
contribute to daily copper intakes well beyond the RI. 
 
There is a large variation in the contribution of copper from gruel and porridge to 
the total intake of copper. Corn gruel from Nestlé had the lowest copper concen-
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tration (0.02 mg/kg), which means that in the quite unlikely scenario of reaching 
the RI for copper from this product only, 66 portions are needed. All products 
based on maize have relatively low copper concentrations. Products to be mixed 
with other milks or infant formula are included in Table 23. These products (2 
gruels and 1 porridge for infants from 6 months of age) did not have lower 
concentrations of copper than products to be mixed with water.  
 
In the product category “Foodstuffs for normal consumption” oat toasted and 
milled and several soydrinks contribute to a high extent to total copper intake. 
Rolled oats and rice-based drinks do not contribute to the same degree.  
 
Table 23. Summary of estimated intakes expressed in terms of the number of 
portions required to reach the RI of 0.3 mg/day. 
Product group Age 
(Months) 
Number of 
products 
Number of 
portions to 
reach the RIa 
Gruel products 6-12 14 8 (3-66) 
Porridge 6-12 14 5 (2-7) 
FSMP as partial feeding 12 3 2 (1-2) 
Foodstuffs for normal 
consumption 
12 12 7 (2-59) 
aValues are median and (range)  
Products for infants < 6 months are not included in the table.  
 
Daily intakes from the analysed products in relation to UL 
In the present investigation the exposure from infant formula does not exceed the 
UL established by EFSA in 2006 (88). Intake of copper by consumption of this 
kind of products varies between 23 - 37% of the UL. However, infant formula is 
consumed by newborn infants and when considering potential effects of excessive 
intake of copper it should be emphasised that the current UL does not apply to 
children younger than 12 months. This implies that the UL of 1,000 μg/day prob-
ably would not be the adequate reference value to be used in a risk assessment of 
the exposure of younger infants.  
 
The contribution of copper from FSMP as the sole source of nutrition can be quite 
high from some products in relation to the UL set by EFSA. The highest intake 
(about 1,230 g daily) is received from Fresubin soya fibre and intake of recom-
mended daily amounts of two other FSMP products − Isosource junior and 
NutriniKid multi fibre −  will result in intakes of about 900 and 780 µg per day. 
Fresubin energy fibre, results in exceeding the UL after an intake of about two 
portions daily. The contribution per portion from gruel and porridge seems to be 
modest and safety margins in relation to UL are rather wide in these product 
categories.  
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Table 24. Summary of estimated  intakes – as a percentage of the tolerable upper 
level (UL). UL for 1- 3 years old, 1000 μg/day, was established by EFSA (2003) a. 
Product group Age 
(Months) 
Number of 
products 
Percent of ULa 
Infant formula 0-4 9 25 (23-37) 
Follow-on formula 6-8 4 17 (33-35) 
FSMP as sole source of nutrition 0-12 24 34 (14-123) 
FSMP as partial feedingb 0-12 3 48 (17-79) 
aValues are median and (range) 
bNutramigen 2 lipil, XP Maxamaid and PKU anamix infant lcp+ (recommended daily intake) 
cA composite sample of human milk collected week 3 post-partum, n=90  
 
Table 25. Number of portions needed in order to reach UL. 
Product group Number of 
products 
Number of portions 
to reach UL a 
Gruel products 14 26 (11-221) 
Porridge products 26 18 (6-61) 
FSMP as partial feeding 3 4 (2-6) 
Foodstuffs for normal consumption 12 23 (7-197) 
aValues are median and (range) 
 
 
Copper in drinking water −  MRL and estimated contribution to intake  
from infant formula  
The EU has established a common maximum residue limit (MRL) for copper in 
drinking water. The MRL is set at 2.0 mg copper/L in order to protect from 
transitional acute gastrointestinal effects. The guideline of WHO also recom-
mends an MRL of 2.0 mg/L (169). According to Swedish regulations (SLVFS 
2001:30 and SOSFS2003:17) water can be used for drinking, though with an 
adverse remark, at copper concentrations exceeding 0.20 mg/L. The risk of 
negative health effects due to increased concentrations of copper in drinking water 
is considered to be low. Infants receiving formula may, however, be more 
vulnerable. Some examples of contributions of copper from drinking water are 
presented below. 
 
Assuming a concentration of copper at 200 µg/L and an intake of 630 mL water 
by a child about 3 weeks old, this would result in a daily intake of 126 μg. A 
consumption of 630 mL is assumed as it would correspond to the amount of water 
needed to prepare 700 mL of infant formula, which is our estimated consumption 
by infants of this age. The median intake of copper from infant formula would 
then increase from 252 μg daily (see Table 21) to about 378 μg daily, but still 
below the UL of 1000 μg daily. As mentioned earlier, this UL does not, however, 
apply to children younger than 12 months. 
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If we assume a type of worst case scenario assuming a water concentration of 
2,000 µg/L (the MRL, set by WHO), the contribution of copper from drinking 
water would be 1,260 μg daily under the same assumptions as above and total 
maximal exposure could be estimated to 1,260 daily + 370* μg daily = 1,630 μg 
daily. For infant formula this exposure would thus result in an intake clearly 
exceeding the UL for children 1-3 years old of 1,000 μg daily. 
*Maximum value in the range stated for infant formula in Table 21. 
Discussion  
Negative health effects due to copper may be related either to deficiency or 
excessive intake. Thus, there is an acceptable or optimal interval for intake of 
copper. Some gruels, especially those made from maize flour, had low copper 
concentrations. However, copper is common in a variety of foods and unless the 
diet has very low variation copper requirements are likely to be met by other 
foods in the diet.  
 
Overall intake of copper from the analysed infant foods, except for some products 
categorised as FSMP, seems to be reasonable in relation to the current UL of 1000 
µg/day for children 1-3 years old. However, applying the UL in assessments of 
risks of copper exposure in children less than 1 year  may underestimate potential 
risks for infants younger than 12 months. The contribution of copper from drink-
ing water to the products may be considerable, and the median concentration of 
infant formula will exceed the UL if the water contains copper in a concentration 
at the maximum guideline level (2.0 mg/L) established by WHO in 2004. How-
ever, applying the guideline level permitted in Sweden (0.2 mg/L) will not result 
in an intake exceeding the UL. As the UL is clearly exceeded after consumption 
of some product categorised as FSMP, the need for copper in the amounts provi-
ded in the products should be verified. These products are intended for children at 
an age of 12 months or older and hence the used UL is applicable. Regarding 
levels of copper in processed cereal-based foods and baby foods for infants and 
young children, the view of the SCF (4) is that since copper intake by children is 
generally sufficient it is not advisable to add copper. The maximum level accord-
ing to legislation for FSMP intended for children at an age of 12 months or older 
is 0.5 mg/100 kcal (SLVFS 2000:15, which is the implementation of directive 
1999/21/EG). Another issue which probably should be paid attention to in this 
context is the  interactions associated with intakes of other essential minerals like 
iron and zink. As it is beyond the scope of this report to discuss these interactions, 
they should be considered in a full risk-benefit assessment.  
Conclusion 
Copper is common in a variety of foods and copper intakes are likely to cover the 
RI for most infants by the intake of the analysed products solely or in combination 
with other foods. Overall intake of copper from the analysed infant foods, except 
for some products categorised as FSMP, seems to be reasonable if the UL of 1000 
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µg/day for children 1-3 years old is applied for infants 0-1 year old. However, this 
approach may not be appropriate and may result in an underestimation of potential 
risks for infants younger than 12 months. Thus, the risk of high copper exposures 
in infancy and childhood is at present of greater public health concern than the 
risk of inadequate copper nutrition. 
 
It is urgently needed to establish an UL for infants younger than 12 months. It 
should be noted that the contribution of copper from drinking water to the 
products may be considerable and precautionary measures should be taken in 
order to assure that infants and young children are not exposed to excess copper 
intakes.   
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General points to consider 
It should be noted that the exposure assessments in this report are based on several 
assumptions. The calculations are made for an infant or child of average weight, 
for the age group for which the product is recommended, and for consumption of 
the product in the amount of the product recommended on the packaging, or an 
average intake for the age group, based on previous research. Variability due to 
individual differences in body weight and in consumption may be large, and this 
is not accounted for in this assessment. Variability in intakes may be particularly 
high for FSMP products, because the consumption of such products is tailored by 
a dietician or physician to satisfy the special needs of an infant or child with a 
particular medical condition. The variations in concentration of contaminants and 
minerals in the different products are assumed to be small, as the food products 
included in our assessment are manufactured under standardised protocols, 
perhaps with the exception of products in the category “Foodstuffs for normal 
consumption”.  
 
The additional contribution to the exposure by water used for product preparation 
was considered to some extent. The contribution from water may potentially be 
high in individual cases, particularly if water from private water wells is used.  
 
We were not able to account for the bioavailabilty of minerals from the analysed 
products. More data on bioavailabilty of the minerals from analysed products 
would be needed for an in-depth assessment of risks and benefits associated with 
certain intakes.  
 
Furthermore, effects of intakes of combinations of metals were not assessed, 
although there are indications of interactions between several of these contami-
nants and minerals. Thus, no attempts were made to quantify the total risk of high 
intakes of contaminants and minerals in products with a high concentration of 
more than one contaminant or mineral. Although infants or young children who 
consume several products with high concentrations of contaminants and minerals 
may be at particular risk of adverse health effects, our data did not allow for 
assessment of such scenarios. 
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Appendix I. Labelling information on products included in the project 
Table 1. Food for Special Medical Purposes for infants (0-12 months)
Product
(English translation)
Id Producer Age 
group
Intended 
use
Labelled 
energy 
kcal/100 
g
Labelled 
Copper
μg/100g1 
Labelled 
Manganese
μg/100g1
Labelled 
Iron
mg/100g1 
Main ingredient Sole 
source 
of
nutrition
Product 
sold as
Althéra M75 Nestlé >1 w Allergy 510 410  5.5 Lactose X P 
Enfalac premature M98 Mead Johnson w 23-402 Prenatal 490 515  8.3 Glucose syrup X P 
Enfamil AR lipil M78 Mead Johnson >1 w Reflux 500 330 300 5.5 Skimmed milk 
powder 
X P 
Enfamil Human Milk 
Fortifier4  
M61 Mead Johnson w 23-402 Prenatal 143 443 103 1.43 Medium chain 
tryglycerides  
 P 
FM 854  M60 Nestlé w 23-402 Prenatal 347 900 130 26 Maltodextrin  P 
Galactomin 19 formula M69 SHS  < 1y Intolerance  534 380 440 3.9 Fructose X P 
Minimax barnsondnäring 
(Minimax enteral formula 
for children)
M82 Nestlé  >6 mo Malnutrition 1205 1105 705 1.05 Skimmed milk X RFU 
Neocate LCP M72 Nutricia <1 y Allergy 475 380 380 7.0 Glucose syrup X P 
Nutramigen 1 lipil M1 Mead Johnson <6 mo Allergy 500 380 300 9 Glucose syrup 
(corn) 
X P 
Nutramigen 2 lipil M48 Mead Johnson >6 mo Allergy 466 349 279 8.2 Glucose syrup 
(corn) 
 P 
Pepti junior  M79 Nutricia < 1 y Allergy 
 
515 314 327 6.0 Glucose syrup 
(corn) 
X P 
Pepticate  M54 Nutricia <1 y Allergy 484 294 55 3.9 Whey protein X P 
PKU anamix infant lcp+ M85 SHS <1 y PKU 457 430 430 8.1 Glucose syrup  P 
Pregestimil lipil M99 Mead Johnson <6 mo Allergy 500 380 300 9 Glucose syrup 
(corn) 
X P 
PreNAN discharge M95 Nestlé w 23-402 Prenatal 510 410 80 5.3 Whey protein X P 
Profylac M103 Semper >1 w Allergy 500 300 320 5.5 Maltodextrin X P 
Id – identification of composite sample; w – week; mo-month; PKU – phenylketonuria; y – year; P – powder; RFU – ready for use 
1 Only presented if the mineral is labelled as an ingredient. 
2 Information from paediatric dieticians (not labelling). 
3 Per 100 ml product when reconstituted, i.e. four packets of Enfamil Human Milk Fortifier, the amount usually added to 100 ml of preterm human milk. 
4 The product should be diluted with breast milk.
5 Per 100 ml ready for use product. 
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Table 2. Food for Special Medical Purposes for young children (1-3 years)  
Product Id Producer Age 
group
Intended 
use
Labelled 
energy 
kcal/100 ml
Labelled 
Copper
μg/100ml1
Labelled
Manganese
μg/100ml1
Labelled 
Iron
mg/100ml1
Main ingredient Sole 
source of 
nutrition
Product 
sold as
Frebini energy fiber drink 
(chocolate flavour) 
M97 Fresenius 
Kabi 
1-12 y Malnutrition 150 150 180 1.5 Maltodextrin  RFU 
Fresubin energy fibre 
(pooled sample different 
flavours) 
M26 Fresenius 
Kabi 
>1 y Malnutrition 150 300 400 2.0 Maltodextrin X RFU 
Fresubin soya fibre M70 Fresenius 
Kabi 
>1 y Malnutrition 100 130 270 1.3 Maltodextrin X RFU 
Isosource junior  M71 Nestlé  >1 y Malnutrition 122 100 200 0.8 Maltodextrin X RFU 
Neocate advance M81 SHS  >1 y Allergy 4002 2402 2002 2.52 Glucose syrup X P 
Nutrini energy multi fiber M83 Nutricia 1-6 y Malnutrition 150 122 230 1.5 Maltodextrin X RFU 
Nutrini multi fiber  M84 Nutricia 1-6 y Malnutrition 100 81 150 1.0 Maltodextrin X RFU 
NutriniKid multi fibre 
(pooled sample different 
flavours) 
M27 Nutricia 1-6 y Malnutrition 150 135 230 1.5 Maltodextrin X RFU 
PKU gel (pooled sample 
different flavours) 
M28 Vitaflo > 1 y PKU 3422 7002 17002 102 Sugar  P 
Resource minimax 
(pooled sample different 
flavours) 
M29 Nestlé  >1 y Malnutrition 120 100 70 1.0 Skimmed milk X RFU 
XP Maxamaid (pooled 
sample different flavours) 
M53 SHS  1-8 y PKU 3092 18002 16002 122 Glucose syrup  P 
Id – identification of composite sample; PKU – phenylketonuria;y – year; P – powder; RFU – ready for use  
1 Only presented if the mineral is labelled as an ingredient. 
2 Per 100 g in products sold as powder.   
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Table 3. Infant formulae  
Product
(English translation)
Id Producer Age group Labelled 
energy
kcal/100g
Labelled 
Copper
μg/100g1
Labelled 
Manganese
μg/100g1
Labelled 
Iron
mg/100g1
Main ingredient2 Product 
sold as
BabySemp 1 Modersmjölksersättning 
(BabySemp 1 infant formula)  
M30 Semper 0-6 mo 633 4013  0.43 Demineralized whey 
powder 
RFU 
BabySemp 1 Modersmjölksersättning 
(BabySemp 1 infant formula)
M2 Semper 0-6 mo 510 320  3.3 Demineralized whey 
powder 
P 
BabySemp 2 Lemolac 
modersmjölksersättning (BabySemp 2 
Lemolac  infant formula) 
M14 Semper 4-12 mo 516 320  5.7 Demineralized whey 
powder 
P 
ECO 1 Modersmjölksersättning 
(ECO 1 infant formula) 
M15 HiPP > 0 mo 507 280 80 4.1 Whey (partly 
demineralized) 
P 
ECO 2 Modersmjölksersättning  
(ECO 2 infant formula) 
M16 HiPP >4 mo 496 285 51 5.3 Skimmed milk P 
Organic Infant milk M80 BabyNat 0-6 mo 517 330 30 5.5 Demineralized whey 
powder 
P 
Eko Modersmjölksersättning 1  
(Organic Infant formula 1) 
M92 Holle > 0 mo 519 290 88 3.2 Skimmed milk P 
NAN 1 Modersmjölksersättning 
(NAN 1 infant formula) 
M10 Nestlé > 0 mo 513 310 115 3.2 Demineralized whey 
powder 
P 
NAN HA 1 Modersmjölksersättning 
(NAN HA 1 infant formula) 
M11 Nestlé > 0 mo 510 410 125 5.5 Lactose P 
Id – identification of composite sample; mo – months; P – powder; RFU – ready for use 
1 Only presented if the mineral is labelled as an ingredient. 
2 All infant formulae were manufactured from cow’s milk proteins.
3 Per 100 ml ready for use product. 
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Table 4. Follow-on formulae  
Product 
(English translation)
Id Producer Age group Labelled 
energy
kcal/100g
Labelled 
Copper
μg/100g1
Labelled 
Manganese
μg/100g1
Labelled 
Iron
mg/100g1
Main 
ingredient2
Product 
sold as
BabySemp 3 Tillskottsnäring 
(BabySemp 3 follow-on-formula)
M13 Semper >8 mo 480 290  7.3 Demineralized 
whey powder 
P 
Eko tillskottsnäring 2 (Organic follow-on-
formula 2) 
M52 Holle >6 mo 494 300 97 6.1 Skimmed milk P 
NAN Pro 2 Tillskottsnäring  
(NAN Pro 2 follow-on-formula) 
M36 Nestlé >6 mo 495 370  7.3 Maltodextrin P 
Optima organic Follow-on-milk M76 BabyNat >6 mo 490 325 33 6 Maltodextrin P 
Id – identification of composite sample; mo – months; P – powder 
1 Only presented if the mineral is labelled as an ingredient. 
2 All infant formulae were manufactured from cow’s milk proteins.
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Table 5. Processed Cereal-based Foods for infants and young children: porridge 
Product
(English translation)
Id Producer Age 
group
Labelled 
energy
kcal/100g
Labelled 
Copper
μg/100g1
Labelled 
Manganese
μg/100g1
Labelled 
Iron
mg/100g1
Main ingredient
(content of wholegrain in 
percent)
Product 
sold as
Wholegrain 
Bio-Babybrei Grieβ (Wheat porridge)  M87 Holle 4 mo 359    Wholegrain wheat (100 %) P 
Eko dinkelgröt (Organic spelt  porridge)  M65 Holle 6 mo 354    Wholegrain spelt (100 %) P 
Eko havregröt (Organic Oat porridge)  M63 Holle 6 mo 386    Wholegrain oat (100 %) P 
Fruktgröt fullkorn (Fruit porridge 
wholegrain)  
M4 Semper 12 mo 450   8.5 Wholegrain flour (40 %) P 
Fullkornsgröt med äpple (Wholegrain 
porridge with apple) 
M17 HiPP 8 mo 432 142 670 3.9 Whey powder partly 
demineralized (20 %) 
P 
Fullkornsgröt multikorn (Wholegrain 
porridge multigrain)  
M39 HiPP 12 mo 422 Missing2 980 4.2 Whey powder partly 
demineralized (41 %) 
P 
Mild fullkornsgröt  
(Mild wholegrain porridge)  
M32 Nestlé 8 mo 410   10 Skimmed milk powder (37 %) P 
Mild fullkornsgröt  
(Mild wholegrain porridge)  
M42 HiPP 8 mo 424  1300 4.9 Whey powder partly 
demineralized (38 %) 
P 
Mild fullkornsgröt  
(Mild wholegrain porridge)  
M33 Semper 8 mo 460   8.5 Demineralized whey powder 
(47 %) 
P 
Mild havregröt  
(Mild oat porridge)  
M22 
 
HiPP 6 mo 434 140 1060 4 Whey powder partly 
demineralized (28 %) 
P 
Musligröt päron-banan  
(Musli porridge pear-banana)  
M9 Nestlé 12 mo 390   10 Oat meal (39 %) P 
Eko hirsgröt (Organic millet porridge)  M64 Holle 4 mo 393    Wholegrain millet (100 %) P 
Organic seven grain cereal3 M51 Organix 7 mo 374    Wholegrain wheat (100 %) P 
Rice porridge
Baby´s first food The ultimate four grain 
porridge3  
M90 Plum 4 mo 376    Quinoa and wholegrain rice 
(100 %) 
P 
Banangröt (Banana porridge) M3 Semper 4 mo 460   8.5 Rice flour P 
Banangröt mjölkfri (Banana porridge dairy 
free) 
M23 EnaGo 6 mo 450    Banana purée P 
Cerelac risgröt (Cerelac rice porridge) M31 Nestlé 4 mo 420   7.5 Rice flour P 
First organic wholegrain baby rice3  M56 Organix 4 mo 374    Wholegrain rice (100 %) P 
God Natt! Risgröt med grönsaker  
(Good night! Rice porridge with vegetables)  
M40 HiPP 4 mo 834    Milk RFU 
Eko risgröt (Organic rice porridge)  M91 Holle 4 mo 382    Wholegrain rice (100 %) P 
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Product
(English translation)
Id Producer Age 
group
Labelled 
energy
kcal/100g
Labelled 
Copper
μg/100g1
Labelled 
Manganese
μg/100g1
Labelled 
Iron
mg/100g1
Main ingredient
(content of wholegrain in 
percent)
Product 
sold as
Risgröt med banan och persika  
(Rice porridge with banana and peach)
M59 HiPP 4 mo 429 130 329 3.3 Whey powder partly 
demineralized 
P 
Risgröt med äpple och mango  
(Rice porridge with apple and mango) 
M25 Semper 5 mo 460   8.5 Rice flour P 
Sinlac specialgröt (Sinlac special porridge) M12 Nestlé 4 mo 420   10 Rice flour P 
Others
Cerelac fruktgröt banan apelsin (Cerelac 
fruit porridge banana orange)
M37 Nestlé 6 mo 420   7.5 Wheat flour P 
Dinkelgröt naturell (Spelt porridge natural) M86 Nestlé 6 mo 410   10 Spelt flour P 
Mild havregröt (Mild oat porridge) M35 Semper 4 mo 460   8.5 Skimmed milk powder P 
(%) – content of main ingredient (wholegrain or rice); Id – identification of composite sample; mo – months; P – powder; RFU – ready for use 
1 Only presented if the mineral is labelled as an ingredient. 
2 According to the list of ingredients copper was added, but the content of copper is not declared in the nutrient declaration.  
3 The product could/should be diluted with other liquids than water. 
4 Per 100 ml ready for use product.
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Table 6. Processed Cereal-based Foods for infants and young children: gruel (välling)  
Product
(English translation)
Id Producer Age 
group
Labelled 
energy
kcal/100g
Labelled 
Copper
μg/100g1
Labelled 
Manganese
μg/100g1
Labelled 
Iron
mg/100g1
Main ingredient
(content of 
wholegrain in 
percent)
Product 
sold as
Gruel           
Drickfärdig mild fullkornsvälling (Ready-to-
drink mild wholegrain gruel)
M34 Semper 8 mo 702   1.22 Skimmed milk RFU 
Fullkornsvälling (Wholegrain gruel) M18 Nestlé 12 mo 450   10 Wholemeal flour 
(44 %) 
P 
Fullkornsvälling havre vete råg (Wholegrain 
gruel oat wheat rye) 
M5 Semper 12 mo 450   8.5 Skimmed milk powder 
(34 %) 
P 
Mild fullkornsvälling (Mild wholegrain gruel)  M8 Semper 8 mo 460   8.5 Skimmed milk powder 
(18 %) 
P 
Mild fullkornsvälling havre (Mild wholegrain 
gruel oat)  
M21 Nestlé 8 mo 460   10 Skimmed milk powder 
(33 %) 
P 
Corn gruel
Låglaktos majsvälling (Low lactose corn gruel) M19 Nestlé 6 mo 480   8 Cornstarch P 
Majsvälling (Corn gruel)   M20 Semper 6 mo 470   8.5 Corn flour P 
Majsvälling (Corn gruel)   M96 HiPP 6 mo 496 255 50 4 Skimmed milk P 
Majsvälling (Corn gruel)   M7 Nestlé 6 mo 470   10 Skimmed milk powder P 
Rice gruel
Céréales Cacao3  M74 Babybio 8 mo 389    Rice flour 84 % P 
First flavour3 M73 Babynat 6 mo 386    Rice flour 89 % P 
Kvällsvälling ris och vete (Evening gruel rice 
and wheat)   
M55 Semper 6 mo 460   8.5 Skimmed milk powder P 
Välling mjölkfri (Gruel dairy free)   M24 EnaGo 6 mo 463   12 Flour (rice-. oat-. 
wheat-) 
P 
Oat gruel
God natt mild havrevälling (Good night mild 
oat  gruel)   
M6 
Nestlé 6 mo 470   10 Cornstarch P 
Id – identification of composite sample; mo – months; P – powder; RFU – ready for use.  
1 Only presented if the mineral is labelled as an ingredient. 
2 Per 100 ml ready for use product.  
3 The product could/should be diluted with other liquids than water. 
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Table 7. Breast milk and “foodstuffs for normal consumption”
Product (English translation) Id Producer Intended use Main ingredient
(content of main 
ingredient in percent)
Product 
sold as
Breast milk (w 3 post-partum. n=90)1 M50  Breastfeeding Human breast milk RFU 
Havredryck apelsin & mango (Oat drink orange & mango) M46 Oatly Oat drink Oat base (oat 10 %) RFU 
Havredryck naturell (Oat drink natural) M41 Carlshamn Oat drink Rolled oats (8.5 %) RFU 
Havregryn (Rolled oats) M47 Lantmännen Porridge Rolled oats P 
Pama minutris (Pama ‘minute rice’ ) M49 Quaker Porridge Rice, polished P 
Rice drink organic M38 Rice Dream Rice drink Rice (14 %) RFU 
Risdryck naturell (Rice drink natural) M45 Carlshamn Rice drink Rice (13 %) RFU 
Skrädmjöl (Oat toasted and milled) M77 Saltå kvarn Gruel or porridge Oat, toasted & milled P 
Sojadryck (Soya drink) M88 Garant Soya drink Soya beans (7.5 %) RFU 
Sojadryck original + Kalcium (Soya drink original + calcium) M58 GoGreen Soya drink Soya beans (6.5 %) RFU 
Solhavre naturell (Oat drink natural) M44 ICA Gott liv Oat drink Oat (10 %) RFU 
Soya drink natural fresh M43 Alpro Soya drink Soya beans (6 %) RFU 
Soya natural M57 Provamel Soya drink Soya beans (7.2 %) RFU 
Id – identification of composite sample; P – powder; RFU – ready for use 
1 Composite sample from 2008 (n=30), 2009 (n=30) and 2010 (n=30) from the ongoing biomonitoring project at the National Food Agency 
‘POPup’(personal communication with project leader Sanna Lignell). For details about sampling see Lignell S, Aune M, Darnerud P.O., Cnattingius 
S, and Glynn A (2009) Persistent organochlorine and organobromine compounds in mother´s milk from Sweden 1996-2006: Compound-specific 
temporal trend. Environmental Research 109:760-767. 
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APPENDIX II: Arsenic (As) 
 
Table 1. Estimated daily intake of arsenic from ready-to-eat infant formula, follow-on formula, FSMP as sole source of nutrition and FSMP as partial feeding. 
Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(ml /day) 
As concentration 
(µg /kg) 
As intake 
(µg/kg bw/day) 
Infant Formula 
NAN 1 Modersmjölksersättning (NAN 1 
Infant formula) 
Nestlé 0 4.2 700 0.78 0.13 
NAN HA 1 Modersmjölksersättning (NAN 
HA 1 Infant formula) 
Nestlé 0 4.2 700 0.71 0.12 
BabySemp 2 Lemolac modersmjölks-
ersättning (BabySemp 2 Lemolac infant 
formula) 
Semper 4 6.6 800 0.69 0.08 
ECO 1 Modersmjölksersättning (ECO 1 
infant formula) 
HiPP 0 4.2 700 0.89 0.15 
ECO 2 Modersmjölksersättning (ECO 2 
infant formula) 
HIPP 4 6.6 800 0.77 0.09 
BabySemp 1 Modersmjölksersättning 
(BabySemp 1 infant formula), powder 
Semper 0 4.2 700 0.69 0.12 
BabySemp 1 Modersmjölksersättning 
(BabySemp 1 infant formula), RFU 
Semper 0 4.2 700 0.90 0.15 
Organic infant milk Babynat 0 4.2 700 0.83 0.14 
Eko 1 Modersmjölksersättning, (Infant 
formula 1) 
Holle 0.5 4.2 700 0.54 0.09 
Follow-on-formula 
BabySemp 3 Tillskottsnäring (BabySemp 3 
follow-on-formula) 
Semper 8 8.5 500 4.6 0.27 
NAN Pro 2 Tillskottsnäring (NAN PRO 2 
follow-on-formula) 
Nestlé 6 7.7 900 0.71 0.08 
Eko tillskottsnäring 2 (Follow-on-formula 2) Holle 6 7.7 900 1.1 0.12 
Optima Organic Follow-on-milk Babynat 6 7.7 900 0.71 0.08 
FSMP used as sole source of nutrition 
Neocate advance SHS 12 9.8 900 0.63 0.06 
Nutrini energy multi fibre Nutricia 12 9.8 600 3.4 0.21 
Nutrini multi fibre Nutricia 12 9.8 900 2.7 0.24 
Resource minimax Nestlé 12 9.8 750 1.9 0.15 
Fresubin soya fibre Fresenius Kabi 12 9.8 900 1.3 0.12 
2 
Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(ml /day) 
As concentration 
(µg /kg) 
As intake 
(µg/kg bw/day) 
Isosource junior Nestlé 12 9.8 900 1.3 0.12 
Nutramigen 1 lipil Mead Johnson 0 4.2 700 1.5 0.24 
Pepticate Nutricia 0 4.2 700 0.57 0.10 
Galactomin 19 formula SHS 0 4.2 700 0.55 0.09 
Neocate LCP Nutricia 0 4.2 700 0.69 0.12 
Althéra Nestlé 0 4.2 700 0.58 0.10 
Enfamil AR lipil Mead Johnson 0 4.2 700 0.67 0.11 
Pepti junior Nutricia 0 4.2 700 0.69 0.11 
Minimax barnsondnäring (Minimax enteral 
formula for children) 
Nestlé 6 7.7 600 11 0.86 
Profylac Semper 0 4.2 700 1.3 0.22 
PreNAN discharge Nestlé  Premature/LBW 2.5 400 0.84 0.14 
Enfalac premature Mead Johnson Premature/LBW 2.5 400 0.97 0.16 
Pregestimil lipil Mead Johnson 0 4.2 700 0.90 0.15 
FM 85a Nestlé Premature 2.5 400 0.62 0.10 
Enfamil Human Milk Fortifiera  Mead Johnson Premature 2.5 400 0.49 0.08 
NutriniKid multi fiber Nutricia 12 9.8 600 3.7 0.23 
FSMP used as partial feedingb 
Nutramigen 2 lipil Mead Johnson 6 7.7 900  1.4  0.17 
XP Maxamaid SHS 12 9.8 300  0.7  0.02 
PKU anamix infant lcp+ SHS 0 4.2 300  0.7  0.05 
aProducts to be mixed with breast milk according to instruction, calculation in table based on product diluted with water  
bThe intake of these products is calculated as daily intakes in accordance with calculations for intakes of follow-on-formula.  LBW=low birth weight 
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Table 2. Estimated intake of arsenic per consumed single portion from gruel, porridge, FSMP as partial feeding and foodstuffs for normal  
consumption (products not intended for infants) 
Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
As concentration 
(µg /kg) 
As intake 
(µg/kg bw/portion) 
Gruel 
Fullkornsvälling (Wholegrain gruel) Nestlé 12 9.8 236 0.68 0.02 
Låglaktos majsvälling (Low lactose corn 
gruel) 
Nestlé 6 7.7 237 0.65 0.02 
Majsvälling (Corn gruel) Semper 6 7.7 229 1.5 0.05 
Mild fullkornsvälling havre (Mild 
wholegrain gruel oat) 
Nestlé 8 8.5 236 0.74 0.02 
Välling mjölkfri (Gruel dairy free) EnaGo 6 7.7 233 19.2 0.58 
Drickfärdig mild fullkornsvälling (Ready for 
use mild wholegrain gruel) 
Semper 8 8.5 200 0.94 0.02 
Fullkornsvälling havre vete råg (Wholgrain 
gruel oat wheat rye) 
Semper 
 
12 9.8 237 0.67 0.02 
Kvällsvälling ris och vete (Evening gruel 
rice and wheat) 
Semper 6 7.7 237 8.4 0.26 
God natt mild havrevälling (Good night mild 
oat gruel) 
Nestlé 6 7.7 220 0.74 0.02 
Majsvälling (Corn gruel) Nestlé 6 7.7 236 0.63 0.02 
First flavora Babynat 6 7.7 234 17.6 0.53 
Céréales cacaoa Babybio 8 8.5 234 16.5 0.46 
Mild fullkornsvälling (Mild wholegrain 
gruel) 
Semper 8 8.5 228 0.64 0.02 
Majsvälling (Corn gruel) HIPP 6 7.7 220 0.54 0.02 
Porridge 
Sinlac specialgröt (Sinlac special porridge) Nestlé 4 6.6 132 28.1 0.56 
Fullkornsgröt med äpple (Wholegrain 
porridge with apple) 
HIPP 8 8.5 169 4.6 0.09 
Mild havregröt (Mild oat porridge) HIPP 6 7.7 167 4.4 0.09 
Banangröt mjölkfri (Banana porridge dairy 
free) 
EnaGo 6 7.7 158 11.4 0.23 
Risgröt med äpple och mango (Rice 
porridge with apple and mango) 
Semper 5 7.2 130 23.1 0.42 
Banangröt (Banana porridge) Semper 4 6.6 130 12.8 0.25 
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Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
As concentration 
(µg /kg) 
As intake 
(µg/kg bw/portion) 
Cerelac risgröt (Cerelac rice porridge) Nestlé 4 6.6 130 28.6 0.56 
Mild fullkornsgröt (Mild wholegrain 
porridge) 
Nestlé 8 8.5 128 1.3 0.02 
Mild fullkornsgröt (Mild wholegrain 
porridge) 
Semper 8 8.5 130 1.1 0.02 
Mild havregröt (Mild oat porridge) Semper 4 6.6 130 0.9 0.02 
Cerelac Fruktgröt banan apelsin (Cerelac 
fruit porridge banana orange) 
Nestlé 6 7.7 130 1.9 0.03 
Fullkornsgröt multikorn (Wholegrain 
porridge multigrain) 
HIPP 12 9.8 158 2.8 0.05 
Fruktgröt fullkorn (Fruit porridge 
wholegrain) 
Semper 12 9.8 133 1.4 0.02 
God Natt! Risgröt med grönsaker (Rice 
porridge with vegetables) 
HIPP 4 6.6 190 22.0 0.63 
Mild fullkornsgröt (Mild wholegrain 
porridge) 
HIPP 8 8.5 158 4.6 0.09 
Organic seven grain cerealb Organix 7 8.1 105 3.1 0.04 
First organic wholegrain baby riceb Organix 4 6.6 51 41.4 0.32 
Risgröt med banan och persika (Rice 
porridge with banana and peach) 
HIPP 4 6.6 167 4.0 0.10 
Eko havregröt (Organic oat porridge) Holle 6 7.7 225 3.0 0.09 
Organic millet porridge Holle 4 6.6 175 1.5 0.04 
Eko dinkelgröt (Organic spelt porridge) Holle 6 7.7 225 1.2 0.03 
Dinkelgröt naturell (Spelt porridge natural) Nestlé 6 7.7 155 0.9 0.02 
Bio-Babybrei Grieβ (Wheat porridge)a Holle 4 6.6 225 1.3 0.05 
Musligröt päron-banan (Musli porridge 
pear-banana) 
Nestlé 12 9.8 118 6.5 0.08 
Baby´s first food The ultimate four grain 
porridgea 
Plum 
 
4 
 
6.6 110 12.5 0.21 
Rice porridgea Holle 4 6.6 188 31.3 0.89 
FSMP used as partial feeding 
Fresubin energy fiber, chocolate flavour Fresenius Kabi 12 9.8 200 ml/portion 2.3 0.05 
PKU gel Vitaflo 12 9.8 50 3.7 0.02 
Frebini energy fiber drink Fresenius Kabi 12 9.8 200 ml/portion 2.0 0.04 
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Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
As concentration 
(µg /kg) 
As intake 
(µg/kg bw/portion) 
Foodstuffs for normal consumption 
Havredryck apelsin & mango (Oat drink 
orange & mango) 
Oatly 12 9.8 100 ml/portion 1.0 0.01 
Havredryck naturell (Oat drink natural) Carlshamn 12 9.8 100 ml/portion 2.0 0.02 
Pama minutris (Pama ’minute rice’) Quaker 12 9.8 130 32.3 0.43 
Ricedrink organic Rice Dream 12 9.8 100 ml/portion 18.3 0.19 
Risdryck naturell (Rice drink natural) Carlshamn 12 9.8 100 ml/portion 30.4 0.31 
Havregryn (Rolled oats) Lantmännen 12 9.8 130 0.5 0.007 
Skrädmjöl (Oat toasted and milled) Saltå Kvarn 12 9.8 130 0.6 0.008 
Sojadryck (Soya drink) Garant 12 9.8 100 ml/portion 0.8 0.009 
Sojadryck original + kalcium (Soya drink 
original + calcium) 
GoGreen 12 9.8 100 ml/portion 0.8 0.008 
Solhavre naturell (Oat drink natural) ICA 12 9.8 130  0.9  0.009 
Soya drink natural fresh Alpro 12 9.8 130  1.7  0.018 
Soya natural Provamel 12 9.8 130  1.1  0.011 
aProducts to be mixed with milk product according to instruction, calculation in table based on product diluted with water. 
6 
APPENDIX III: Cadmium (Cd) 
 
Table 1. Estimated daily intake of cadmium from ready-to-eat infant formula, follow-on formula, FSMP as sole source of nutrition and FSMP as partial feeding. 
Product (English translation) 
 
Producer 
 
Age (months) Weight 
(kg) 
Consumption 
(ml/day) 
Cd concentration 
(µg/kg) 
Cd intake 
(μg/kg bw/day) 
% of TDIa 
 
Infant formula 
NAN 1 Modersmjölksersättning (NAN 1 
Infant formula) 
Nestlé 0 4.2 700 0.3 0.05 15 
NAN HA 1 Modersmjölksersättning 
(NAN HA 1 Infant formula) 
Nestlé 0 4.2 700 0.2 0.04 10 
BabySemp 2 Lemolac 
Modersmjölksersättning (BabySemp 2 
Lemolac infant formula) 
Semper 4 6.6 800 0.3 0.04 11 
ECO 1 Modersmjölksersättning (ECO 1 
infant formula) 
HIPP 0 4.2 700 0.1 0.02 5 
ECO 2 Modersmjölksersättning (ECO 2 
infant formula) 
HIPP 4 6.6 800 0.6 0.08 21 
BabySemp 1 Modersmjölksersättning 
(BabySemp 1 infant formula), powder 
Semper 0 4.2 700 0.3 0.06 15 
BabySemp 1 Modersmjölksersättning 
(BabySemp 1 infant formula), RFU 
Semper 0 4.2 700 0.1 0.01 3 
Organic infant milk Babynat 0 4.2 700 0.1 0.01 4 
Eko 1 Modersmjölksersättning, (Infant 
formula 1) 
Holle 0.5 4.2 700 0.4 0.07 19 
Follow-on-formula 
BabySemp 3 Tillskottsnäring (BabySemp 
3 follow-on-formula) 
Semper 8 8.5 500 0.6 0.04 11 
NAN Pro 2 Tillskottsnäring (NAN PRO 2 
follow-on-formula) 
Nestlé 6 7.7 900 0.2 0.02 6 
Eko tillskottsnäring 2 (Follow-on-
formula 2) 
Holle 6 7.7 900 0.3 0.03 9 
Optima Organic Follow-on-milk Babynat 6 7.7 900 0.1 0.01 3 
FSMP used as sole source of nutrition 
Neocate advance SHS  12 9.8 900 0.1 0.01 4 
Nutrini energy multi fibre Nutricia 12 9.8 600 0.4 0.02 6 
Nutrini multi fibre Nutricia 12 9.8 900 0.3 0.03 8 
Resource minimax Nestlé 12 9.8 750 0.7 0.05 14 
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Product (English translation) 
 
Producer 
 
Age (months) Weight 
(kg) 
Consumption 
(ml/day) 
Cd concentration 
(µg/kg) 
Cd intake 
(μg/kg bw/day) 
% of TDIa 
 
Fresubin soya fibre Fresenius 
Kabi 
12 9.8 900 2.2 0.20 55 
Isosource junior Nestlé 12 9.8 900 0.4 0.04 10 
Nutramigen 1 lipil Mead 
Johnson 
0 4.2 700 0.2 0.03 10 
Pepticate Nutricia 0 4.2 700 0.2 0.03 9 
Galactomin 19 formula SHS  0 4.2 700 0.2 0.03 9 
Neocate LCP Nutricia 0 4.2 700 0.6 0.10 28 
Althéra Nestlé 0 4.2 700 0.2 0.03 9 
Enfamil AR lipil Mead 
Johnson 
0 4.2 700 0.2 0.03 9 
Pepti junior Nutricia 0 4.2 700 0.4 0.07 19 
Minimax barnsondnäring (Minimax 
enteral formula for children) 
Nestlé 6 7.7 600 0.3 0.02 6 
Profylac Semper 0 4.2 700 0.1 0.02 6 
PreNAN discharge 
 
Nestlé  Premature/LBW 2.5 
 
400 
 
0.5 
 
0.08 
 
22 
 
Enfalac premature 
 
Mead 
Johnson 
Premature/LBW 2.5 
 
400 
 
0.3 
 
0.04 
 
12 
 
Pregestimil lipil Mead 
Johnson 
0 4.2 700 0.3 0.04 12 
FM 85b Nestlé Premature 2.5 400 0.2 0.03 9 
Enfamil Human Milk Fortifierb  Mead 
Johnson 
Premature 
 
2.5 
 
400 
 
0.2 
 
0.03 
 
7 
 
NutriniKid multi fiber Nutricia 12 9.8 600 0.4 0.02 6 
FSMP used as partial feedingc 
Nutramigen 2 lipil Mead 
Johnson 
6 7.7 900 0.4 0.04 12 
XP Maxamaid SHS  12 9.8 300 0.5 0.01 4 
PKU anamix infant lcp+ SHS 0 4.2 300 0.3 0.02 7 
aThe tolerable daily intake (TDI) is 0.36 μg/kg bw/day established by EFSA in 2009. bProducts to be mixed with breast milk according to instruction, calculation in table based on 
product diluted with water 
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Table 2. Estimated intake of cadmium per consumed portion from gruel, porridge, FSMP as partial feeding and foodstuffs for normal consumption (products not 
intended for infants) 
Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
Cd concentration 
(µg/kg) 
Cd intake 
(μg/kg 
bw/portion) 
No. of portions 
to reach TDIa 
Gruel 
Fullkornsvälling (Wholegrain gruel) Nestlé 12 9.8 236 2.4 0.06 6 
Låglaktos majsvälling (Low lactose corn 
gruel) 
Nestlé 6 7.7 237 0.2 0.01 66 
Majsvälling (Corn gruel) Semper 6 7.7 229 0.2 0.01 53 
Mild fullkornsvälling havre (Mild wholegrain 
gruel oat) 
Nestlé 8 8.5 236 1.2 0.03 11 
Välling mjölkfri (Gruel dairy free) EnaGo 6 7.7 233 3.9 0.12 3 
Drickfärdig mild fullkornsvälling (Ready for 
use mild wholegrain gruel) 
Semper 8 8.5 200 0.7 0.02 23 
Fullkornsvälling havre vete råg (Wholgrain 
gruel oat wheat rye) 
Semper 
 
12 
 
9.8 
 
237 
 
2.0 
 
0.05 
 
7 
 
Kvällsvälling ris och vete (Evening gruel rice 
and wheat) 
Semper 6 7.7 237 0.6 0.02 20 
God natt mild havrevälling (Good night mild 
oat gruel) 
Nestlé 6 7.7 220 1.0 0.03 13 
Majsvälling (Corn gruel) Nestlé 6 7.7 236 0.1 0.003 104 
First flavorb Babynat 6 7.7 234 3.0 0.09 4 
Céréales cacaob Babybio 8 8.5 234 6.9 0.19 2 
Mild fullkornsvälling (Mild wholegrain gruel) Semper 8 8.5 228 1.3 0.04 10 
Majsvälling (Corn gruel) HIPP 6 7.7 220 0.1 0.003 105 
Porridge 
Sinlac specialgröt (Sinlac special porridge) Nestlé 4 6.6 132 5.3 0.11 3 
Fullkornsgröt med äpple (Wholegrain 
porridge with apple) 
HIPP 8 8.5 169 1.5 0.03 12 
Mild havregröt (Mild oat porridge) HIPP 6 7.7 167 2.5 0.05 7 
Banangröt mjölkfri (Banana porridge dairy 
free) 
EnaGo 6 7.7 158 6.0 0.12 3 
Risgröt med äpple och mango (Rice porridge 
with apple and mango) 
Semper 5 7.2 130 2.4 0.04 8 
Banangröt (Banana porridge) Semper 4 6.6 130 3.3 0.07 6 
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Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
Cd concentration 
(µg/kg) 
Cd intake 
(μg/kg 
bw/portion) 
No. of portions 
to reach TDIa 
Cerelac risgröt (Cerelac rice porridge) Nestlé 4 6.6 130 3.8 0.08 5 
Mild fullkornsgröt (Mild wholegrain 
porridge) 
Nestlé 8 8.5 128 3.7 0.06 6 
Mild fullkornsgröt (Mild wholegrain 
porridge) 
Semper 8 8.5 130 3.8 0.06 6 
Mild havregröt (Mild oat porridge) Semper 4 6.6 130 2.3 0.05 8 
Cerelac Fruktgröt banan apelsin (Cerelac fruit 
porridge banana orange) 
Nestlé 6 7.7 130 1.6 0.03 14 
Fullkornsgröt multikorn (Wholegrain porridge 
multigrain) 
HIPP 12 9.8 158 2.2 0.04 10 
Fruktgröt fullkorn (Fruit porridge 
wholegrain) 
Semper 12 9.8 133 4.3 0.06 6 
God Natt! Risgröt med grönsaker (Rice 
porridge with vegetables) 
HIPP 4 6.6 190 5.4 0.16 2 
Mild fullkornsgröt (Mild wholegrain 
porridge) 
HIPP 8 8.5 158 2.2 0.04 9 
Organic seven grain cerealb Organix 7 8.1 105 2.2 0.03 13 
First organic wholegrain baby riceb Organix 4 6.6 51 0.3 0.002 175 
Risgröt med banan och persika (Rice porridge 
with banana and peach) 
HIPP 4 6.6 167 0.9 0.02 16 
Eko havregröt (Organic oat porridge ) Holle 6 7.7 225 2.7 0.08 5 
Organic millet porridge Holle 4 6.6 175 2.1 0.06 6 
Eko dinkelgröt (Organic spelt porridge) Holle 6 7.7 225 3.5 0.10 4 
Dinkelgröt naturell (Spelt porridge natural) Nestlé 6 7.7 155 1.9 0.04 9 
Bio-Babybrei Grieβ (Wheat porridge)b Holle 4 6.6 225 2.2 0.07 5 
Musligröt päron-banan (Musli porridge pear-
banana) 
Nestlé 12 9.8 118 2.2 0.03 13 
Baby´s first food The ultimate four grain 
porridgeb 
Plum 
 
4 
 
6.6 
 
110 
 
2.1 
 
0.04 
 
10 
 
Rice porridgeb Holle 4 6.6 188 1.3 0.04 10 
FSMP used as partial feeding 
Fresubin energy fiber, chocolate flavour Fresenius 
Kabi 
12 9.8 200 ml/portion 1.1 0.02 16 
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Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
Cd concentration 
(µg/kg) 
Cd intake 
(μg/kg 
bw/portion) 
No. of portions 
to reach TDIa 
PKU gel Vitaflo 12 9.8 50 1.1 0.01 67 
Frebini energy fiber drink Fresenius 
Kabi 
12 9.8 200 ml/portion 2.1 0.04 9 
Foodstuffs for normal consumption 
Havredryck apelsin & mango (Oat drink 
orange& mango) 
Oatly 12 9.8 100 ml/portion 0.3 0.003 105 
Havredryck naturell (Oat drink natural) Carlshamn 12 9.8 100 ml/portion 2.4 0.02 15 
Pama minutris (Pama ’minute rice’) Quaker 12 9.8 130 2.7 0.04 10 
Ricedrink organic Rice Dream 12 9.8 100 ml/portion 0.5 0.01 71 
Risdryck naturell (Rice drink natural) Carlshamn 12 9.8 100 ml/portion 4.5 0.05 8 
Havregryn (Rolled oats) Lantmännen 12 9.8 130 4.9 0.07 6 
Skrädmjöl (Oat toasted and milled) Saltå kvarn 12 9.8 130 10.8 0.14 3 
Sojadryck (Soya drink) Garant 12 9.8 100 ml/portion 8.3 0.09 4 
Sojadryck original + kalcium (Soya drink 
original + calcium) 
GoGreen 12 9.8 100 ml/portion 7.3 0.07 5 
Solhavre naturell (Oat drink natural) ICA 12 9.8 100 ml/portion 0.1 0.001 442 
Soya drink natural fresh Alpro 12 9.8 100 ml/portion 1.9 0.02 19 
Soya natural Provamel 12 9.8 100 ml/portion 1.9 0.02 19 
aThe tolerable daily intake (TDI) is 0.36 μg/kg bw/day established by EFSA in 2009. 
 bProducts to be mixed with milk product according to instruction, calculation in table based on product diluted with water. 
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APPENDIX IV: Lead (Pb) 
Table 1. Estimated daily intake of lead from ready-to-eat infant formula, follow-on formula, FSMP as sole source of nutrition and FSMP as partial feeding. 
Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption  
(ml/day) 
Pb 
concentration  
(µg/kg) 
Pb intake 
(μg/kg 
bw/day) 
% of RPa 
 
Infant Formula 
NAN 1 Modersmjölksersättning (NAN 1 
Infant formula) 
Nestlé 0 4.2 700 0.5 0.08 16 
NAN HA 1 Modersmjölksersättning 
(NAN HA 1 Infant formula) 
Nestlé 0 4.2 700 0.4 0.06 12 
BabySemp 2 Lemolac 
modersmjölksersättning (BabySemp 2 
Lemolac infant formula) 
Semper 4 6.6 800 0.4 0.04 8 
ECO 1 Modersmjölksersättning (ECO 1 
infant formula) 
HIPP 0 4.2 700 0.3 0.04 9 
ECO 2 Modersmjölksersättning (ECO 2 
infant formula) 
HIPP 4 6.6 800 0.3 0.04 7 
BabySemp 1 Modersmjölksersättning 
(BabySemp 1 infant formula), powder 
Semper 0 4.2 700 0.2 0.04 7 
BabySemp 1 Modersmjölksersättning 
(BabySemp 1 infant formula), RFU 
Semper 0 4.2 700 0.2 0.04 8 
Organic infant milk Babynat 0 4.2 700 0.3 0.04 8 
Eko 1 Modersmjölksersättning, (Infant 
formula 1) 
Holle 0.5 4.2 700 0.3 0.06 11 
Follow-on-formula 
BabySemp 3 Tillskottsnäring (BabySemp 
3 follow-on-formula) 
Semper 8 8.5 500 0.5 0.03 6 
NAN Pro 2 Tillskottsnäring (NAN PRO 2 
follow-on-formula) 
Nestlé 6 7.7 900 0.6 0.07 14 
Eko tillskottsnäring 2 (Follow-on-
formula 2) 
Holle 6 7.7 900 1.2 0.14 27 
Optima organic Follow-on-milk Babynat 6 7.7 900 0.3 0.03 7 
FSMP used as sole source of nutrition 
Neocate advance SHS 12 9.8 900 0.3 0.03 6 
Nutrini energy multi fibre Nutricia 12 9.8 600 0.9 0.06 12 
Nutrini multi fibre Nutricia 12 9.8 900 1.1 0.10 21 
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Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption  
(ml/day) 
Pb 
concentration  
(µg/kg) 
Pb intake 
(μg/kg 
bw/day) 
% of RPa 
 
Resource minimax Nestlé 12 9.8 750 0.7 0.05 11 
Fresubin soya fibre Fresenius Kabi 12 9.8 900 1.2 0.11 21 
Isosource junior Nestlé 12 9.8 900 1.5 0.14 27 
Nutramigen 1 lipil Mead Johnson 0 4.2 700 0.7 0.11 22 
Pepticate Nutricia 0 4.2 700 0.5 0.08 15 
Galactomin 19 formula SHS  0 4.2 700 0.8 0.13 27 
Neocate LCP Nutricia 0 4.2 700 0.4 0.07 14 
Althéra Nestlé 0 4.2 700 0.3 0.05 10 
Enfamil AR lipil Mead Johnson 0 4.2 700 0.5 0.08 17 
Pepti junior Nutricia 0 4.2 700 0.5 0.09 18 
Minimax barnsondnäring (Minimax 
enteral formula for children) 
Nestlé 6 7.7 600 0.5 0.04 7 
Profylac Semper 0 4.2 700 0.3 0.04 8 
PreNAN discharge 
 
Nestlé  Premature
/LBW 
2.5 
 
400 
 
0.4 
 
0.06 
 
12 
 
Enfalac premature 
 
Mead Johnson Premature
/LBW 
2.5 
 
400 
 
0.4 
 
0.07 
 
13 
 
Pregestimil lipil Mead Johnson 0 4.2 700 0.6 0.11 22 
FM 85b Nestlé Premature 2.5 400 0.3 0.04 9 
Enfamil Human Milk Fortifierb  Mead Johnson Premature 
 
2.5 
 
400 
 
0.5 
 
0.08 
 
15 
 
NutriniKid multi fiber Nutricia 12 9.8 600 0.9 0.06 11 
FSMP used as partial feedingc 
Nutramigen 2 lipil Mead Johnson 6 7.7 900 0.9 0.10 20 
XP Maxamaid SHS 12 9.8 300 0.8 0.02 5 
PKU anamix infant lcp+ SHS 0 4.2 300 0.6 0.04 8 
aThe reference point (RP) is 0.5 μg/kg bw/day established by EFSA in 2010. 
b Products to be mixed with breast milk according to instruction, calculation in table based on product diluted with water 
cThe intake of these products is calculated as daily intakes in accordance with calculations for intakes of follow-on formulas.  
 
LBW=low birth weight 
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Table 2. Estimated intake of lead per consumed portion from gruel, porridge, FSMP as partial feeding and foodstuffs for normal consumption (products not intended 
for infants) 
Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
Pb 
concentration 
(µg/kg) 
Pb intake 
(μg/kg 
bw/portion) 
No. of 
portion to 
reach RPa 
Gruel 
Fullkornsvälling (Wholegrain gruel) Nestlé 12 9.8 236 0.5 0.01 39 
Låglaktos majsvälling (Low lactose corn gruel) Nestlé 6 7.7 237 0.7 0.02 23 
Majsvälling (Corn gruel) Semper 6 7.7 229 0.3 0.01 59 
Mild fullkornsvälling havre (Mild wholegrain 
gruel oat) 
Nestlé 8 8.5 236 3.1 0.09 6 
Välling mjölkfri (Gruel dairy free) EnaGo 6 7.7 233 6.9 0.21 2 
Drickfärdig mild fullkornsvälling (Ready for use 
mild wholegrain gruel) 
Semper 8 8.5 200 0.2 0.01 86 
Fullkornsvälling havre vete råg (Wholgrain gruel 
oat wheat rye) 
Semper 
 
12 
 
9.8 
 
237 
 
0.3 
 
0.01 
 
65 
 
Kvällsvälling ris och vete (Evening gruel rice and 
wheat) 
Semper 6 7.7 237 0.6 0.02 27 
God natt mild havrevälling (Good night mild oat 
gruel) 
Nestlé 6 7.7 220 0.6 0.02 30 
Majsvälling (Corn gruel) Nestlé 6 7.7 236 0.3 0.01 51 
First flavorb Babynat 6 7.7 234 0.2 0.01 76 
Céréales cacaob Babybio 8 8.5 234 0.4 0.01 49 
Mild fullkornsvälling (Mild wholegrain gruel) Semper 8 8.5 228 0.3 0.01 73 
Majsvälling (Corn gruel) HIPP 6 7.7 220 0.3 0.01 63 
Porridge 
Sinlac specialgröt (Sinlac special porridge) Nestlé 4 6.6 132 1.4 0.03 18 
Fullkornsgröt med äpple (Wholegrain porridge 
with apple) 
HIPP 8 8.5 169 1.3 0.02 20 
Mild havregröt (Mild oat porridge) HIPP 6 7.7 167 0.5 0.01 50 
Banangröt mjölkfri (Banana porridge dairy free) EnaGo 6 7.7 158 12.6 0.26 2 
Risgröt med äpple och mango (Rice porridge with 
apple and mango) 
Semper 5 7.2 130 1.3 0.02 22 
Banangröt (Banana porridge) Semper 4 6.6 130 0.6 0.01 39 
Cerelac risgröt (Cerelac rice porridge) Nestlé 4 6.6 130 0.5 0.01 56 
14 
Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
Pb 
concentration 
(µg/kg) 
Pb intake 
(μg/kg 
bw/portion) 
No. of 
portion to 
reach RPa 
Mild fullkornsgröt (Mild wholegrain porridge) Nestlé 8 8.5 128 0.9 0.01 38 
Mild fullkornsgröt (Mild wholegrain porridge) Semper 8 8.5 130 0.5 0.01 62 
Mild havregröt (Mild oat porridge) Semper 4 6.6 130 2.2 0.04 12 
Cerelac Fruktgröt banan apelsin (Cerelac fruit 
porridge banana orange) 
Nestlé 6 7.7 130 0.6 0.01 47 
Fullkornsgröt multikorn (Wholegrain porridge 
multigrain) 
HIPP 12 9.8 158 0.4 0.01 76 
Fruktgröt fullkorn (Fruit porridge wholegrain) Semper 12 9.8 133 0.7 0.01 55 
God Natt! Risgröt med grönsaker (Rice porridge 
with vegetables) 
HIPP 4 6.6 190 1.9 0.05 9 
Mild fullkornsgröt (Mild wholegrain porridge) HIPP 8 8.5 158 0.4 0.01 62 
Organic seven grain cerealb Organix 7 8.1 105 0.5 0.01 75 
First organic wholegrain baby riceb Organix 4 6.6 51 0.5 0.004 119 
Risgröt med banan och persika (Rice porridge with 
banana and peach) 
HIPP 4 6.6 167 1.5 0.04 13 
Eko havregröt (Organic oat porridge ) Holle 6 7.7 225 0.3 0.01 52 
Organic millet porridge Holle 4 6.6 175 0.9 0.02 22 
Eko dinkelgröt (Organic spelt porridge) Holle 6 7.7 225 0.3 0.01 56 
Dinkelgröt naturell (Spelt porridge natural) Nestlé 6 7.7 155 0.5 0.01 54 
Bio-Babybrei Grieβ (Wheat porridge)b Holle 4 6.6 225 0.3 0.01 55 
Musligröt päron-banan (Musli porridge pear-
banana) 
Nestlé 12 9.8 118 1.9 0.02 22 
Baby´s first food The ultimate four grain porridge b Plum 4 6.6 110 0.6 0.01 46 
Rice porridgeb Holle 4 6.6 188 0.3 0.01 64 
FSMP used as partial feeding 
Fresubin energy fiber, chocolate flavour Fresenius Kabi 12 9.8 200 ml/portion 1.9 0.04 13 
PKU gel Vitaflo 12 9.8 50 22.6 0.12 4 
Frebini energy fiber drink Fresenius Kabi 12 9.8 200 ml/portion 2.2 0.04 11 
Foodstuffs for normal consumption 
Havredryck apelsin & mango (Oat drink orange& 
mango) 
Oatly 12 9.8 100 ml/portion 0.2 0.003 198 
Havredryck naturell (Oat drink natural) Carlshamn 12 9.8 100 ml/portion 1.3 0.01 39 
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Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
Pb 
concentration 
(µg/kg) 
Pb intake 
(μg/kg 
bw/portion) 
No. of 
portion to 
reach RPa 
Pama minutris (Pama ’minute rice’) Quaker 12 9.8 130 0.1 0.002 308 
Ricedrink organic Rice Dream 12 9.8 100 ml/portion 0.2 0.002 302 
Risdryck naturell (Rice drink natural) Carlshamn 12 9.8 100 ml/portion 1.4 0.01 36 
Havregryn (Rolled oats) Lantmännen 12 9.8 130 0.3 0.004 127 
Skrädmjöl (Oat toasted and milled) Saltå kvarn 12 9.8 130 0.6 0.01 63 
Sojadryck (Soya drink) Garant 12 9.8 100 ml/portion 1.3 0.01 37 
Sojadryck original + kalcium (Soya drink original 
+ calcium) 
GoGreen 12 9.8 100 ml/portion 1.1 0.01 43 
Solhavre naturell (Oat drink natural) ICA 12 9.8 100 ml/portion 0.1 0.001 454 
Soya drink natural fresh Alpro 12 9.8 100 ml/portion 0.2 0.002 277 
Soya natural Provamel 12 9.8 100 ml/portion 0.1 0.001 340 
aThe reference point (RP) is 0.5 μg/kg bw/day established by EFSA in 2010. 
bProducts to be mixed with milk product according to instruction, calculation in table based on product diluted with water. 
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APPENDIX V: Manganese (Mn) 
 
Table 1. Estimated daily intake of manganese from ready-to-eat infant formula, follow-on formula, FSMP as sole source of nutrition and FSMP as partial feeding. 
Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption  
(ml/day) 
Mn 
concentration  
(mg/kg) 
Mn intake 
(µg/day) 
% of 
AIa 
Mn intake 
(µg/kg 
bw/day) 
% of TDIb 
Infant Formula 
NAN 1 Modersmjölksersättning (NAN 
1 Infant formula) 
Nestlé 0 4.2 700 0.16 110 3680 26 44 
NAN HA 1 Modersmjölksersättning 
(NAN HA 1 Infant formula) 
Nestlé 0 4.2 700 0.13 90 3000 21 36 
BabySemp 2 Lemolac 
modersmjölksersättning (BabySemp 2 
Lemolac infant formula) 
Semper 4 6.6 800 0.07 57 1910 9 14 
ECO 1 Modersmjölksersättning (ECO 
1 infant formula) 
HIPP 0 4.2 700 0.10 68 2260 16 27 
ECO 2 Modersmjölksersättning (ECO 
2 infant formula) 
HIPP 4 6.6 800 0.08 66 2210 10 17 
BabySemp 1 Modersmjölksersättning 
(BabySemp 1 infant formula), powder 
Semper 0 4.2 700 0.02 15 510 4 6 
BabySemp 1 Modersmjölksersättning 
(BabySemp 1 infant formula), RFU 
Semper 0 4.2 700 0.05 32 1070 8 13 
Organic infant milk Babynat 0 4.2 700 0.05 35 1170 8 14 
Eko 1 Modersmjölksersättning, 
(Infant formula 1) 
Holle 0.5 4.2 700 0.11 76 2540 18 30 
Follow-on-formula 
BabySemp 3 Tillskottsnäring 
(BabySemp 3 follow-on-formula) 
Semper 8 8.5 500 0.36 180 30 21 35 
NAN Pro 2 Tillskottsnäring (NAN 
PRO 2 follow-on-formula) 
Nestlé 6 7.7 900 0.12 111 3720 14 24 
Eko tillskottsnäring 2 (Follow-on-
formula 2) 
Holle 6 7.7 900 0.18 161 5380 21 35 
Optima Organic Follow-on-milk Babynat 6 7.7 900 0.04 39 1300 5 8 
FSMP used as sole source of nutrition 
Neocate advance SHS  12 9.8 900 0.56 508 42 52 86 
Nutrini energy multi fibre Nutricia 12 9.8 600 2.01 208 101 123 205 
Nutrini multi fibre Nutricia 12 9.8 900 1.62 461 122 149 248 
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Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption  
(ml/day) 
Mn 
concentration  
(mg/kg) 
Mn intake 
(µg/day) 
% of 
AIa 
Mn intake 
(µg/kg 
bw/day) 
% of TDIb 
Resource minimax Nestlé 12 9.8 750 0.76 566 47 58 96 
Fresubin soya fibre Fresenius Kabi 12 9.8 900 2.51 2256 188 230 384 
Isosource junior Nestlé 12 9.8 900 1.65 1489 124 152 253 
Nutramigen 1 lipil Mead Johnson 0 4.2 700 0.48 336 11190 80 133 
Pepticate Nutricia 0 4.2 700 0.10 73 2440 17 29 
Galactomin 19 formula SHS  0 4.2 700 0.39 275 9170 66 109 
Neocate LCP Nutricia 0 4.2 700 0.45 316 10530 75 125 
Althéra Nestlé 0 4.2 700 0.05 34 1140 8 14 
Enfamil AR lipil Mead Johnson 0 4.2 700 0.41 290 9680 69 115 
Pepti junior Nutricia 0 4.2 700 0.42 297 9890 71 118 
Minimax barnsondnäring (Minimax 
enteral formula for children) 
Nestlé 6 7.7 600 0.76 454 15130 59 98 
Profylac Semper 0 4.2 700 0.45 312 10390 74 124 
PreNAN discharge Nestlé  Premature/LBW 2.5 400 0.12 48 1590 19 32 
Enfalac premature 
 
Mead Johnson Premature/LBW 2.5 400 0.11 42 1420 17 28 
Pregestimil lipil Mead Johnson 0 4.2 700 0.46 323 10760 77 128 
FM 85c Nestlé Premature 2.5 400 0.12 48 1600 19 32 
Enfamil Human Milk Fortifierc  Mead Johnson Premature 2.5 400 0.14 57 1920 23 38 
NutriniKid multi fiber Nutricia 12 9.8 600 0.14 1074 90 9 15 
FSMP used as partial feedingd 
Nutramigen 2 lipil Mead Johnson 6 7.7 900 0.64 580 19333 75 125 
XP Maxamaid SHS 12 9.8 300 2.60 780 130 80 133 
PKU anamix infant lcp+ SHS 0 4.2 300 0.67 200 6666 48 79 
aThe Adequate intake (AI) is for 0-6 months 3µg, for 7-12 months 600 µg and for 1-3 years 1200 µg (IOM, 2001). 
bThe tolerable daily intake (TDI) is 60 µg/kg bw/day established by WHO in 2003.  
c Products to be mixed with breast milk according to instruction, calculation in table based on product diluted with water 
dThe intake of these products is calculated as daily intakes in accordance with calculations for intakes of follow-on formula.  
 
LBW=low birth weight. 
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Table 2. Estimated intake of manganese per consumed portion from gruel, porridge, FSMP as partial feeding and foodstuffs for normal consumption (products not 
intended for infants) 
Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
Mn 
concentration  
(mg/kg) 
Mn intake 
(µg/portion) 
No. of 
portions to 
reach AIa 
Mn intake 
(µg/kg 
bw/portion) 
No. of 
portions to 
reach TDIb 
Gruel 
Fullkornsvälling (Wholegrain gruel) Nestlé 12 9.8 236 1.42 340 4 34 2 
Låglaktos majsvälling (Low lactose 
corn gruel) 
Nestlé 6 7.7 237 0.07 20 0 2 28 
Majsvälling (Corn gruel) Semper 6 7.7 229 0.21 50 0 6 10 
Mild fullkornsvälling havre (Mild 
wholegrain gruel oat) 
Nestlé 8 8.5 236 1.43 340 2 40 2 
Välling mjölkfri (Gruel dairy free) EnaGo 6 7.7 233 1.51 350 0 46 1 
Drickfärdig mild fullkornsvälling 
(Ready for use mild wholegrain gruel) 
Semper 8 8.5 200 0.74 150 4 17 3 
Fullkornsvälling havre vete råg 
(Wholgrain gruel oat wheat rye) 
Semper 
 
12 9.8 237 1.39 330 4 34 2 
Kvällsvälling ris och vete (Evening 
gruel rice and wheat) 
Semper 6 7.7 237 0.50 120 0 15 4 
God natt mild havrevälling (Good 
night mild oat gruel) 
Nestlé 6 7.7 220 1.18 260 0 34 2 
Majsvälling (Corn gruel) Nestlé 6 7.7 236 0.04 10 0 1 53 
First flavorc Babynat 6 7.7 234 1.09 260 0 33 2 
Céréales cacaoc Babybio 8 8.5 234 1.32 310 2 36 2 
Mild fullkornsvälling (Mild 
wholegrain gruel) 
Semper 8 8.5 228 1.27 290 2 34 2 
Majsvälling (Corn gruel) HIPP 6 7.7 220 0.08 20 0 2 26 
Porridge 
Sinlac specialgröt (Sinlac special 
porridge) 
Nestlé 4 6.6 132 4.63 610 0 93 1 
Fullkornsgröt med äpple (Wholegrain 
porridge with apple) 
HIPP 8 8.5 169 2.33 390 2 46 1 
Mild havregröt (Mild oat porridge) HIPP 6 7.7 167 2.25 370 0 49 1 
Banangröt mjölkfri (Banana porridge 
dairy free) 
EnaGo 6 7.7 158 3.27 520 0 67 1 
Risgröt med äpple och mango (Rice 
porridge with apple and mango) 
Semper 5 7.2 130 0.88 110 0 16 4 
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Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
Mn 
concentration  
(mg/kg) 
Mn intake 
(µg/portion) 
No. of 
portions to 
reach AIa 
Mn intake 
(µg/kg 
bw/portion) 
No. of 
portions to 
reach TDIb 
Banangröt (Banana porridge) Semper 4 6.6 130 1.11 140 0 22 3 
Cerelac risgröt (Cerelac rice 
porridge) 
Nestlé 4 6.6 130 1.53 200 0 30 2 
Mild fullkornsgröt (Mild wholegrain 
porridge) 
Nestlé 8 8.5 128 2.57 330 2 39 2 
Mild fullkornsgröt (Mild wholegrain 
porridge) 
Semper 8 8.5 130 3.32 430 2 51 1 
Mild havregröt (Mild oat porridge) Semper 4 6.6 130 1.76 230 0 35 2 
Cerelac Fruktgröt banan apelsin (Ce-
relac fruit porridge banana orange) 
Nestlé 6 7.7 130 1.64 210 0 28 2 
Fullkornsgröt multikorn (Wholegrain 
porridge multigrain) 
HIPP 12 9.8 158 2.51 400 3 40 1 
Fruktgröt fullkorn (Fruit porridge 
wholegrain) 
Semper 12 9.8 133 2.26 300 4 31 2 
God Natt! Risgröt med grönsaker 
(Rice porridge with vegetables) 
HIPP 4 6.6 190 1.24 240 0 36 2 
Mild fullkornsgröt (Mild wholegrain 
porridge) 
HIPP 8 8.5 158 2.70 430 2 50 1 
Organic seven grain cerealc Organix 7 8.1 105 3.59 380 2 47 1 
First organic wholegrain baby ricec Organix 4 6.6 51 2.59 130 0 20 3 
Risgröt med banan och persika (Rice 
porridge with banana and peach) 
HIPP 4 6.6 167 0.75 120 0 19 3 
Eko havregröt (Organic oat porridge) Holle 6 7.7 225 4.40 990 0 128 0 
Organic millet porridge Holle 4 6.6 175 0.89 160 0 24 3 
Eko dinkelgröt (Organic spelt 
porridge) 
Holle 6 7.7 225 3.21 720 0 94 1 
Dinkelgröt naturell (Spelt porridge 
natural) 
Nestlé 6 7.7 155 3.24 500 0 65 1 
Bio-Babybrei Grieβ (Wheat 
porridge)c 
Holle 4 6.6 225 2.81 630 0 96 1 
Musligröt päron-banan (Musli 
porridge pear-banana) 
Nestlé 12 9.8 118 3.76 440 3 45 1 
Baby´s first food The ultimate four 
grain porridgec 
Plum 
 
4 6.6 110 1.47 160 0 24 2 
20 
Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
Mn 
concentration  
(mg/kg) 
Mn intake 
(µg/portion) 
No. of 
portions to 
reach AIa 
Mn intake 
(µg/kg 
bw/portion) 
No. of 
portions to 
reach TDIb 
Rice porridgec Holle 4 6.6 188 2.93 550 0 84 1 
FSMP used as partial feeding 
Fresubin energy fiber, chocolate 
flavour 
Fresenius 
Kabi 
12 9.8 200  
ml/portion 
3.82 760 2 78 1 
PKU gel Vitaflo 12 9.8 50 8.30 420 3 42 1 
Frebini energy fiber drink Fresenius 
Kabi 
12 9.8 200  
ml/portion 
1.76 350 3 36 2 
Foodstuffs for normal consumption 
Havredryck apelsin & mango (Oat 
drink orange & mango) 
Oatly 12 9.8 100  
ml/portion 
0.80 80 15 8.2 7 
Havredryck naturell (Oat drink 
natural) 
Carlshamn 12 9.8 100  
ml/portion 
0.67 67 18 6.8 9 
Pama minutris (Pama ’minute rice’) Quaker 12 9.8 130 1.06 138 9 14.1 4 
Ricedrink organic Rice Dream 12 9.8 100 
ml/portion 
0.22 22 53 2.3 26 
Risdryck naturell (Rice drink natural) Carlshamn 12 9.8 100 
ml/portion 
0.70 70 17 7.1 8 
Havregryn (Rolled oats) Lantmännen 12 9.8 130 4.65 605 2 61.7 1 
Skrädmjöl (Oat toasted and milled) Saltå kvarn 12 9.8 130 8.87 1154 1 117.7 1 
Sojadryck (Soya drink) Garant 12 9.8 100  
ml/portion 
1.95 195 6 19.9 3 
Sojadryck original + kalcium (Soya 
drink original + calcium) 
GoGreen 12 9.8 100  
ml/portion 
1.56 156 8 15.9 4 
Solhavre naturell (Oat drink natural) ICA 12 9.8 100  
ml/portion 
0.16 16 76 1.6 37 
Soya drink natural fresh Alpro 12 9.8 100  
ml/portion 
1.57 157 7 16.0 4 
Soya natural Provamel 12 9.8 100  
ml/portion 
1.98 198 6 20.2 3 
aThe Adequate intake (AI) is for 0-6 months 3µg, for 7-12 months 600 µg and for 1-3 years 1200 µg (IOM, 2001). 
bThe tolerable daily intake (TDI) is 60 µg/kg bw/day established by WHO in 2003.  
cProducts to be mixed with milk product according to instruction, calculation in table based on product diluted with water. 
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APPENDIX VI: Iron (Fe) 
 
Table 1. Estimated daily intake of iron from ready-to-eat infant formula, follow-on formula, FSMP as sole source of nutrition and FSMP as partial feeding. 
Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption  
(ml /day) 
Fe concentration 
(mg/kg) 
Fe intake 
(mg/day) 
% of RIa 
 
Infant Formula 
NAN 1 Modersmjölksersättning (NAN 1 
Infant formula) 
Nestlé 0 4.2 700 3.8 2.7 NA 
NAN HA 1 Modersmjölksersättning 
(NAN HA 1 Infant formula) 
Nestlé 0 4.2 700 6.2 4.3 NA 
BabySemp 2 Lemolac 
modersmjölksersättning (BabySemp 2 
Lemolac infant formula) 
Semper 4 6.6 800 5.6 4.5 NA 
ECO 1 Modersmjölksersättning (ECO 1 
infant formula) 
HIPP 0 4.2 700 5.7 4.0 NA 
ECO 2 Modersmjölksersättning (ECO 2 
infant formula) 
HIPP 4 6.6 800 6.4 5.1 NA 
BabySemp 1 Modersmjölksersättning 
(BabySemp 1 infant formula), powder 
Semper 0 4.2 700 3.5 2.5 NA 
BabySemp 1 Modersmjölksersättning 
(BabySemp 1 infant formula), RFU 
Semper 0 4.2 700 4.1 2.9 NA 
Organic infant milk Babynat 0 4.2 700 6.9 4.8 NA 
Eko 1 Modersmjölksersättning, (Infant 
formula 1) 
Holle 0.5 4.2 700 3.5 2.4 NA 
Follow-on-formula 
BabySemp 3 Tillskottsnäring (BabySemp 
3 follow-on-formula) 
Semper 8 8.5 500 9.4 4.7 59 
NAN Pro 2 Tillskottsnäring (NAN PRO 2 
follow-on-formula) 
Nestlé 6 7.7 900 8.8 7.9 99 
Eko tillskottsnäring 2 (Follow-on-
formula 2) 
Holle 6 7.7 900 7.9 7.1 89 
Optima Organic Follow-on-milk Babynat 6 7.7 900 7.8 7.0 88 
FSMP used as sole source of nutrition 
Neocate advance SHS 12 9.8 900 6.0 5.4 68 
Nutrini energy multi fibre Nutricia 12 9.8 600 13.0 7.8 98 
Nutrini multi fibre Nutricia 12 9.8 900 9.9 8.9 111 
Resource minimax Nestlé 12 9.8 750 10.7 8.0 100 
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Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption  
(ml /day) 
Fe concentration 
(mg/kg) 
Fe intake 
(mg/day) 
% of RIa 
 
Fresubin soya fibre Fresenius Kabi 12 9.8 900 11.6 10 125 
Isosource junior Nestlé 12 9.8 900 8.2 7.4 93 
Nutramigen 1 lipil Mead Johnson 0 4.2 700 11.4 8.0 NA 
Pepticate Nutricia 0 4.2 700 5.0 3.5 NA 
Galactomin 19 formula SHS 0 4.2 700 3.9 2.7 NA 
Neocate LCP Nutricia 0 4.2 700 7.4 5.2 NA 
Althéra Nestlé 0 4.2 700 6.5 4.6 NA 
Enfamil AR lipil Mead Johnson 0 4.2 700 7.3 5.1 NA 
Pepti junior Nutricia 0 4.2 700 7.1 4.9 NA 
Minimax barnsondnäring (Minimax 
enteral formula for children) 
Nestlé 6 7.7 600 9.0 5.4 68 
Profylac Semper 0 4.2 700 6.2 4.3 NA 
PreNAN discharge Nestlé  Premature/L
BW 
2.5 400 7.5 3.0 NA 
Enfalac premature Mead Johnson Premature/L
BW 
2.5 400 10.2 4.1 NA 
Pregestimil lipil Mead Johnson 0 4.2 700 11.5 8.0 NA 
FM 85b Nestlé Premature 2.5 400 10.4 4.2 NA 
Enfamil Human Milk Fortifierb  Mead Johnson Premature 2.5 400 13.4 5.3 NA 
NutriniKid multi fiber Nutricia 12 9.8 600 13.4 8.0 100 
FSMP used as partial feedingc 
Nutramigen 2 lipil Mead Johnson 6 7.7 900 12.1 10.9 136 
XP Maxamaid SHS 12 9.8 300 15.9 4.8 53 
PKU anamix infant lcp+ SHS 0 4.2 300 7.3 2.2 NA 
aThe recommended daily intake (RI) from 6 months is 8.0 mg/d established by SNR 2005. 
b Products to be mixed with breast milk according to instruction, calculation in table based on product diluted with water 
cThe intake of these products is calculated as daily intakes in accordance with calculations for intakes of follow-on formula.  
 
NA=not applicable because the product is intended for infants less than 6 months for which there is no RI. 
LBW=low birth weight 
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Table 2. Estimated intake of iron per consumed portion from gruel, porridge, FSMP as partial feeding and foodstuffs for normal consumption (products not intended 
for infants) 
Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
Fe 
concentration  
(mg/kg) 
Fe intake 
(mg/portion) 
No. of portions 
to reach RIa 
Gruel 
Fullkornsvälling (Wholegrain gruel) Nestlé 12 9.8 236 11.4 2.7 3 
Låglaktos majsvälling (Low lactose corn 
gruel) 
Nestlé 6 7.7 237 10.8 2.6 3 
Majsvälling (Corn gruel) Semper 6 7.7 229 12.1 2.8 3 
Mild fullkornsvälling havre (Mild 
wholegrain gruel oat) 
Nestlé 8 8.5 236 11.1 2.6 3 
Välling mjölkfri (Gruel dairy free) EnaGo 6 7.7 233 16.2 3.8 2 
Drickfärdig mild fullkornsvälling (Ready for 
use mild wholegrain gruel) 
Semper 8 8.5 200 9.4 1.9 4 
Fullkornsvälling havre vete råg (Wholgrain 
gruel oat wheat rye) 
Semper 
 
12 9.8 237 13.0 3.1 3 
Kvällsvälling ris och vete (Evening gruel 
rice and wheat) 
Semper 6 7.7 237 11.4 2.7 3 
God natt mild havrevälling (Good night mild 
oat gruel) 
Nestlé 6 7.7 220 11.9 2.6 3 
Majsvälling (Corn gruel) Nestlé 6 7.7 236 10.1 2.4 3 
First flavorb Babynat 6 7.7 234 0.6 0.1 (55) 
Céréales cacaob Babybio 8 8.5 234 1.8 0.4 (20) 
Mild fullkornsvälling (Mild wholegrain 
gruel) 
Semper 8 8.5 228 12.8 2.9 3 
Majsvälling (Corn gruel) HIPP 6 7.7 220 5.4 1.2 7 
Porridge 
Sinlac specialgröt (Sinlac special porridge) Nestlé 4 6.6 132 23.8 3.1 NA 
Fullkornsgröt med äpple (Wholegrain 
porridge with apple) 
HIPP 8 8.5 169 12.0 2.0 4 
Mild havregröt (Mild oat porridge) HIPP 6 7.7 167 6.2 1.0 8 
Banangröt mjölkfri (Banana porridge dairy 
free) 
EnaGo 6 7.7 158 13.2 2.1 4 
Risgröt med äpple och mango (Rice 
porridge with apple and mango) 
Semper 5 7.2 130 21.6 2.8 NA 
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Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
Fe 
concentration  
(mg/kg) 
Fe intake 
(mg/portion) 
No. of portions 
to reach RIa 
Banangröt (Banana porridge) Semper 4 6.6 130 18.8 2.4 NA 
Cerelac risgröt (Cerelac rice porridge) Nestlé 4 6.6 130 17.2 2.2 NA 
Mild fullkornsgröt (Mild wholegrain 
porridge) 
Nestlé 8 8.5 128 22.3 2.8 3 
Mild fullkornsgröt (Mild wholegrain 
porridge) 
Semper 8 8.5 130 18.7 2.4 3 
Mild havregröt (Mild oat porridge) Semper 4 6.6 130 20.2 2.6 NA 
Cerelac Fruktgröt banan apelsin (Cerelac 
fruit porridge banana orange) 
Nestlé 6 7.7 130 16.5 2.2 4 
Fullkornsgröt multikorn (Wholegrain 
porridge multigrain) 
HIPP 12 9.8 158 5.4 0.9 9 
Fruktgröt fullkorn (Fruit porridge 
wholegrain) 
Semper 12 9.8 133 21.0 2.8 3 
God Natt! Risgröt med grönsaker (Rice 
porridge with vegetables) 
HIPP 4 6.6 190 1.5 0.3 NA 
Mild fullkornsgröt (Mild wholegrain 
porridge) 
HIPP 8 8.5 158 11.2 1.8 5 
Organic seven grain cerealb Organix 7 8.1 105 4.3 0.5 (18) 
First organic wholegrain baby riceb Organix 4 6.6 51 2.1 0.1 NA 
Risgröt med banan och persika (Rice 
porridge with banana and peach) 
HIPP 4 6.6 167 3.2 0.5 NA 
Eko havregröt (Organic oat porridge ) Holle 6 7.7 225 3.6 0.8 10 
Organic millet porridge Holle 4 6.6 175 3.3 0.6 NA 
Eko dinkelgröt (Organic spelt porridge) Holle 6 7.7 225 3.6 0.8 10 
Dinkelgröt naturell (Spelt porridge natural) Nestlé 6 7.7 155 19.1 3.0 3 
Bio-Babybrei Grieβ (Wheat porridge)b Holle 4 6.6 225 2.7 0.6 NA 
Musligröt päron-banan (Musli porridge 
pear-banana) 
Nestlé 12 9.8 118 19.5 2.3 3 
Baby´s first food The ultimate four grain 
porridgeb 
Plum 
 
4 6.6 110 2.7 0.3 NA 
Rice porridgeb Holle 4 6.6 188 1.1 0.2 NA 
FSMP used as partial feeding 
Fresubin energy fiber, chocolate flavour Fresenius Kabi 12 9.8 200 ml/portion 19.7 3.9 2 
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Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
Fe 
concentration  
(mg/kg) 
Fe intake 
(mg/portion) 
No. of portions 
to reach RIa 
PKU gel Vitaflo 12 9.8 50 60.3 3.0 3 
Frebini energy fiber drink Fresenius Kabi 12 9.8 200 ml/portion 14.0 2.8 3 
Foodstuffs for normal consumption 
Havredryck apelsin & mango (Oat drink 
orange & mango) 
Oatly 12 9.8 100 ml/portion 0.9 0.09 86 
Havredryck naturell (Oat drink natural) Carlshamn 12 9.8 100 ml/portion 0.8 0.08 94 
Pama minutris (Pama ’minute rice’) Quaker 12 9.8 130 0.2 0.03 315 
Ricedrink organic Rice Dream 12 9.8 100 ml/portion 0.1 0.01 700 
Risdryck naturell (Rice drink natural) Carlshamn 12 9.8 100 ml/portion 0.8 0.08 103 
Havregryn (Rolled oats) Lantmännen 12 9.8 130 5.5 0.71 11 
Skrädmjöl (Oat toasted and milled) Saltå kvarn 12 9.8 130 9.4 1.22 7 
Sojadryck (Soya drink) Garant 12 9.8 100 ml/portion 6.5 0.65 12 
Sojadryck original + kalcium (Soya drink 
original + calcium) 
GoGreen 12 9.8 100 ml/portion 5.0 0.50 7 
Solhavre naturell (Oat drink natural) ICA 12 9.8 100 ml/portion 0.5 0.05 12 
Soya drink natural fresh Alpro 12 9.8 100 ml/portion 4.2 0.42 16 
Soya natural Provamel 12 9.8 100 ml/portion 3.3 0.33 25 
aThe recommended daily intake (RI) is 8.0 mg/d established by SNR in 2005. 
bProducts to be mixed with milk product according to instruction, calculation in table based on product diluted with water.NA=not applicable because the product is 
intended for infants less than 6 months for which there is no RI. 
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APPENDIX VII: Copper (Cu) 
 
Table 1. Estimated daily intake of copper from ready-to-eat infant formula, follow-on formula, FSMP as sole source of nutrition and FSMP as partial feeding 
Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption  
(ml/day) 
Cu 
concentration  
(mg/kg) 
Cu intake 
(µg/day) 
% of RIa % of ULb 
Infant Formula 
NAN 1 Modersmjölksersättning (NAN 1 
Infant formula) 
Nestlé 0 4.2 700 0.35 246 NA 25 
NAN HA 1 Modersmjölksersättning (NAN 
HA 1 Infant formula) 
Nestlé 0 4.2 700 0.51 354 NA 35 
BabySemp 2 Lemolac modersmjölks-
ersättning (BabySemp 2 Lemolac infant 
formula) 
Semper 4 6.6 800 0.46 370 NA 37 
ECO 1 Modersmjölksersättning (ECO 1 
infant formula) 
HIPP 0 4.2 700 0.33 232 NA 23 
ECO 2 Modersmjölksersättning (ECO 2 
infant formula) 
HIPP 4 6.6 800 0.39 308 NA 31 
BabySemp 1 Modersmjölksersättning 
(BabySemp 1 infant formula), powder 
Semper 0 4.2 700 0.34 239 NA 24 
BabySemp 1 Modersmjölksersättning 
(BabySemp 1 infant formula), RFU 
Semper 0 4.2 700 0.38 263 NA 26 
Organic infant milk Babynat 0 4.2 700 0.36 252 NA 25 
Eko 1 Modersmjölksersättning, (Infant 
formula 1) 
Holle 0.5 4.2 700 0.34 239 NA 24 
Follow-on-formula 
BabySemp 3 Tillskottsnäring (BabySemp 3 
follow-on-formula) 
Semper 8 8.5 500 0.33 166 55 17 
NAN Pro 2 Tillskottsnäring (NAN PRO 2 
follow-on-formula) 
Nestlé 6 7.7 900 0.47 419 140 42 
Eko tillskottsnäring 2 (Follow-on-formula 2) Holle 6 7.7 900 0.36 327 109 33 
Optima Organic Follow-on-milk Babynat 6 7.7 900 0.39 353 118 35 
FSMP used as sole source of nutrition 
Neocate advance SHS  12 9.8 900 0.57 511 170 51 
Nutrini energy multi fibre Nutricia 12 9.8 600 1.11 666 222 67 
Nutrini multi fibre Nutricia 12 9.8 900 0.76 684 228 68 
Resource minimax Nestlé 12 9.8 750 1.01 755 252 76 
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Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption  
(ml/day) 
Cu 
concentration  
(mg/kg) 
Cu intake 
(µg/day) 
% of RIa % of ULb 
Fresubin soya fibre Fresenius 
Kabi 
12 9.8 900 1.37 1233 411 123 
Isosource junior Nestlé 12 9.8 900 1.02 914 305 91 
Nutramigen 1 lipil Mead Johnson 0 4.2 700 0.46 325 NA 33 
Pepticate Nutricia 0 4.2 700 0.44 311 NA 31 
Galactomin 19 formula SHS  0 4.2 700 0.39 270 NA 27 
Neocate LCP Nutricia 0 4.2 700 0.46 324 NA 32 
Althéra Nestlé 0 4.2 700 0.57 398 NA 40 
Enfamil AR lipil Mead Johnson 0 4.2 700 0.49 345 NA 35 
Pepti junior Nutricia 0 4.2 700 0.37 258 NA 26 
Minimax barnsondnäring (Minimax enteral 
formula for children) 
Nestlé 6 7.7 600 1.09 655 218 66 
Profylac Semper 0 4.2 700 0.40 278 NA 28 
PreNAN discharge 
 
Nestlé  Premature/
LBW 
2.5 400 0.56 225 NA 23 
Enfalac premature Mead Johnson Premature/
LBW 
2.5 400 0.76 303 NA 30 
Pregestimil lipil Mead Johnson 0 4.2 700 0.51 360 NA 36 
FM 85c Nestlé Premature 2.5 400 0.35 140 NA 14 
Enfamil Human Milk Fortifierc  Mead Johnson Premature 2.5 400 0.54 220 NA 22 
NutriniKid multi fiber Nutricia 12 9.8 600 1.30 778 259 78 
FSMP used as partial nutritiond 
Nutramigen 2 lipil Mead Johnson 6 7.7 900 0.54 484 161 48 
XP Maxamaid SHS 12 9.8 300 2.62 786 262 79 
PKU anamix infant lcp+ SHS 0 4.2 300 0.57 170 NA 17 
aThe recommended intake (RI) from 6 months is 0.3 mg/day established by SNR in 2005. 
bThe tolerable upper intake level (UL) is 1000 µg/day established by EFSA in 2003. 
c Products to be mixed with breast milk according to instruction, calculation in table based on product diluted with water 
dThe intake of these products is calculated as daily intakes in accordance with calculations for intakes of follow-on formulas. 
 
NA=not applicable because the product is intended for infants less than 6 months for which there is no RI 
LBW=low birth weight 
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Table 2. Estimated intake of copper per consumed portion from gruel, porridge, FSMP as partial feeding and foodstuffs for normal consumption (products not 
intended for infants) 
Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
Cu 
concentration 
(mg/kg) 
Cu intake 
(µg/portion) 
No. of 
portions to 
reach RIa 
No. of 
portions to 
reach ULb 
Gruel 
Fullkornsvälling (Wholegrain gruel) Nestlé 12 9.8 236 0.23 55 5 18 
Låglaktos majsvälling (Low lactose 
corn gruel) 
Nestlé 6 7.7 237 0.04 9 33 110 
Majsvälling (Corn gruel) Semper 6 7.7 229 0.06 15 20 67 
Mild fullkornsvälling havre (Mild 
wholegrain gruel oat) 
Nestlé 8 8.5 236 0.17 40 7 25 
Välling mjölkfri (Gruel dairy free) EnaGo 6 7.7 233 0.38 89 3 11 
Drickfärdig mild fullkornsvälling 
(Ready for use mild wholegrain gruel) 
Semper 8 8.5 200 0.11 22 14 46 
Fullkornsvälling havre vete råg 
(Wholgrain gruel oat wheat rye) 
Semper 
 
12 9.8 237 0.21 50 6 20 
Kvällsvälling ris och vete (Evening 
gruel rice and wheat) 
Semper 6 7.7 237 0.10 24 12 41 
God natt mild havrevälling (Good 
night mild oat gruel) 
Nestlé 6 7.7 220 0.12 27 11 37 
Majsvälling (Corn gruel) Nestlé 6 7.7 236 0.02 5 66 221 
First flavorc Babynat 6 7.7 234 0.21 48 6 21 
Céréales cacaoc Babybio 8 8.5 234 0.40 94 3 11 
Mild fullkornsvälling (Mild 
wholegrain gruel) 
Semper 8 8.5 228 0.16 37 8 27 
Majsvälling (Corn gruel) HIPP 6 7.7 220 0.33 73 4 14 
Porridge 
Sinlac specialgröt (Sinlac special 
porridge) 
Nestlé 4 6.6 132 1.22 161 NA 6 
Fullkornsgröt med äpple (Wholegrain 
porridge with apple) 
HIPP 8 8.5 169 0.45 76 4 13 
Mild havregröt (Mild oat porridge) HIPP 6 7.7 167 0.34 57 5 17 
Banangröt mjölkfri (Banana porridge 
dairy free) 
EnaGo 6 7.7 158 0.84 133 2 8 
Risgröt med äpple och mango (Rice 
porridge with apple and mango) 
Semper 5 7.2 130 0.19 25 NA 40 
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Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
Cu 
concentration 
(mg/kg) 
Cu intake 
(µg/portion) 
No. of 
portions to 
reach RIa 
No. of 
portions to 
reach ULb 
Banangröt (Banana porridge) Semper 4 6.6 130 0.25 32 NA 31 
Cerelac risgröt (Cerelac rice 
porridge) 
Nestlé 4 6.6 130 0.22 29 NA 35 
Mild fullkornsgröt (Mild wholegrain 
porridge) 
Nestlé 8 8.5 128 0.33 43 7 23 
Mild fullkornsgröt (Mild wholegrain 
porridge) 
Semper 8 8.5 130 0.46 59 5 17 
Mild havregröt (Mild oat porridge) Semper 4 6.6 130 0.26 33 NA 30 
Cerelac Fruktgröt banan apelsin 
(Cerelac fruit porridge banana 
orange) 
Nestlé 6 7.7 130 0.39 50 6 20 
Fullkornsgröt multikorn (Wholegrain 
porridge multigrain) 
HIPP 12 9.8 158 0.37 58 3 17 
Fruktgröt fullkorn (Fruit porridge 
wholegrain) 
Semper 12 9.8 133 0.39 52 4 19 
God Natt! Risgröt med grönsaker 
(Rice porridge with vegetables) 
HIPP 4 6.6 190 0.35 66 NA 15 
Mild fullkornsgröt (Mild wholegrain 
porridge) 
HIPP 8 8.5 158 0.38 60 5 17 
Organic seven grain cerealc Organix 7 8.1 105 0.53 55 5 18 
First organic wholegrain baby ricec Organix 4 6.6 51 0.32 17 NA 61 
Risgröt med banan och persika (Rice 
porridge with banana and peach) 
HIPP 4 6.6 167 0.32 54 NA 18 
Eko havregröt (Organic oat porridge ) Holle 6 7.7 225 0.41 91 3 11 
Organic millet porridge Holle 4 6.6 175 0.70 123 NA 8 
Eko dinkelgröt (Organic spelt 
porridge) 
Holle 6 7.7 225 0.58 130 2 8 
Dinkelgröt naturell (Spelt porridge 
natural) 
Nestlé 6 7.7 155 0.34 52 6 19 
Bio-Babybrei Grieβ (Wheat 
porridge)c 
Holle 4 6.6 225 0.38 85 NA 12 
Musligröt päron-banan (Musli 
porridge pear-banana) 
Nestlé 12 9.8 118 0.46 54 6 18 
Baby´s first food The ultimate four 
grain porridgec 
Plum 
 
4 6.6 110 0.37 41 NA 24 
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Product (English translation) 
 
Producer 
 
Age 
(months) 
Weight 
(kg) 
Consumption 
(g/portion) 
Cu 
concentration 
(mg/kg) 
Cu intake 
(µg/portion) 
No. of 
portions to 
reach RIa 
No. of 
portions to 
reach ULb 
Rice porridgec Holle 4 6.6 188 0.22 42 NA 24 
FSMP used as partial feeding 
Fresubin energy fiber, chocolate 
flavour 
Fresenius 
Kabi 
12 9.8 200 ml/portion 2.90 580 1 2 
PKU gel Vitaflo 12 9.8 50 3.19 160 2 6 
Frebini energy fiber drink Fresenius 
Kabi 
12 9.8 200 ml/portion 1.54 308 1 3 
Foodstuffs for normal consumption 
Havredryck apelsin & mango (Oat 
drink orange & mango) 
Oatly 12 9.8 100 ml/portion 0.27 27 11 36 
Havredryck naturell (Oat drink 
natural) 
Carlshamn 12 9.8 100 ml/portion 0.22 22 14 46 
Pama minutris (Pama ’minute rice’) Quaker 12 9.8 130 0.24 31 10 33 
Ricedrink organic Rice Dream 12 9.8 100 ml/portion 0.05 5 59 197 
Risdryck naturell (Rice drink natural) Carlshamn 12 9.8 100 ml/portion 0.09 9 32 107 
Havregryn (Rolled oats) Lantmännen 12 9.8 130 0.56 72 4 14 
Skrädmjöl (Oat toasted and milled) Saltå kvarn 12 9.8 130 1.02 132 2 8 
Sojadryck (Soya drink) Garant 12 9.8 100 ml/portion 1.43 143 2 7 
Sojadryck original + kalcium (Soya 
drink original + calcium) 
GoGreen 12 9.8 100 ml/portion 1.10 110 3 9 
Solhavre naturell (Oat drink natural) ICA 12 9.8 100 ml/portion 0.15 15 20 65 
Soya drink natural fresh Alpro 12 9.8 100 ml/portion 1.02 102 3 10 
Soya natural Provamel 12 9.8 100 ml/portion 0.90 90 3 11 
aThe recommended intake (RI) is 0.3 mg/day established by SNR in 2005. 
bThe tolerable upper intake level (UL) is 1000 µg/day established by EFSA in 2003. 
cProducts to be mixed with milk product according to instruction, calculation in table based on product diluted with water. NA=not applicable because the product is 
intended for infants less than 6 months for which there is no RI. 
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